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ABSTRACT 
 
Nour Abdo: The 1000 Genomes Toxicity Screening Project: Utilizing the power of human 
genome variation for population-scale in vitro testing 
(Under the direction of Ivan Rusyn, M.D., Ph.D.) 
 
Incorporation of novel toxicity screening approaches is a crucial tool for tackling the complex 
contemporary challenges in evaluating the human health hazards of exposure to chemicals. 
Current in vitro testing paradigms still have major gaps that need addressing, such as population-
based in vitro approaches to qHTS screening. This study evaluated the hypothesis that 
comparative population genomics with efficient in vitro experimental design can be used for the 
evaluation of the potential hazard, mode of action, and the extent of population variability in 
response to chemicals. In Aim 1, we evaluated and assessed the validity of in vitro genetically–
anchored population human model system in assessing chemical toxicity and identifying 
candidate genetic susceptibility. We screened 81 human lymphoblast cell lines with 240 
chemicals at 12 different concentrations and assessed the toxic response using different 
endpoints (cell death and caspase production). We evaluated the toxic responses to a panel of 
chemicals observed in lymphoblast cell lines, and compared them to other toxic responses seen 
with different cell lines that originate from different sources. In Aim 2, we expanded our model 
to include more than one population. The goals were to (1) quantitatively assess population-
based toxicological hazard to environmental contaminants, (2) determine the extent of human 
inter-individual variability in chemical toxicity, identify susceptible sub-populations or races, (3) 
understand the genetic determinants of the inter-individual variability, (4) generate testable 
hypotheses about toxicity pathways by leveraging genetic and genomic data from 1000 Genomes 
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and HapMap Projects, and (5) use the data obtained from this research to build predictive in 
silico models. In Aim 3, we addressed some of the remaining challenges in our model, such as 
the ability to screen chemical mixtures. We explored the potential and efficiency of our model in 
assessing new challenges such as the evaluation of environmental chemical mixtures in a 
population in vitro screening, and the extrapolation of the in vitro hazard to an oral equivalent 
dose. In summary, this research not only will use novel tools to investigate population 
genetically anchored variability, but it will also offer exceptional methodology for incorporating 
scientifically-based estimates of uncertainty in risk assessment. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
A. THE OVERARCHING NECESSITY TO REGULATE THOUSANDS OF 
CHEMICALS. 
 
Several federal agencies in the United States have been bestowed the responsibility to 
regulate a diverse variety of environmental compounds. For example, the Toxic Substances 
Control Act (TSCA), which was passed in 1976, granted authority to the U.S. Environmental 
Protection Agency (EPA) to oversee the safety of chemical products in commerce to both the 
public and the environment, and to ensure continuous reviewing and regulation of chemicals in 
commerce (EPA 2012). Consequently, those federal agencies are responsible for implementing 
regulations that sets the maximum permissible thresholds for environmental compounds in 
drinking water, establish acceptable limits of exposure in occupational settings, and to determine 
tolerances for pesticides residues in food, among other tasks (National Research Council 2006).  
Previously, the US EPA has relied primarily on information obtained from in vivo animal 
models. Traditional toxicity testing is carried out in laboratory animals to assess the hazards and 
risks associated with exposure to environmental agents. Animal models have afforded valuable 
information on the possible harmful effects of exposure to a chemical and the associated dose at 
which effects may be observed. With limited confounding, controlled experimental design, and 
whole intact body system, in vivo animal models were deemed an invaluable resource for 
understanding toxicity risk.  
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With traditional animal models, each chemical requires multiple tests, can use up to 5000 
animals (or even 12,000 for some pesticides), costs millions of dollars, and take up to 5 years of 
testing or more. These disadvantages are in addition to ethical concerns that have been raised 
about animal welfare (Abbot 2005). There are more than 10,000 chemicals in commercial use in 
the United States, with hundreds being introduced each year (Anastas et al. 2010). However, 
only a small fraction of these chemical have been adequately evaluated for their potential risk to 
human health (Anastas et al. 2010; Judson et al. 2008). Accordingly, there has been a growing 
concern from governmental agencies about the need to adequately and accurately assess 
thousands of chemicals in a rapid and efficient manner. New paradigms are inevitably needed for 
the fast and accurate evaluation of the potential human health hazard of environmental chemicals 
(Collins et al. 2008). 
The emerging massive demand for to identify data sources for regulating chemicals is not 
limited to the United States. There is a global awareness of the challenges associated with 
toxicology testing. The European Union's Registration, Evaluation, Authorisation, and 
Restriction of Chemicals (REACH) legislation is one of the international agencies that have set 
out to better understand and manage risks to human health and the environment that arise from 
the manufacture and use of chemicals (Anastas et al. 2010).  
Incorporation of novel toxicity screening approaches is a crucial tool for tackling the 
complex contemporary challenges in evaluating the human health hazards of exposure to 
chemicals. A shift in toxicity testing from in vivo to in vitro methods may efficiently prioritize 
compounds, reveal new mechanisms, and enable predictive modeling. The emergence of new 
toxicity methods and strategies might address several risk assessment needs, as well as bring 
about new challenges. The following sections discuss current toxicity approaches and major 
 3 
 
remaining challenges to meet risk assessment demands for chemicals with variable modes of 
action.  
 
 
1. The shortcomings of traditional toxicological methods to inform risk assessment. 
 
Using animal models to evaluate toxicological response depends primarily on observing an 
adverse health outcome with high doses of a chemical. Uncertainties associated with animal data 
are usually handled by the use of a 10-fold interspecies uncertainty factor when extrapolating 
from laboratory animals to humans (EPA, 2004). However, the 10-fold interspecies uncertainty 
factor does not account for the additional uncertainty in extrapolating from high doses in animal 
experiments to environmental exposure levels that are orders of magnitude lower (Andersen and 
Krewski 2009). Although studies using animal models have improved dramatically in recent 
years in term of dosing, existing challenges and limitations remain. These include the high cost 
and labor required to handle animals, the extensive amount of time needed to conduct, assess and 
fully evaluate the health outcomes seen in animals, the challenges in translating human relevance 
in toxicological outcomes that are species dependent, the limited capability of assessing multiple 
compounds simultaneously, the inability to assess mixtures or several compounds at once, and 
most importantly the limited ability to provide timely relevant information to support informed 
regulation of environmental compounds. Due to the above reasons, growing concern and 
frustration has been expressed by health protection and regulatory agencies, leading to the 
request for improved alternative models that are faster and more efficient in tackling the 
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hundreds of thousands of commercial chemicals that require proper assessment and evaluation 
(Andersen and Krewski 2009). 
 
 
 
 
2. What alternatives to animal models exist to meet the high demand of regulating thousands 
of chemicals? Toxicity Testing in the 21
st
 Century. 
 
The growing concern from regulatory agencies, such as the Registration, Evaluation, 
Authorization and Restriction of Chemicals (REACH) in Europe and the Toxic Substances 
Control Act reform in the US, to meet the high demand of regulation of thousands of chemicals 
that are being released to the environment has resulted in a shift in toxicity assessment from in 
vivo to in vitro and in silico methods (Plunkett et al. 2010). The proposed shift should be carried 
out by the development of rapid screening methods based on the mechanistic understanding of 
biological processes (Plunkett et al. 2010; Judson et al. 2010). It is necessary to merge high-
information content biology and modeling with mechanistic research to build a predictive 
framework of an intact biological system (Chiu et al. 2011).  
Several recent governmental initiatives have been established in the US to meet the 
requirements and needs of exploration of new methodologies in toxicology to be incorporated 
into current and future risk assessments. For example, the Tox21 program (Collins et al. 2008), a 
partnership between four governmental agencies (EPA, NTP: National Toxicology Program, 
NCGC: NIH Chemical Genomics Center, and FDA: Food and Drug Administration), is currently 
screening thousands of chemicals for their potential to disturb biological pathways that may 
result in human disease, with a broad spectrum of in vitro assays utilizing quantitative high 
throughput screening (qHTS) format (Xia et al. 2008a). Such data from toxicologically relevant 
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in vitro endpoints can be utilized as toxicity-based triggers to assist in decision-making (Reif et 
al. 2010), act as predictive surrogates for in vivo toxicity (Zhu et al. 2008; Martin et al. 2010), or 
to generate testable hypotheses on the mechanisms of toxicity (Xia et al. 2008a). Another 
governmental initiative is The NexGen program, a collaborative effort between EPA, NTP, 
ATSDR, NCGC and CalEPA (US EPA, 2011), which is developing new approaches and 
methods to better utilize novel molecular toxicology data to understand the risks posed by 
environmental exposures. The NexGen program provides the opportunity to address challenges 
and opportunities of converting data generated through Tox21 into knowledge and ultimately 
into the scientific basis for NexGen risk assessments (US EPA 2011).  
Nevertheless, a major gap that is not being currently addressed in either Tox21 or NexGen, 
but is the focus of the research detailed herein, is the population-based in vitro approach to qHTS 
screening. The availability of genetically diverse defined renewable sources of human cells, such 
as transformed lymphoblasts, will allow for the investigation of the hazard and degree of inter-
individual biological variability in the human population, as well as to understand and 
comprehensively characterize the role of human genome sequence variation in observed 
inherited variation in toxicity phenotypes. 
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3. Current in vitro paradigms do not measure population variability and rely on rigid 
unproven assumptions.  
Risk assessments need to be regularly reviewed and modified to meet the demands of 
new discoveries and evolving technologies. With the recent shift from in vivo to in vitro in 
toxicity testing, the Committee on Toxicity Testing and Assessment of Environmental 
Agents of the National 
Research Council (National 
Research Council 2007) has 
recommended certain 
visionary guidelines for 
assessing in vitro testing as 
depicted in Figure 1 (fully 
reproduced from (Crump et 
al. 2010). The suggested 
paradigm proposes a similar 
modified approach to deal 
with in vitro data to the 
previous current in vivo 
paradigm. The future model 
includes different 
components to make it a 
successful and valuable tool. Two of those important components and suggestions are: (i) to 
test cell lines from many human donors that are representative of diverse populations and (ii) 
Figure 1.1: Schematic comparison of current and envisioned risk 
assessment paradigm adapted from  EHS (Crump et al. 2010). Fully 
reproduced from PMC under 
 “The following PMC journals are U.S. Government publications: 
Addiction Science & Clinical Practice (vol. 1 through vol. 6) 
Emerging Infectious Diseases 
Environmental Health Perspectives 
Preventing Chronic Disease 
 
All material published in these journals is in the public domain and 
may be used and reproduced without special permission. However, 
anyone using the material is requested to properly cite and 
acknowledge the source. ” 
http://www.ncbi.nlm.nih.gov/pmc/about/copyright/ 
taken June 20
th
  2014 
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to incorporate certain safety and host susceptibility factors that require a large degree of 
scientific judgment to derive a meaningful human reference dose (Crump et al. 2010). While 
the Tox21 program is currently screening thousands of environmental chemicals for their 
potential to affect biological pathways that may result in human disease (Xia et al. 2008a), 
the current screening paradigms do not contain enough human cell lines to assess the degree 
of inter-individual biological variability in the human population. Such variability is of 
particular importance in assessing potential human health hazard (National Research Council 
2007). Instead, the current default assumption for inter-individual variability, which is not 
based on any biological assessment, is a 3-fold difference in toxicodynamic studies and a 3-
fold difference in toxicokinetics studies (International Programme for Chemical Safety 
2001). 
 
 
B. GAUGING POPULATION VARIABILITY 
Exposure to environmental chemicals may result in a variety of health outcomes that are 
different in type or magnitude among individuals and/or populations. Those differences in 
response are due to underlying human variability and should be addressed for a valuable human 
health risk assessment of chemicals (Guyton et al. 2009; Hattis 1997; National Research Council 
2009). The variety of health outcomes from exposure to chemicals can be a result of intrinsic 
factors (genetic variability), extrinsic factors (life style, environment, etc), or the interaction of 
both intrinsic and external factors (Zeise et al. 2013). Human variability is currently assessed by 
applying “uncertainty” or “adjustment” factors (U.S. EPA, 2011). A factor of 1, 3, or 10 has been 
used to account for inter-individual variability in human population. In some cases, the factor is 
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further divided to separately account for variation in pharmacokinetics and pharmacodynamics 
(US EPA 2011) (Sonich-Mullin et al. 2001). 
Characterizing genetic variability can enhance our understanding of population variability in 
response to chemicals. The finding of genetic loci associated with susceptibility can potentially 
inform us of important cellular proteins that affect health outcome and can uncover novel 
toxicity pathways. Endeavors to map human variability have been focused on discovering 
genetic variations (Schadt and Bjorkegren 2012), or other -omics variations including  
epigenomics, transcriptomics, proteomics, and metabolomics (Chen et al. 2008; Emilsson et al. 
2008; Illig et al. 2010; Manolio 2010; Cornelis et al. 2010; Schadt 2009). Genetic 
polymorphisms may act together or separately to alter susceptibility to adverse effects of 
exposure to environmental agent. Thus, understanding genetic susceptibility has the potential for 
predicting toxicity pathways (National Research Council 2009). For instance, adverse health 
outcome to occupational exposure to welding fumes has been associated with genetic 
polymorphisms in DNA repair and detoxifying genes. Consequently, sensitive individuals have 
evidence of higher chromosomal and DNA damage (Iarmarcovai et al. 2005). 
Modern approaches to genetic epidemiology include valuable approaches to integrate toxicity 
exposure in population-based setting to potentially associated genetic loci. Several studies have 
been able to utilize genetic epidemiology to determine the relationship between specific genes in 
the population and adverse health outcomes from environmental chemical exposure. For 
example, human epidemiological studies have provided information on DNA damage in arsenic-
exposed populations(Andrew et al. 2006). Further in vitro studies were able to elucidate the 
specific DNA-repair pathways affected by arsenic (Andrew et al. 2006). While genetic 
epidemiology holds a great value in population risk assessment, several factors might hinder its 
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ability to overcome new challenges in toxicology. First, it is difficult to estimate and accurately 
measure environmental exposure amounts.  Furthermore, it is challenging to link the exposure 
with the outcome. The level of exposure (by amount in air, or water) does not necessarily reflect 
the actual dose that enters the body. While certain biomarkers could reflect internal 
ingested/inhaled exposure, they are seldom measured. Biomarkers might be invasive, expensive 
to measure, or/and not characterized or known for certain chemicals. Genetic epidemiology 
depends on actual real human exposures. This means we can only evaluate chemicals that 
individuals are exposed to and cannot make assessments on new chemicals. Second, genetic 
epidemiology can be enormously expensive and requires large sample sizes (Burton  et al. 2009). 
Except for a few diseases, health outcomes are complex and the contribution of individual 
genetic loci is modest at best (Manolio et al. 2009). In order to have enough power to detect 
potentially associated loci, thousands of individuals need to be exposed and genotyped for a 
meaningful study. With humans, confounding factors are  a major issue, where  individuals are 
exposed to other potential chemicals and have predisposed internal and external factors that 
could confound the outcome or increase variability of outcomes. While large sample sizes and 
careful epidemiological designs can potentially decrease confounding, it is difficult to achieve 
pure design principles with the reality of real human exposures. Third and most importantly, the 
overarching challenge of evaluating thousands of chemicals and mixtures in a short amount of 
time in epidemiological studies is not tenable.  
Other potential ways to investigate population variability is either through in vivo or in vitro 
toxicity testing paradigms. Several in vivo studies with genetically defined mouse models were 
designed to discover the genetic determinants of susceptibility and population variability (Rusyn 
et al. 2010). However, the extrapolation of population variability from animal models to human 
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population, in addition to the human relevance of the detected susceptibility loci in mice has yet 
to be fully determined (Rusyn et al. 2010). Moreover, animal model studies are labor intensive, 
not amenable to high-throughput screening, and can only effectively evaluate one chemical at a 
time.  
In vitro population based testing paradigms have been deemed useful in identifying adverse 
health outcomes that were not detected in preclinical and clinical testing for pharmaceutical 
products (IOM 2007), and in tailoring chemotherapy treatment based on patient’s genetics 
(Phillips and Mallal 2010) or tumor type (La Thangue and Kerr 2011). With the expense of 
developing new drugs, pharmacogenomics studies have been aimed to maximize effective 
therapy response and to minimize adverse reactions by prescribing treatment based on a patient’s 
genetic profile (Wheeler and Dolan 2012).  
 
 
 
 
C. LYMPHOBLASTOID CELL LINES IN PHARMACOGENOMIC DISCOVERY AND 
CLINICAL TRANSLATION. 
 
1. Establishment of lymphoblastoid cell lines (LCLs). 
 
I. The 1000 Genomes Project  
 
The 1000 Genomes Project is an international consortium with multiple centers, platforms, 
and funders to construct a foundational data set for human genetics (Kuehn 2008; Clarke 2012). 
The main purpose of the project is set to discover virtually all common human variations by 
investigating many genomes at the base pair level (Kuehn 2008; Clarke 2012). It aims to 
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discover population level human genetic variations of all types (95% of variation > 1% 
frequency), define haplotype structure in the human genome, and develop sequence analysis 
methods, tools, and other reagents that can be transferred to other sequencing projects (Kuehn 
2008; Clarke 2012).  
The consortium recruited healthy adult volunteers from different continents, representing 
wide variation in genetic ancestries. From blood samples, the consortium isolated B-
Lymphocytes to be later transformed to lymphoblastoid cell lines (LCLs) and genotyped via 
standard array technologies, and eventually these individuals will be sequenced to high coverage 
(Clarke 2012). The consortium also included cell lines developed as part of the HapMap project, 
including early CEPH populations (Clarke 2012). Figure 2 illustrate the up-to-date populations 
that were included in the 1000 Genomes Project.  
 
 
Figure 1.2: The 1000 Genomes Project Populations. Obtained from 
http://www.1000genomes.org/cell-lines-and-dna-coriell 
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II. Transformation of B-Lymphocytes to LCLs 
 
Immortalization is the process of transforming normal primary B-Lymphocytes to LCLs and 
giving them the ability to indefinitely proliferate. Consequently, having an unlimited life span 
with no other additional changes (Miller 1982). Normal cells are mortal, in part because their 
telomeres shorten with each cell division (Higaki et al. 2004). Telomeres are repetitive 
nucleotides at the end of chromosomes that act as a buffer layer to protect chromosomes from 
fusing together and genes from being lost during cell division. With cell division and replication, 
the DNA duplicates and the telomere sequences become shorter (Qian et al. 2014). Replenishing 
telomeres is dependent upon the enzyme telomerase reverse transcriptase (Qian et al. 2014).  
LCLs are immortalized by developing strong telomerase activity and other cellular changes upon 
Epstein-Barr virus (EBV) integration (Miller et al. 1982). In vitro infection with EBV of B-
Lymphocytes aids in their transformation to LCLs (Miller et al. 1982). EBV, which is a human 
herpes virus, is a common virus in humans and has been associated with mononucleosis (Weiss 
and O'Malley 2013), autoimmune diseases such as multiple sclerosis, dermatomyositis, systemic 
lupus erythematosus, rheumatoid arthritis (Toussirot and Roudier 2008; Dreyfus et al. 2011; 
Pender et al. 2012; Ascherio and Munger 2010), various forms of cancer such as Hodgkin's 
lymphoma, Burkitt's lymphoma, nasopharyngeal carcinoma (Niedobitek et al. 2001; Epstein 
2001), and conditions associated with human immunodeficiency virus (HIV) such as hairy 
leukoplakia and central nervous system lymphomas (Kawa 2000; Maeda et al. 2009). 
It was discovered in 1968 that EBV infects resting primary human B cells, activates them, 
and establishes a latent infection in them (Henle and Henle 1980).  After in vitro infection with 
EBV, the B-lymphocytes continue proliferating and give rise to stable LCLs with genomic virion 
DNA that is approximately 170 Kbp (Kalla and Hammerschmidt 2012; Amon et al. 2004). The 
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virion DNA exists as independent complete multicopy circular extrachromosomal plasmid-like 
DNA, and is not integrated into the cell’s chromosomes (Miller 1982). Moreover, the virion 
DNA replicates as the cellular DNA in the nucleus replicates in latency, infected proliferating B 
cells (Kalla and Hammerschmidt 2012) and mostly does not express its genetic information 
except for some viral products (Miller 1982). 
 
2. Utility of LCLs in pharmacogenomics discovery 
 
The utilization of lymphoblastoid cell lines (LCLs) as a human model has emerged as a 
promising tool in the study of the genetics of drug response. Many studies have used LCLs for 
pharmacogenomics discoveries by observing response to chemotherapeutics (Wheeler and Dolan 
2012), radiation (Smirnov et al. 2009; Niu et al. 2010), statins (Simon et al. 2006; Mangravite et 
al. 2008; Wilke et al. 2008; Medina et al. 2008), selective serotonin reuptake inhibitors (Morag et 
al. 2011), immunosuppressants (Wheeler and Dolan 2012), pain relievers and β-blockers 
(Wheeler and Dolan 2012). 
Pharmacogenomics studies using LCLs have not only proven to yield suggestive 
associations between genetic variants and drugs, but these associations have been supported in 
real clinical data. For example, LCL-based GWAS led to the discovery of an association between 
cytarabine arabinoside cytotoxicity and FKBP5 gene expression (Li et al. 2008). In a follow up 
clinical targeted gene study, both event-free and overall survival for acute myeloid leukemia 
patients treated with cytarabine arabinoside were associated with SNPs located in the FKBP5 
gene (Mitra et al. 2011). Successful clinical translation of LCL pharmacogenomics discoveries is 
not limited to the previous example. Several other studies have found value in performing 
GWAS and/or eQTL when compared to a cohort of cancer patients (Wheeler and Dolan 2012). 
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The following table (Table 1.1) illustrates the biggest GWA pharmacogenomics studies, showing 
the number of cell lines and the drugs that were utilized in each study.  
 
 
 
 
Table 1.1. Largest pharmacogenomics studies that utilized LCLs for GWAS analysis.  
Author (Year) Journal  # of Cell 
Lines 
# of 
Compounds 
(Wheeler et al. 2013) Pharmacogenomics J. 608 2 
(Brown et al., 2014) Pharmacogenomics J. 520 29 
(Innocenti et al. 2009) Cancer Chemother Pharmacol. 372 4 
(Gamazon et al. 2010) PNAS 343 5 
(Stark et al. 2010)  Pharmacogenomics J 270 11 
(Aksoy et al. 2009) Pharmacogenet Genomics 240 3 
(O'Donnell et al. 2010)  Pharmacogenet Genomics. 206 2 
(Li et al. 2009) Cancer Res 197 2 
(Li et al. 2010) Drug Metab Dispos. 194 3 
(Huang et al. 2007a) Molec. Therap.  176 4 
(Huang et al. 2007b) PNAS 176 2 
(Fridley et al. 2011)  Pharmacogenet Genomics. 175 2 
(Li et al. 2009) PLoS One 174 2 
(Peters et al. 2011) Pharmacogenomics. 124 29 
(Huang et al. 2011) RNA biol. 107 3 
(Wheeler et al. 2011) PLoS One. 83 4 
(Kulkarni et al. 2012) BMC Med Genomics. 55 2 
(Brown et al. 2012)* Pharmacogenet Genomics 516 1 
This table is sorted by the number of LCLs in each study. Studies with more the 50 LCLs and 
more than one drug were included. *This study represents the biggest study that evaluated one 
drug and included the largest number of LCLs. 
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D. UTILIZING LYMPHOBLASTOID CELL LINES IN TOXICOGENOMIC 
POPULATION-BASED IN VITRO TOXICITY SCREENING. 
 
Pharmacogenomics studies were among the first to recognize the utility of LCLs as a model 
in testing pharmaceutical drugs. They mainly employed LCLs to discover genetic loci that are 
associated with either drug toxicity and/or survival prognosis. With the realization of the full 
potential of LCLs in addressing major gaps in current risk assessment, the present work aimed to 
extend their utility to (i) quantitatively assess and address population based toxicological effects 
or hazard of environmental contaminants, (ii) determine the extent of human inter-individual 
variability in chemical toxicity, (iii) identify susceptible sub-populations or races, (iv) understand 
the genetic determinants of the inter-individual variability, (v) generate testable hypotheses about 
toxicity pathways by leveraging genetic and genomic data from 1000 Genomes and HapMap 
Projects and (vi) use the data obtained from this research to build predictive in silico models. 
 
 
1. Advantages and Limitations of Utilizing LCLs in Toxicogenomic Discovery 
 
Our novel central hypothesis is that human lymphoblast cells derived from various human 
populations can be efficiently utilized to better understand the hazard and magnitude of human 
inter-individual variability in response to different environmental chemicals. LCLs are derived 
from various human populations representing diverse genetic ancestries and are publicly 
available for researchers from the 1000 Genomes Project (1000 Genomes Project Consortium et 
al. 2012). Because they are immortalized, LCLs represent a renewable source for repeated 
cultures. Thus, they provide a relatively cost-effective testing system with controlled 
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experimental manipulation. Unlike human epidemiological studies or in vivo animal 
experiments, the same cell lines could be treated with different concentrations of multiple 
compounds at the same time. Therefore, LCLs are amenable for high throughput screening and 
lack the confounders that are often present in in vivo studies. Genome-wide genotype (The SNP 
Consortium; International HapMap Project; The 1000 Genomes Project; Human Variation Panel 
dbGaP Access) and gene expression data (Gene Expression Omnibus; Gene Expression Omnibus 
b; CEU RNA-Seq Data), including next-generation sequencing (DNA and RNA-Seq) data, is 
publicly available for hundreds of established LCLs.  
Like any toxicological model system, in vitro assessment using LCLs presents a number 
of technical challenges for extrapolation to humans, including lack of metabolism, and the 
inability to establish cell-cell interactions or evaluate chronic toxicity. The liver is the major site 
of xenobiotic metabolism and plays a central role in preventing accumulation of a wide range of 
compounds by converting them into a form suitable for elimination (Lerapetritou et al. 2009). 
Human lymphoblast cell lines are not hepatocytes and their main role is not meant to metabolize 
chemicals.  Although lymphocytes do not have the metabolic capacity of the liver, or even that of 
freshly isolated hepatocytes, they do express a number of nuclear receptors, as well as most 
genes of phase I and II metabolism, and transporters (Siest et al. 2008). A comparison of the 
population-wide (250+ individuals of various races, ages and gender) variability in mRNA levels 
for several dozen liver-specific thyroid hormone-related genes between human liver (Schadt et 
al. 2008) and lymphoblast cell lines (Stranger et al. 2007) showed that most of the nuclear 
receptors and metabolism genes are expressed in lymphoblasts, albeit at a 10- to 100-times lower 
quantity than hepatocytes (unpublished data).  
 17 
 
Potential confounders that affect the utility of LCLs include baseline growth rates, EBV 
copy numbers and ATP levels (Choy et al. 2008). While growth rate of LCLs was associated 
with chemotherapeutic-induced cytotoxicity in one study (Stark et al. 2010), it was not, in 
aggregate, associated with the cytotoxicity of 100+ chemicals in Lock et al. (2012). Altered 
apoptosis has been observed as a result of EBV transformation in LCLs with cancer drugs (Liu et 
al. 2004).  
The immortalization process or EBV transformation has been observed to affect gene-
expression and promoter-methylation profiles of majority of genes compared to primary B cells 
(Caliskan et al. 2011). However, the difference in expression levels between the primary and 
immortalized cells was small in magnitude (<1.5 fold). Moreover, the inter-individual variability 
in gene expression was the same between primary B cells and LCLs (Caliskan et al. 2011). 
Furthermore, many expression quantitative trait loci eQTLs observed in LCLs were observed in 
primary tissues like the liver, lung, and skin (Schadt et al. 2008; Bullaughey et al. 2009; Ding et 
al. 2010). 
  
2. Toxicity Phenotype  
With the recent shift in toxicology from in vivo to in vitro, hundreds of toxicity assays were 
developed to assess different cellular or biological endpoints. While those assays vary widely in 
their phenotypes and qualities, a good assay should be sensitive, robust, and able to 
quantitatively measure toxicity endpoint in a high throughput manner.  
Generally, toxicity phenotypes can be classified to include general hazard, 
carcinogenicity, genotoxicity, developmental toxicity, reproductive toxicity, and chronic toxicity 
(Judson et al. 2009). With the Tox21 initiative, thousands of chemicals have been screened for 
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their potential hazard (Knudsen et al. 2013). More than 650 in vitro assays including biochemical 
assays, human cells and cell lines, and alternative models such as mouse embryonic stem cells 
and zebrafish embryo development have been developed and utilized for these chemicals, to 
understand their mechanisms and potential hazards (Knudsen et al. 2013). 
The definition of “hazard” in chemical evaluation is broad and includes multiple potential 
definitions. A “hazardous” chemical evaluation could be derived from an acute and subchronic 
rodent study, or from material safety data sheets (Judson et al. 2009). To evaluate the in vitro 
potential hazard for a wide range of compounds, two essential things need to be properly 
selected: an appropriate end-point phenotype that represents general toxicity and is sensitive and 
broadly applicable to a variety of compounds, and a human relevant concentration range to 
determine the concentration for which the chemical will elicit toxicity. Determining the 
concentration at which chemical might elicit an endpoint is not enough, by itself, to quantify 
hazard. Because the in vitro assay endpoint does not incorporate metabolic clearance and plasma 
protein binding, ranking the chemicals by nominal assay concentrations might result in over- or 
under- estimation of the steady-state of a chemical (Rotroff et al 2010). However, incorporation 
of reverse dosimetry and exposure estimates when exploring concentration-response 
relationships for individual chemicals can aid tremendously in assessing human hazard and has 
been assessed by EPA and others (Rotroff et al. 2010; Judson et al. 2011) as a proposed 
approach.  
The “CellTiter-GloTM Luminescent Cell Viability Assay” is a commonly used assay in 
toxicity screening for cytotoxicity evaluation. It is a homogeneous “add-mix-measure” method to 
determine the number of viable cells in culture based on quantification of Adenosine 
Triphosphate (ATP) content (Promega). The quantity of ATP contents is a direct measurement of 
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the number of viable metabolically active cells (Promega). The assay results in cell lysis and a 
luciferase reaction. It is well-known that luciferase from fireflies or bacteria can be used to 
measure ATP (Fan and Wood 2007). A highly stabilized form of luciferase created by optimized 
strategies (Hall et al., 1998) is utilized in the CellTitelGlo assay, reacting with ATP to produce 
luciferyl adenylate, which is oxidized to produce a glow-like luminescent signal, among other 
products.  The final signal has been shown to be proportional to the amount of ATP (Fraga et al. 
2006). The luminescent signal, produced by the modified luciferase reaction, has a prolonged 
half-life (>5 hrs), making it resistant to a broad spectrum of detergents and suitable for batch-
mode processing of multiple plates (Riss et al., 2006;Fan et al., 2005).  
In a normal living cell, the generation of ATP requires harmonized interactions of many 
enzymes (Fan and Wood 2007). ATP concentrations are sustained upon equilibrium between 
consumption and demand enzyme pathways (Fan and Wood 2007). Upon cell death, the 
enzymes that generate ATP cease to function while the enzymes that consume ATP keep 
working, resulting in ATP consumption. Therefore, the concentration of intracellular ATP drops 
instantaneously upon cell death with a corresponding loss of luminescence when assayed using 
luciferase (Fan and Wood 2007).  
CellTiter-Glo
TM
 Luminescent Cell Viability Assay has many advantages that make it a 
great choice for quantitative high throughput screening. First, the unique homogeneous format 
reduces pipetting errors that may be introduced during the multiple steps required by other ATP 
measurement methods, thus decreasing experimental inconstancies. Second, the assay is 
extremely sensitive in the measurement of number of cells below the detection limits of standard 
colorimetric and fluorometric assays, reducing the number of cells required per assay. Third, the 
assay is fast (10 minutes) and flexible for different detection techniques, including automated 
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high-throughput protocols. Fourth, among all cytotoxicity assays, bioluminescent ATP assays 
have been the most widely used in high-throughput applications (Riss et al. 2006; Melnick et al. 
2006). Finally, the assay is very robust with extremely stable luminescent and a long half-life (>5 
hrs).  The homogeneous assay procedure involves the addition of a single reagent (CellTiter-
Glo
TM
 Reagent) directly to cells cultured in serum-supplemented medium. Cell washing, removal 
of medium or multiple pipetting steps are not required (Promega).  
Moreover, the CellTiter-Glo
TM
 Luminescent Cell Viability Assay has been utilized and 
extensively evaluated for in vitro screening of cytotoxicity in high-throughput settings with 
proper evaluation of time points at the National Institutes of Health Chemical Genomics Center 
(NCGC) (Xia et al. 2008a). It was used to screen the NTP 1,408-compound library for 
cytotoxicity in 13 cell types (9 human, 2 rat, 2 mouse) (Xia et al. 2008b). The cell types 
originated from different tissues and included cell lines, cell strains, and primary cell populations 
(Tice et al. 2013). While some compounds were cytotoxic to all cell types, others were only toxic 
in some cell lines but not others. The results indicated that no single cell type would be 
universally informative for cytotoxicity or other endpoints, such as apoptosis (Xia et al. 2008a; 
Tice et al. 2013; Huang et al. 2008).  
 
3. How can in vitro data inform systematic risk assessment? 
 
Thousands of chemicals are being currently screened with hundreds of in vitro assays in 
the Tox21 and Toxcast projects. The predominant question is how to move forward from an in 
vitro endpoint to an overall comprehensive risk assessment? One way, as illustrated in Figure 1, 
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is to apply the findings of an in vitro study to a more traditional in vivo risk assessment. First, the 
hazard is established from a concentration-response in vitro assay. It is recommended that the in 
vitro testing be established from cell lines representing populations with sensitive individuals. 
Second, PK modeling is applied to derive the dose that results in the hazardous outcome. Third, 
uncertainty factors are applied to establish a human reference dose (Crump et al. 2010).  
Another approach is to find the biological pathway altering dose (BPAD) for high-
throughput risk assessment (HTRA). With this framework, a biological pathway is defined that is 
linked to adverse effects. Then, the in vitro concentration that perturbs the specified biological 
pathway is measured. Furthermore, PK modeling is applied to estimate the in vivo dose that 
could result in the hazardous concentration. From there, uncertainty and population variability 
estimates are incorporated to identify the protective exposure limit (Judson et al. 2011).  
A third approach for toxicity assessment of in vitro assays is the tiered step-wise decision 
tree (Thomas et al. 2013). In this approach, chemicals are ranked based on their relative 
selectivity and the point of departure (POD) is established from the in vitro assays. Reverse 
toxicokinetic modeling (Rotroff et al. 2010; Wetmore et al. 2013; Wetmore et al. 2012) can then 
be applied to estimate the corresponding dose for the in vitro POD. The calculated external dose 
can then be computed to human exposure estimates to establish the margin of exposure (MOE).  
In the second tier, after selecting chemicals from tier I, in vivo animal testing is carried out with a 
focus on refining dose-response, PK evaluations, and other estimates. The third tier is 
characterized by traditional animal studies that are currently used to assess chemicals.  
Regardless of the paradigm implemented to assess potential adverse health outcomes that 
are associated with chemical exposures from in vitro assays, one thing is standard and consistent 
among all: assessing human variability and identifying sensitive subpopulations is of key 
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importance. Testing human cell lines that represent various populations and identify sensitive 
subpopulations can substantially improve any risk assessment paradigm where decision making 
will be relied on actual estimated rather than mere statistical assumptions that may or may not be 
satisfied.   
 
 
E. SPECIFIC AIMS 
 
 Quantitative assessment of the degree of inter-individual biological variability in the 
human population is a major aspect for properly evaluating potential human health hazards. A 
comprehensive characterization of human genome sequence variation is important for 
understanding inherited sources of variation in toxicity phenotypes. Genetic polymorphisms can 
have a profound influence on disease risk after drug or toxicant exposure. However, such 
characterization and assessment is difficult to quantitatively evaluate using current in vivo animal 
test systems or in vitro methods with established cell lines. The availability of genetically- and 
geographically-representative diverse and genetically-defined renewable sources of human cells, 
such as lymphoblasts from the International HapMap and 1000 Genomes projects, enables in 
vitro testing at the population level. As the focus of risk assessment processes shifts toward in 
vitro data, the quantitative assessment of inter-individual variability in response to chemicals, 
and an understanding of the underlying genetic causes are necessary for regulatory decisions to 
be based on scientific data rather than on default assumptions. 
 Previous pilot work showed that utilizing those lymphoblasts for in vitro toxicity 
assessment was very successful in assessing inter-individual variability and the molecular 
underpinnings of such variability. These novel findings form a solid foundation for this 
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proposal’s central hypothesis that genetic variability and chemical toxicity can be assessed using 
a lymphoblast cell line-based in vitro model that serves as a model for the human population. To 
accomplish the objective of this application, this hypothesis was tested by pursuing the following 
specific aims: 
 
Aim 1: To evaluate and assess the validity of an in vitro, genetically–anchored human 
population model system in assessing chemical toxicity and identifying candidate genetic 
susceptibility.  
In this Aim, we hypothesized that genetic variability and chemical toxicity can be assessed 
using an in vitro model of lymphoblast cell lines that represent a human population. To 
demonstrate the feasibility of an in vitro model system to assess inter-individual and 
population-wide variability of chemical-induced toxicity phenotypes, cells from over 80 
Centre d’Etude du Polymorphisme Humain (CEPH) cell lines were exposed to 12 
concentrations of 240 environmental chemicals.  The induction of caspase-3/7, indicative of 
apoptosis, was then assessed and intracellular levels of adenosine triphosphate (ATP) as a 
surrogate for cell number, was measured to evaluate cytotoxicity. We utilized the available 
dense genetic data to perform a Genome Wide Association Study (GWAS). We also assessed 
the validity of the in vitro genetics–anchored human model system by comparing it to similar 
human models and non-human models. 
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Aim 2: To quantitatively evaluate inter-individual variability for diverse environmental 
chemicals using high throughput large scale in-vitro model across genetically-defined 
genetically-diverse populations. 
In this aim, we developed an in-vitro screening model that had sufficient power to 
quantitatively assess the potential human health hazards and inter-individual variability in 
chemical toxicity, identify susceptible sub-populations, understand the genetic determinants 
of the inter-individual variability, generate testable hypotheses about toxicity pathways by 
leveraging genetic and genomic data from 1000 Genomes and HapMap Projects, and use the 
data obtained from this research to build predictive in silico models. We screened 1104 
lymphoblast cell lines from 9 ancestrally and geographically diverse populations representing 
5 continents. Those cell lines were chosen based on availability of dense genetic information 
and were exposed to 180 diverse environmental chemicals at 8 different concentrations. We 
assessed cytotoxicity based on measuring intracellular levels of ATP. 
 
Aim 3: To investigate remaining challenges of in vitro genetically–anchored population 
human model, such as the potential to screen complex mixtures. 
This specific aim addressed remaining challenges that require further assessment to increase 
the utility of the information obtained from this model, including limited metabolic capacity 
of lymphoblasts and the potential to screen complex mixtures. We selected lymphoblast cell 
lines from 4 ancestrally and geographically diverse populations based on availability of 
genome sequence and basal RNA-seq information. The cell lines were exposed to 2 pesticide 
chemical mixtures, at 8 different concentrations. This design enabled us to investigate the 
utility of our model in assessing chemical mixtures. 
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A. ABSTRACT 
 A shift in toxicity testing from in vivo to in vitro may efficiently prioritize compounds, 
reveal new mechanisms, and enable predictive modeling. Quantitative high-throughput screening 
(qHTS) is a major source of data for computational toxicology, and our goal in this study was to 
aid in the development of predictive in vitro models of chemical-induced toxicity, anchored on 
inter-individual genetic variability. Eighty-one human lymphoblast cell lines from 27 Centre 
d’Etude du Polymorphisme Humain (CEPH) trios were exposed to 240 chemical substances (12 
concentrations, 0.26 nM-46.0 uM) and evaluated for cytotoxicity and apoptosis. qHTS screening 
in the genetically-defined population produced robust and reproducible results, which allowed 
for cross-compound, -assay and -individual comparisons. Some compounds were cytotoxic to all 
cell types at similar concentrations, whereas others exhibited inter-individual differences in 
cytotoxicity.  Specifically, the quantitative high-throughput screening in a population-based 
human in vitro model system has several unique aspects that are of utility for toxicity testing, 
chemical prioritization, and high-throughput risk assessment. First, standardized and high-quality 
concentration-response profiling, with reproducibility confirmed by comparison with previous 
experiments, enables prioritization of chemicals for variability in inter-individual range in 
cytotoxicity. Second, genome-wide association analysis of cytotoxicity phenotypes allows 
exploration of the potential genetic determinants of inter-individual variability in toxicity. 
Furthermore, highly significant associations identified through the analysis of population-level 
correlations between basal gene expression variability and chemical-induced toxicity suggest 
plausible mode of action hypotheses for follow up analyses. We conclude that as the improved 
resolution of genetic profiling can now be matched with high-quality in vitro screening data, the 
evaluation of the toxicity pathways and the effects of genetic diversity are now feasible through 
the use of human lymphoblast cell lines. 
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B. INTRODUCTION 
       The “Registration, Evaluation, Authorisation and Restriction of Chemicals” (REACH) 
regulations in Europe and Toxic Substances Control Act reform activities in the US are creating 
substantial pressure to develop improved methods for evaluating potential chemical hazards 
(Plunkett et al., 2010). Current chemical safety evaluation (National Research Council, 2007) 
relies on in vivo animal testing. In Europe alone, it is expected that 100,000+ chemicals will 
require new safety data, yet the worldwide capacity to evaluate chemicals for the most animal-
intensive in vivo tests is 200–300 chemicals each year (Hartung and Rovida, 2009).  
      In the US, the Tox21 program (Collins et al., 2008) is a collaborative initiative of four 
government agencies. This effort leads the field in its use of a broad spectrum of in vitro assays, 
many in quantitative High Throughput Screening (qHTS) format (Inglese et al., 2006), to screen 
thousands of environmental chemicals for their potential to affect biological pathways that may 
result in human disease (Xia et al., 2008). Such data on toxicologically relevant in vitro 
endpoints can assist in decision-making (Reif et al., 2010), serve as predictive surrogates for in 
vivo toxicity (Martin et al., 2010; Zhu et al., 2008), and generate testable hypotheses on the 
mechanisms (Xia et al., 2009).  
 Another important consideration in assessing the potential human health hazard is the 
degree of inter-individual biological variability in the human population (National Research 
Council, 2008). A comprehensive characterization of human genome sequence variation is 
important for understanding observed inherited variation in toxicity phenotypes. Indeed, genetic 
polymorphisms can have a profound influence on disease risk after drug or toxicant exposure 
(Harrill et al., 2009), yet these factors are difficult to quantitatively evaluate using current in vivo 
animal test systems or established cell lines (Rusyn et al., 2010). The availability of genetically-
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diverse, genetically-defined renewable sources of human cells, such as lymphoblasts from the 
International HapMap (International HapMap Consortium, 2005) and 1000 Genomes (Durbin et 
al., 2010) projects, enables in vitro testing at the population scale. As the risk assessment process 
shifts towards in vitro data, the quantitative assessment of inter-individual variability in 
responses to chemicals, as well as an understanding of the underlying genetic causes, are needed 
so that regulatory decisions can be based on data rather than default assumptions. 
 To demonstrate the feasibility of an in vitro model system to assess inter-individual and 
population-wide variability of chemical-induced toxicity phenotypes, we exposed cells from over 
80 CEPH cell lines (O'Shea et al., 2011) to 3 concentrations of 14 environmental chemicals, and 
assessed induction of caspase-3/7, indicative of apoptosis, and cytotoxicity, based on measuring 
intracellular levels of adenosine triphosphate (ATP) as a surrogate for cell number. This study 
showed that an in vitro genetics-anchored human model system can be utilized in a population-
level screen for chemical toxicity, with the potential to identify candidate genetic susceptibility 
factors for further study. As a next step, we report here on a larger-scale population-based qHTS 
screening using hundreds of compounds and covering a more comprehensive range of 
concentrations. The quantitative assessment of inter-individual variability in response at this 
scale demonstrates the potential of this methodology for toxicity screening, hazard evaluation 
and exploration of genetic determinants of susceptibility. 
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C. MATERIALS AND METHODS 
Experimental Design 
       Chemicals. A sub-set (240 compounds) of the National Toxicology Program’s 1,408 
chemical library (Xia et al., 2008) was used in these experiments. See Table 2.1 for a complete 
list of chemicals used in these experiments. Chemicals were dissolved with dimethyl sulfoxide 
(DMSO) into 12 different stock concentrations ranging from 56.5nM to 10 mM and were 
aliquoted to 1536-well plate format via pin tool (Kalypsys, San Diego, CA, USA). The final 
concentration ranges from 0.26 nM to 46.08 uM in the assay plates. The negative control was 
DMSO at 0.5% v/v; the positive control was staurosporine at the tested concentration range. 
       Cell lines. A set of 81 immortalized lymphoblastoid cell lines was acquired from Coriell 
Cell Repositories (Camden, NJ, USA). The 81 cell lines were from HapMap Consortium’s 
Centre d’Etude du Polymorphisme Humain (CEPH) panel and consisted of 27 trios (father, 
mother and a child). Screening was conducted in 3 batches and cell lines were randomly divided 
into batches without regard to family structure. Cells were cultured at 37ºC with 5% CO2 in 
suspension in flasks with upright position in RPMI 1640 media (Gibco, Carlsbad, CA, USA) 
supplemented with 15% fetal bovine serum (HyClone, South Logan, UT, USA) and 0.1% 
penicillin-streptomycin (Gibco). Media was changed every 3 days. Cell counts and viability were 
assessed prior to chemical treatment using Cellometer Auto T4 Plus (Nexcelem Bioscience, 
Lawrence, MA, USA). Cells were grown to a concentration up to 10
6
 cells/mL, volume of at 
least 100 mL, and viability of >85% before treatment. After centrifugation, the cells were re-
suspended in fresh media. The cell suspension was filtered through a 40 um nylon cell strainer 
(BD Biosciences, Durham, NC, USA). Cell stock was diluted with fresh media to final 
concentrations of 3-4x105cells/mL, and plated into a tissue-culture treated 1,536-well white/solid 
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bottom assay plates (Grenier Bio-One North America, Monroe, NC, USA) at 2000 
cells/5µL/well using a flying reagent dispenser (Aurora Discovery, Carlsbad, CA, USA).To 
increase the robustness of the data and evaluate reproducibility, each cell line was seeded on 
multiple plates (6 plates except for 2 cell lines where 5 plates were seeded) so that each 
compound was screened in each cell line on 2-3 plates (chemicals were randomly divided in half 
to enable screening of 120 compound x 12 concentrations on each plate). 
      Cytotoxicity and Caspase-3/7 assays. Two assays were chosen to evaluate cytotoxicity 
according to the manufacturer’s protocols. Cell-Titer-Glo® Luminescent Cell Viability 
(Promega Corporation, Madison, WI, USA) assay was used to assess intra-cellular ATP 
concentration, a marker for cytotoxicity, 40 hours post treatment. Caspase-Glo® 3/7 (Promega) 
was used to assess activity of caspase-3/7, a marker of apoptosis, 16 hours post treatment. These 
assays were selected based on their utility for in vitro screening of cytotoxicity in cell type- (Xia 
et al., 2008) and individual-independent (Choy et al., 2008) manner. Time points were selected 
based on previous experiments at NCGC (Xia et al., 2008). A ViewLux plate reader 
(PerkinElmer, Shelton, CT, USA) was used to detect luminescent intensity in each well for both 
assays. Data is publicly available from PubChem (AIDs: 588812 and 588813). 
       
Data Processing 
       Response Normalization & Curve Fitting. Data was normalized relative to the 
positive/negative controls and corrected as detailed elsewhere (Xia et al., 2008). Concentration-
response titration points were fitted to a Hill equation for each chemical. Chemicals were 
classified into 3 categories based on their concentration-response curves: active, non-active, and 
inconclusive (Huang et al., 2008; Xia et al., 2008). Specifically, in data from cytotoxicity assay 
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the curve classes -1.1, -1.2,-2.1 were classified as “active,” any positive curve class as “non-
active,” and others as “inconclusive.” For data from caspase-3/7 assay, curve classes 1.1, 1.2, 2.1 
were classified as “active,” any negative curve class as “non-active,” and others as 
“inconclusive.”  
 CurveP. To evaluate the cytotoxic potency of each compound, we calculated a “curve P” 
value for each compound-cell line pair. Curve P is defined as the lowest concentration which 
showed a consistent deviation from the baseline response and derived as detailed in (Sedykh et 
al., 2011). It can be regarded as a close approximation for the point of departure. Curve P was 
derived for all compounds even if little or no toxicity was observed. For the latter compounds, to 
enable the follow-up statistical analyses, the curve P was assigned to a concentration of 50 uM. 
Batch effects were adjusted using the ComBat method (Johnson et al., 2007). 
 
Data Analysis 
       Assessing variability across individual, chemical, and assay. The Pearson correlation 
coefficient (r) between pairs of replicate plates was used to assess experimental reproducibility. 
For this analysis, two replicate plates were randomly selected for each chemical and cell line pair 
(240 chemicals x 81 cell lines = 19,440 total replicate pairs sampled). 
      Kruskal-Wallis ANOVA (Kruskal and Wallis, 1952) was used to assess the significance 
of a cell line effect (versus experimental effect) in curve P for each chemical. The Benjamini-
Hochberg FDR (Johnson et al., 2007) was used to correct for multiple comparisons. To measure 
potential confounding with basal metabolic rate, the Spearman rank correlation coefficient 
between curve P and the average ATP level in DMSO-treated cells was computed for each 
chemical. The Spearman (rank) correlation between the average curve P value for the 
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cytotoxicity assay and the average curve P value for the apoptosis assay for each chemical was 
computed to measure an overall relationship between the two assays. Furthermore, within each 
chemical, the correlation between the two assays across cell lines (averaged over replications) 
was computed separately. For both assays, chemical-by-chemical correlation heatmaps were 
used to identify clusters of chemicals with similar response across cell lines. The order of the 
chemicals in these heatmaps was determined by complete-linkage distance clustering. 
 All computations, graphs and heatmaps used the R programming environment for 
statistical computing and graphics (2.10.0, R Development Core Team, Vienna, Austria). 
       Dose-response for populations and individuals. For the ATP assay data for progesterone, 
a four-parameter logistic model was fit to the assay vs. vs. dose data for each cell line, using 
maximum likelihood and the optim routine in R. The model can be written 
  )(dosefassay , where 
 ))exp(1()exp(min)(maxmin)( 1010 dosedosedosef   , ),0(~
2 N , and {min, 
max, 0 , 1 ,
2 } are cell line-specific parameter vectors. For a negative dose-response 
relationship, EC10 is the dose for which  
.9.0))exp(1()exp( 1010  dosedose   
The variation in the EC10 estimates was used as illustrative of population variation in true EC10 
values, although additional sampling variation underlies each EC10 estimate. An overall logistic 
dose-response curve was fit to the aggregated data across all individuals. 
       Assessing heritability and genetic associations. Heritability calculations were used to 
determine overall familial effects among the 27 CEPH trios for each chemical, on both assays. 
Calculations were motivated by the mid-parent regression model        (     )   , 
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where   is the child’s response,    is the father’s response,    is the mother’s response and   is 
an error term. A likelihood ratio significance test is then based on the heritability h
2
: the 
variability in response due to shared genetics as a proportion of total variability in response. For 
this analysis, curve P values for each chemical were quantile-normalized to the standard 
Gaussian distribution. 
 To measure genotype-toxicity relationships, genome-wide association studies (GWAS) 
were performed in R using the GenABEL package (Aulchenko et al., 2007). Phase III genotype 
data, on approximately 1.4 x 10
6
 single nucleotide polymorphisms (SNPs), was obtained for each 
cell line from the International HapMap Project (International HapMap Consortium, 2005). 
GWAS was performed for each chemical on both assays, with quantile normalized curve P 
values as the response phenotype. The significance of an association between a given SNP and 
the response was measured using a likelihood-based score test (Schaid et al., 2002) (qtscore in 
genABEL). For our initial screen, the familial trio relationships were not used for the analysis, 
due to the low evidence for overall heritability, on the grounds that methods such as transmission 
disequilibrium testing would reduce power, and with the intent to follow any significant findings 
with further testing. LocusZoom (Pruim et al., 2010) was used to visualize the genomic context 
for suggestive loci determined by GWAS. 
       RNA-Seq expression vs. toxicity assays. The 42 cell lines in common between 
Montgomery et al. (Montgomery et al., 2010) and the present study were matched with HapMap 
IDs, using RNA-Seq tag counts mapped to the genome as previously described for 20,000 genes 
(Zhou et al., 2011). For computational efficiency, simple read proportions consisting of number 
of tag counts per gene divided by the mapped library size (Zhou et al., 2011) were used in linear 
regression as predictors for the cytotoxicity assays. FDR q-values were then obtained for the 
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entire set of genes and chemicals, using p.adjust in R. For the caspase assay, ~5,000 genes were 
determined to have at least one chemical with q<0.01, and these genes were retained for 
clustering. Hierarchical clustering with average linkage was performed directly on the FDR q-
values using the heatmap function in R. 
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D. RESULTS 
 
qHTS screening in a population of human lymphoblasts yields robust and reproducible data 
       Screening was conducted in a 1,536-well plate format using a robotic system. The 81 cell 
lines were randomly sub-divided into 3 batches and each line was screened against 240 chemical 
substances (see Table 2.1 for a complete list) at 12 concentrations (0.26 nM-46.0 uM). Each 
1,536-well plate contained one cell line exposed to 120 chemicals accompanied by concurrent 
vehicle (DMSO) and positive controls. To increase the robustness of the data, duplicates or 
triplicates of each plate were run. Assays for intracellular ATP content and caspase-3/7 activity 
were used based on their utility for in vitro screening of cytotoxicity and apoptosis, respectively, 
in cell type- and individual-independent manner (Choy et al., 2008; Xia et al., 2008). A 
combination of the two assays allows for the role of apoptosis in the cytotoxicity response to be 
evaluated (Shi et al., 2010). 
       Several metrics were used to evaluate the reproducibility of the toxicity phenotypes. First, 
the concentration-response curve class (Parham et al., 2009) was identical across replicate plates 
95.2% of the time for cytotoxicity and 94.1% for apoptosis. Second, the pair-wise Pearson 
correlation among replicate plate pairs using log(AC50) values for the compounds with active 
curve classes for the cytotoxicity and apoptosis assays was r=0.99 and r=0.98, respectively. 
Third, to evaluate the effects correlation for all compounds, we calculated a “curve P” value, the 
lowest concentration which showed a consistent deviation from the baseline response (Sedykh et 
al., 2011), which can be regarded as a close approximation for the Lowest Observed Adverse 
Effect Level. For chemicals exhibiting no effect across the concentrations tested, the curve P was 
assigned to 50 uM to enable straightforward statistical analyses. The pair-wise correlation among 
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replicate plates of the log(curve P) values was equally high (r[cytotoxicity]=0.91, 
r[apoptosis]=0.95) when all compounds were included (Fig. 2.1.a, 2.1.b). Finally, there were 8 
duplicates among the compounds screened. High concordance in median and range of responses 
for these was observed (Fig. 2.1.c,2.1.d). 
 
Range in cytotoxicity across the chemicals 
      The chemicals selected for screening were a subset of 1,408 compounds previously tested 
in one or more traditional toxicological assays, and had been profiled for cytotoxicity and 
caspase-3/7 induction by NTP and NCGC using qHTS (Xia et al., 2008) in (i) 13 human and 
rodent cells derived from liver, blood, kidney, nerve, lung, skin; and  (ii) 26 human lymphoblast 
cells (data available from PubChem AID: 963-989). Of these, 240 compounds that were clearly 
active in those experiments were selected for the current study (iii). 
       Comparison of the cytotoxicity average log(curve P) from the current study showed high 
concordance with that in panels (i) and (ii), see above. Pair-wise correlation analysis for the 240 
chemicals across three data sets was highly significant (p<0.0001). High correlation (r=0.87; 
rank correlation=0.83) was observed between lymphoblast panels (ii) and (iii), while the 
correlations with the diverse panel (i) were moderately high (r=0.74 or 0.75; rank 
correlation=0.72 or 0.75 with (ii) and (iii), respectively). Together, the results indicate high 
external reproducibility for this measurement of cytotoxicity and, importantly, the potential 
utility of lymphoblast cell lines as a toll for population-based toxicity screening. 
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Inter-individual variability in response across cell lines 
       In contrast to the highly invariant reproducible results found within individual cell lines, 
the chemicals induced a wide range of responses among the lymphoblast lines. The percentage of 
compounds classified as active in the cytotoxicity assay varied from 28% to 56% (Fig. 2.2a); an 
equally broad range of activity (i.e., 24 to 45%) was seen in the caspase-3/7 assay (Fig. 2.2b). 
Among actives, a wide range of potency, assessed from the curve P, was observed for each cell 
line in both assays (Fig. 2.2c,d). 
       Some chemicals were classified as active for cytotoxicity and caspase-3/7 induction in all 
of the lymphoblast lines, while others were not active for either endpoint (Fig. 2.3a,b). In both 
assays, most chemicals were active in some cell lines while not active in others, indicative of 
inter-individual (cell line) variability in response. The significant correlation (rank 
correlation=0.77; p=2.2E-16; all compounds tested) between the chemical’s average curveP for 
cytotoxicity and caspase-3/7 (Fig. 2.3c) indicates the primary cause of cell death for these 
compounds is most likely via apoptosis. A heatmap shows correlations between average 
log(curveP) for all chemicals in both assays (Fig. 2.3d). Clusters of chemicals with highly 
concordant responses across cell lines were evident for cytotoxicity, apoptosis, or both 
phenotypes. A significant (FDR<5%) correlation between responses in cytotoxicity and 
apoptosis assays was observed for most of the compounds screened.  
       Inter-individual variability in cytotoxicity was visualized using box plots of log(curveP) 
for each chemical (Fig. 2.4a,b). Although median cytotoxicity differed between chemicals tested, 
inter-individual variability was observed even for the most active chemicals. Variance-
components heritability testing for each chemical/assay showed that none of the derived h2 
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statistics was significant after adjusting for multiple comparisons, an observation which was 
confirmed using mid-parent assays’ values compared to those of the offspring (data not shown).  
       Inter-individual (between cell lines) vs. experimental (between replicates) variability for 
each chemical was evaluated using Kruskal-Wallis ANOVA (Kruskal and Wallis, 1952). Most 
chemicals show a significant (FDR<5%) cell line effect (Fig. 2.4c,d). It has been suggested that 
differences in chemical’s toxicity among lymphoblast lines could be partly attributed to 
differences in baseline growth rate and metabolic status (Choy et al., 2008). Correcting for these 
measurements reduces effect correlation that would otherwise make responses across chemicals 
appear more similar. We therefore normalized for control levels of intracellular ATP (e.g., 
metabolic activity) and basal activity of caspase-3/7, as well as for the response of the positive 
control cytotoxicant. In addition, we directly assessed for each chemical whether the basal 
metabolic rate, an endpoint which correlates closely with the growth rate (Choy et al., 2008), 
significantly correlated with cytotoxicity. Approximately80% and 90% of chemicals (Fig. 2.4c,d; 
black dots) exhibited no correlation (FDR>0.05)between basal metabolic rate (ATP level in 
vehicle-treated cells) and cytotoxicity or apoptosis, respectively, across the cell panel.  
 
Assessing relationships between cytotoxicity and genotype 
       With variability among cells from different individuals demonstrated, we then asked if 
we could identify genetic loci responsible, utilizing toxicity phenotypes as quantitative traits and 
publicly available genotypes (International HapMap Consortium, 2005) (Fig. 2.5). The top two 
plots in Figure 5 show p-values for the most significant SNP associated with cytotoxicity (Fig. 
2.5a) or induction of caspase-3/7 (Fig. 2.5b) for each chemical. The inset shows a plot of -
log10(p-values) for SNP-endpoint associations for the selected chemicals. Progesterone had the 
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lowest p-value SNPs on chromosome 9, while Guggulsterones Z (4,17(20)-pregnadiene-3,16-
dione, z-isoform) exhibited many suggestive associations on chromosome 6p. Fig. 2.5c,d provide 
a zoomed-in view of the genomic context for these suggestive regions. 
       Progesterone was not highly cytotoxic, yet showed an appreciable degree of inter-
individual variability in curve P values (Fig. 2.5c inset). A characteristic pattern of SNPs with 
low p-values in linkage disequilibrium is evident in a ~300 kb region containing two genes, 
structural maintenance of chromosomes protein 5 (SMC5) and MAM domain containing 2 
(MAMDC2). Guggulsterone Z, a bioactive constituent of resinous sap from Commiphora mukul, 
is a farnesoid X receptor antagonist and is used widely as a nutraceutical. It is known to suppress 
expression of anti-apoptotic genes, promote apoptosis, and inhibit NF-B (Shishodia and 
Aggarwal, 2004). In our study, it was moderately active in inducing caspase-3/7 (Fig. 2.5d inset) 
and exhibited inter-individual variability. A narrow 100 Kb region on chromosome 6p, 
containing the gene human immunodeficiency virus type I enhancer binding protein 1 (HIVEP1), 
shows association with the apoptosis phenotype. 
 
Dose-response for populations and individuals 
       The availability of cytotoxicity screens on 80+ individuals, with the assays performed 
under controlled conditions, enables sensitive investigation of variation in individual dose-
response profiles (National Research Council, 2008). This concept is illustrated in Fig.2.6a, in 
which the progesterone ATP assay values are shown in grey for each concentration for all 
individuals. Separate logistic curve fits were performed, providing for each individual cell line 
an “effective concentration 10%” (EC10), the estimated concentration at which the response 
deviates by at least 10% from the control baseline, and these are shown as a histogram. The 
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mean of these EC10 values offers a population-wide summary of the activity (e.g., cytotoxicity, 
caspase-3/7) of a chemical, and is very similar to the EC10 produced when the data are first 
pooled for all individuals and then fit using a single dose-response curve (red dashed curve in 
Fig.2.6a). However, aggregation across the population ignores the variability in toxic 
susceptibility, and the EC10 estimated 5th percentile may be used to illustrate the concept of a 
“vulnerable” sub-population. 
       
Defining mode-of-action chemical-perturbed pathways 
       Gene expression data forms another rich source of publicly available data, which can be 
matched with cytotoxicity profiles to provide further evidence of toxicity pathway activity. Many 
of the HapMap cell lines have been profiled for expression in a number of studies, including 
highly sensitive RNA-Seq profiling (Montgomery et al., 2010). For the 42 cell lines for which 
RNA-Seq data are publicly available, expression values for each of ~20,000 genes were 
compared to the caspase-3/7 and cytotoxicity assay results, with a number of highly-significant 
associations. A heatmap of clustering performed on FDR q-values (Fig.2.6b) shows striking 
patterns of gene-chemical relationships, with much of the structure resolving into distinct sets of 
genes associated with sets of chemicals. The results for progesterone are shown as a highly 
specific subgroup, with lymphoblast cytotoxicity for several chemicals being significantly 
associated with background RNA levels for 6 transcripts and several microRNAs. 
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Comparing cytotoxicity of LCLs across different cell lines  
 
We wanted to test the hypothesis that if a chemical causes toxicity, it will have a similar 
toxic effect on different cell lines from different tissues or species. To test this hypothesis we 
compared the cytotoxicity results obtained from specific aim 1 to another two experiments done 
by other researchers that utilized the same chemicals with the same assay in different cell lines. 
The first experiment, labeled twins study (NCGC-U Penn), was a study that exposed 
lymphoblast cell lines from pairs of twins to the same set of chemicals (unpublished data). The 
other experiment was collaboration between NCGC and NTP, and exposed 13 human and rodent 
cell types derived from six common targets of xenobiotic toxicity (liver, blood, kidney, nerve, 
lung, skin) to the same set of chemicals (Xia et al. 2008a).  
A pairwise correlation between the cytotoxic response (curve P) of common screened 
chemicals across our 81 cell lines in our experiment, paired twin lymphoblast cell lines in U 
Penn study, and the 13 cell lines in the NTP study showed significant correlation (Spearman rank 
correlation of 0.83 and 0.75 respectively) (Fig 2.7).  
We picked the 30 most toxic chemicals in our panel and plotted the range of toxicity 
expressed by Curve P across cell lines for each study in a box and whisker plot shown in (Fig 
2.8). While the median of cytotoxicity was similar in all the three studies, the range across tested 
cell lines was largest among the 13 cell type study coming from rodents and humans. Both LCL 
studies had similar range of cytotoxicity (Fig 2.8). 
 
 
 
 
 52 
 
E. DISCUSSION 
 
       New paradigms for the rapid and accurate evaluation of the potential health hazard from 
environmental chemicals are needed, given the large number of environmental chemicals to be 
evaluated, and the high cost and low throughput of traditional toxicity testing approaches 
(Collins et al., 2008). Development of in vitro toxicity tests that can be utilized in a tiered 
framework is necessary, feasible and consistent with the needs of scientifically-rigorous high-
throughput risk assessment (Kavlock et al., 2009). A particular challenge in developing such 
next-generation toxicity testing schemata is the assessment of differential susceptibility among 
individuals.  The results presented here provide proof of principle of such a testing system, 
demonstrating the feasibility and utility of screening a panel of cells from genetically diverse 
individuals, whereby both population-wide and individual responses can be evaluated. 
       The in vitro toxicity screening paradigm detailed here has focused on a population-based 
cell culture model, an approach that affords several key benefits compared to collections of 
unrelated cell lines from different species and tissues (Xia et al., 2008). Our results show that 
many chemicals exhibit inter-individual variation in induction of toxicity and this information is 
crucial for chemical testing prioritization. This screening paradigm also provides quantitative 
data on population-wide variability in toxicity which may be used to establish data-driven 
uncertainty estimates when extrapolating from in vitro data to potential in vivo toxicity (Judson 
et al., 2011). Even though the data collected herein is on a limited population (81 individuals), it 
is immediately interpretable for ranking and prioritizing chemicals. For example, a population-
based view of dose-response is an important concept that directly addresses the issue of sub-
populations (National Research Council, 2008); however, actual experimental data-driven 
implementation has been limited. We reason that the population-based concentration-response in 
 53 
 
vitro qHTS data allows for the development of models to estimate in vitro point-of-departure and 
safety/uncertainty factors (Crump et al., 2010), because variation between genetically-defined/-
diverse cell lines may be treated as reflective of that among individuals. The recognition of 
underlying genetic causes may further enhance extrapolation and understanding of the shape of 
the dose-response relationships. In addition, the data may be used to explore potential 
differences/similarities in modes of action between chemicals on the population-wide level. 
 By combining toxicity data with publicly available genetic information, such as that 
provided by the HapMap (International HapMap Consortium, 2005), 1000 Genomes (Durbin et 
al., 2010), and public RNA sequencing projects (Montgomery et al., 2011), it is possible to probe 
the contribution of genomics to toxicity phenotypes. Such an approach represents a substantial 
savings of cost and time, capitalizing on the extensive prior characterization of these samples. 
Accordingly, we have begun to explore variation in toxicity susceptibility as a function of 
genotype, as well as the relationship between toxic response and basal expression profiles.  
       Genotype-phenotype relationships are likely to reflect causal action of underlying 
physiological variation, and are thus of great interest to epidemiologists for understanding the 
ultimate sources of population variation. However, the effect sizes are typically small, as has 
been the source of considerable discussion in the genomics community (Manolio et al., 2009). 
Variation in basal mRNA expression, in contrast, may reflect cascades of responses controlled 
by the underlying genotype, and typically involves a smaller multiple testing penalty. Thus, we 
likely have more power to detect association of expression with toxicity response phenotypes, 
even though the underlying causality relationships may remain elusive. The highly significant 
associations identified through the analysis of population-level correlations between basal gene 
expression variability and chemical-induced toxicity have revealed several reasonable mode of 
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action hypotheses. For example, the in vitro toxicity of 1,3-indandione-containing rodenticides 
has been shown to occur through the inhibition of the pyrimidine synthetic pathway(Hall et al., 
1994), and thioredoxin reductase (e.g., TXNRD3IT1) is required for dNTP pool maintenance 
during S phase (Koc et al., 2006). Expression of somatostatin receptor (SSTR)4 correlates with 
progesterone receptor levels in human breast tumors (Kumar et al., 2005). Thioredoxin reductase 
affects expression of progesterone receptor-controlled genes in MCF-7 cells (Rao et al., 2009). 
       Similarly, the quantitative assessment of inter-individual genetic variability in responses 
to environmental agents in vitro demonstrates the potential of this approach to explore the 
genetic basis for susceptibility through genome-wide association analysis. The genes SMC5 and 
MAMDC2 implicated in this study as associated with progesterone-induced toxicity are highly 
plausible and belong to pathways critical for development. The same locus was reported as 
associated with developmental abnormalities cleft palate and Kabuki syndrome (Kuniba et al., 
2009; Marazita et al., 2004), and exposure to progesterone during gestation is known to cause 
cleft palate in rabbits (Andrew and Staples, 1977). Likewise, the association between 
Guggulsterone Z and polymorphisms in HIVEP1 is highly credible, given the known effects of 
Guggulsterone Z on apoptosis through NF-B-related signaling (Shishodia and Aggarwal, 2004). 
HIVEP1 belongs to a family of large zinc finger-containing transcription factors that bind 
specifically to the NF-B motif and related sequences (Yu et al., 2009). The alternative splice 
variant of HIVEP1, the GAAP-1 protein, can regulate p53 and IRF-1 dependent cell 
proliferation and apoptosis (Lallemand et al., 2002).  
       Important limitations to in vitro toxicity profiling using lymphoblasts, as compared to 
primary cells that may be obtained from other tissues of interest, include inability to assess target 
organ adverse effects, or a potential role of other environmental factors such as lifestyle, diet, or 
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co-exposures. In addition, the challenge of assessing the potential toxicity of chemical’s 
metabolites, or the potential lack of the receptor-mediated signaling that may be critical for the 
downstream adverse molecular events, in lymphoblast cell lines also should be taken into 
consideration when interpreting the data. Still, whereas lymphocytes do not have the metabolic 
capacity of the liver, or even that of freshly isolated hepatocytes, they do express a number of 
nuclear receptors, as well as most genes of the phase I and II metabolism, and transporters (Siest 
et al., 2008). A comparison of the population-wide (250+ individuals of various races, ages and 
gender) variability in mRNA levels for several dozen liver-specific thyroid hormone-related 
genes between human liver (Schadt et al., 2008) and lymphoblast cell lines (Stranger et al., 2007) 
shows that most of the nuclear receptors and metabolism genes are expressed in lymphoblasts, 
albeit at 10- to 100-times lower quantity. Importantly, the between-subject variability in 
expression of these genes in either human liver or lymphoblasts is also of appreciable magnitude 
(4- to 10-fold). To overcome these limitations, both higher concentrations and known 
metabolites can be tested in vitro because of high throughput. Correcting for the cell growth rate 
and baseline metabolic rate also reduces effect correlation that may make responses across 
chemicals appear more similar (Choy et al., 2008). 
       Based on these results, we reason that a full and sensitive analysis of genomic predictors 
of toxicity response will be feasible through the joint use of toxicity phenotypes, genotype and 
expression information, though considerably larger sample sizes– likely on the order of several 
hundred or 1000s of individual cell lines – will be necessary. Such a population-based in vitro 
survey would greatly advance our understanding of the genetic underpinnings of susceptibility-
related regulatory networks, and is ongoing in our laboratories. 
 
 56 
 
FIGURES 
 
 
Figure 2.1. Experimental Reproducibility.Intra-experimental reproducibility for cytotoxicity 
(panels a and c) and caspase-3/7 (panels b and d) assays. Panels a and b show log(curve P) 
values for randomly selected pairs of replicate plates within each chemical and cell line (240 
chemicals x 81 cell lines=19,440 replicate pairs displayed). Panels c and d show side-by-side 
boxplots for eight duplicate compounds that were tested in 2 independent wells on each plate.  
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Figure 2.2. Cytotoxicity Distributions across Chemicals. Distribution of cytotoxicity across 
chemicals for cytotoxicity (panels a and c) and caspase-3/7 (panels b and d) assays. Panels a and 
b give the percentage of chemicals classified as ‘active’, ‘non-active’, or ‘inconclusive’ for each 
cell line. Panels c and d give the range of potency (curve P) for active chemicals in each cell line. 
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Figure 2.3. Cytotoxicity Distributions across Cell Lines. The percent of cell lines exhibiting 
activity for each chemical for cytotoxicity (panel a) and caspase-3/7 (panel b) assays. Panel c 
displays the rank of the mean ATP curve P value versus the mean caspase curve P value for each 
chemical. Panel d shows a heatmap of the correlations between log(curve P) values for all 
chemical-assay combinations. 
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Figure 2.4. Inter-individual Variability Range for the 240 Chemicals. Boxplots of curve P 
values for each of the 240 chemicals (arranged by mean activity) across the 81 cell lines are 
shown for cytotoxicity (panel a) and caspase-3/7 (panel b) assays. For cytotoxicity (panel c) and 
caspase-3/7 (panel d) assays, –log(p-values, Kruskal-Wallis test) were plotted against mean 
 60 
 
curveP (µM). The blue line gives a False Discovery Rate-adjusted significance threshold 
(FDR=0.05). Chemicals colored in red had a significant correlation between activity and basal 
metabolic rate (ATP level in vehicle-treated cells) across the panel of cell lines (Spearman rank 
correlation; FDR<0.05). 
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Figure 2.5. Toxicity-Genotype Associations. Toxicity-genotype relationships were assessed 
using GWAS analysis for the 240 chemicals on both cytotoxicity (panels a and c) and caspase-
3/7 (panels b and d) assays. Panels a and b give p-values for the most significant SNP associated 
with toxicity for each chemical. The inset in the diagram gives –log(p-values) for SNP-toxicity 
associations across the entire genome, for progesterone (cytotoxicity assay, inset in panel a) and 
Guggulsterones Z (caspase-3/7 assay, inset in panel b). Panels c and d provide a zoomed-in look 
at the locus with the most significant p-value for each of the two compounds, respectively. 
Correlation between SNPs is identified with colors. SNP and gene tracks are also shown. Inset: 
box & whiskers plots for each compound’s curve P. 
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Figure 2.6. Toxicity-RNA expression Associations. Panel a, a population concentration-
response was modeled using in vitro qHTS data using progesterone data (cytotoxicity assay) as 
an example. Logistic dose-response modeling was performed for each individual to the values 
shown in grey, providing individual 10% effect effective dose values (EC10). The EC10 
obtained by performing the modeling on average assay values for each dose (see frequency 
distribution) are shown in the inset. Panel b, a heatmap of clustered false discovery rates (q-
values, see color bar) for association of the data from caspase-3/7 assay with publicly-available 
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RNA-Seq expression data on a subset of cell lines. A sample subcluster containing progesterone 
is also shown. 
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Figure 2.7. Comparison of Cytotoxicity across Different Studies. Cytotoxicity across 
different cells from different organs and species. A scatter plot of pairwise correlation between 
the cytotoxic response (curve P: the lowest concentration, which showed a consistent deviation 
from the baseline response and derived as detailed in Sedykh et al. (Sedykh et al. 2011) of 
common screened chemicals across our 81 cell lines in our experiment, paired twin lymphoblast 
cell lines in U Penn study, and the 13 cell lines in the NTP study. 
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Figure 2.8. Comparison of Cytotoxicity Range across Different Studies. Boxplot of 30 most 
toxic chemicals in our experiments across cell lines in each study. White represents UNC-
NCGC-NTP study, blue represents U-Penn-NCGC twins study, and red represents NCGC-NTP 
13 cell lines study. We picked the 30 most toxic chemicals in our panel and plotted the range of 
toxicity expressed by CurveP across cell lines for each study in a box and whisker plot shown. 
This is the blue color coded box, and is cited as the first experiment (see comment above).The 
first experiment, labeled twins study (NCGC-U Penn), was a study that exposed lymphoblast cell 
lines from pairs of twins to the same set of chemicals (unpublished data). The other experiment 
was collaboration between NCGC and NTP, and exposed 13 cell lines coming from humans and 
rodents to the same set of chemicals (Xia et al. 2008a). 
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Table 2.1 List of 240 Screened Chemicals 
Sequence 
ID 
Screening ID 
(CID) 
CASRN Chemical Name 
1 AB02509330-01 59870 Nitrofurazone 
2 AB02509332-01 25152845 2,4-Decadienal 
3 AB02509368-01 148243 8-Hydroxyquinoline 
4 AB02509400-01 77439760 3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone, (MX) 
5 AB02509551-01 126987 Methacrylonitrile 
6 AB02540517-01 65646686 4-Hydroxyphenyl retinamide 
7 AB02540519-01 7789120 Sodium dichromate dihydrate (VI) 
8 AB02540526-01 34256821 Acetochlor 
9 AB02540527-01 7778509 Potassium dichromate 
10 AB02540528-01 127479 all-trans-Retinyl acetate 
11 AB02540529-01 75330755 Lovastatin 
12 AB02540531-01 148823 Melphalan 
13 AB02540538-01 15972608 Alachlor 
14 AB02540539-01 15663271 cis-Dichlorodiamine platinum 
15 AB02540542-01 72559069 Rifabutin 
16 AB02540564-01 458377 Curcumin 
17 AB02540565-01 54965241 Tamoxifen, citrate salt 
18 AB02540575-01 55981094 Nitazoxanide 
19 AB02540576-01 7220793 Methylene blue trihydrate 
20 AB02540577-01 25316409 Adriamycin, hydrochloride 
21 AB02540586-01 10026241 Cobalt sulfate heptahydrate 
22 AB02540589-01 140647 Pentamidine isethionate 
23 AB02540601-01 1.6E+08 Nelfinavir mesylate 
24 AB02911345-01 142836 2,4-Hexadienal 
25 AB02911369-01 1948330 tert-Butylhydroquinone 
26 AB02911410-01 91532 Ethoxyquin 
27 AB02911423-01 116063 Aldicarb 
28 AB02914401-01 50760 Actinomycin D 
29 AB07859937-01 20830755 Digoxin 
30 AB07930213-01 57830 Progesterone 
31 AB07930229-01 17924924 Zearalenone 
32 AB07930241-01 123308 p-Aminophenol 
33 AB07930243-01 97187 2,2'-Thiobis(4,6-dichlorophenol) 
34 AB07930251-01 472866 13-cis-Retinal (Vitamin A aldehyde) 
35 AB07930253-01 61702441 2-Chloro-p-phenylenediamine SO4 
36 AB07930263-01 95067 Sulfallate 
37 AB07930274-01 446866 Azathioprine 
38 AB07930275-01 533744 Dazomet 
39 AB07930277-01 879390 2,3,4,5-Tetrachloronitrobenzene 
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Sequence 
ID 
Screening ID CASRN Chemical Name 
40 AB07930285-01 2243767 Alizarin Yellow R, sodium salt 
41 AB07930286-01 520365 Apigenin 
42 AB07930288-01 961115 Tetrachlorvinphos (Gardona) 
43 AB07930292-01 115093 Methyl mercuric (II) chloride 
44 AB07930298-01 320672 5-Azacytidine 
45 AB07931485-01 83261 2-Pivalyl-1,3-indandione 
46 AB07934770-01 74317 N,N'-Diphenyl-p-phenylenediamine 
47 AB07935027-01 396010 Triamterene 
48 AB07935479-01 24169026 Econazole nitrate 
49 AB07935653-01 154427 6-Thioguanine (6-TG) 
50 AB07935671-01 130267 Iodochlorohydroxyquinoline 
51 AB07935672-01 123319 Hydroquinone 
52 AB07935817-01 612839 3,3'-Dichlorobenzidine 2HCl 
53 AB07935832-01 95545 o-Phenylenediamine 
54 AB07944034-01 104405 p -n -Nonylphenol 
55 AB07944048-01 10108642 Cadmium II chloride 
56 AB07944059-01 65558692 1,3-Diiminobenz (f)-isoindoline 
57 AB07944071-01 77929 Citric Acid 
58 AB07944077-01 818611 Hydroxyethyl acrylate 
59 AB07944095-01 102363 3,4-Dichlorophenyl isocyanate 
60 AB07944097-01 10563298 dimethyldipropylene-triamine 
61 AB07944109-01 446355 2,4-Difluoronitrobenzene 
62 AB07944128-01 66819 Cycloheximide 
63 AB07944329-01 143500 Kepone 
64 AB07944331-01 538716 Domiphen bromide 
65 AB07944340-01 9002931 Triton X-100 
66 AB07944343-01 64868 Colchicine  
67 AB07944355-01 50022 Dexamethasone 
68 AB07944366-01 14866332 tetra-N-Octylammonium bromide 
69 AB07944367-01 140727 Cetylpyridinium bromide 
70 AB07944368-01 57830 Progesterone 
71 AB07944378-01 55561 Chlorhexidine 
72 AB07944380-01 549188 Amitriptyline HCl 
73 AB07944388-01 68047063 4-Hydroxytamoxifen 
74 AB07944390-01 152114 Verapamil HCl 
75 AB07944392-01 17831719 Tetraethylene glycol diacrylate 
76 AB07944400-01 17924924 Zearalenone 
77 AB07944404-01 133062 Captan 90-concentrate (solid) 
78 AB07944715-01 62384 Phenyl mercuric acetate 
79 AB07944716-01 13463417 Zinc pyrithione 
80 AB07944719-01 66819 Cycloheximide 
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81 AB07944721-01 106514 p-Quinone 
82 AB07944724-01 100425 Styrene 
83 AB07944726-01 463401 Linolenic acid 
84 AB07944736-01 110576 trans-1,4-Dichloro-2-butene 
85 AB07944738-01 1191419 Ethyl linolenate 
86 AB07944741-01 67970 Vitamin D3 
87 AB07944749-01 116314 trans-Retinal (Vitamin A aldehyde) 
88 AB07944762-01 134327 1-Naphthylamine 
89 AB07944765-01 5153673 beta-Nitrostyrene 
90 AB07944785-01 111308 Glutaraldehyde (Glutaric dialdehyde) 
91 AB07944787-01 548629 Hexamethyl-p-rosaniline chloride (Gentian violet) 
92 AB07944788-01 379793 Ergotamine tartrate 
93 AB07944790-01 305033 Chlorambucil 
94 AB07944791-01 485472 Ninhydrin 
95 AB07944800-01 3018120 Dichloroacetonitrile 
96 AB07949036-01 105113 p-Quinone dioxime (p-Benzoquinone dioxime) 
97 AB07949142-01 72140 Sulfathiazole 
98 AB07949247-01 90415 2-Aminobiphenyl 
99 AB07949372-01 100221 N,N,N',N'-Tetramethyl-p-phenylenediamine 
100 AB07975480-01 517282 Hematoxylin (C.I. 75290) 
101 AB07976081-01 2451629 Tris(2,3-epoxypropyl)isocyanurate 
102 AB07980848-01 95556 o-Aminophenol 
103 AB07980929-01 70304 Hexachlorophene 
104 AB07980947-01 2016888 Amiloride HCl 
105 AB07980958-01 66717 o-Phenanthroline 
106 AB07980986-01 532274 Chloroacetophenone 
107 AB07981003-01 2425798 1,4-Butanediol diglycidyl ether 
108 AB07981015-01 4074888 Diethylene glycol diacrylate 
109 AB07981053-01 81550 1,8-Dihydroxy-4,5-dinitroanthraquinone 
110 AB07981054-01 62737 Dichlorvos (Vapona) 
111 AB07981076-01 58140 Pyrimethamine 
112 AB07981077-01 610399 3,4-Dinitrotoluene 
113 AB07981167-01 2465272 Auramine 
114 AB07981200-01 74975 Bromochloromethane 
115 AB07981244-01 99989 N,N-Dimethyl-p-phenylenediamine 
116 AB07981253-01 764421 Fumaronitrile 
117 AB07981260-01 71589 Medroxyprogesterone acetate 
118 AB07981274-01 33229344 HC blue 2 
119 AB07981291-01 50555 Reserpine 
120 AB07981301-01 118752 Chloranil 
121 AB07981317-01 13048334 1,6-Hexanediol diacrylate 
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122 AB07981330-01 4252782 2,2',4'-Trichloroacetophenone 
123 AB07981368-01 120809 Catechol (1,2-Benzenediol) 
124 AB07981464-01 496720 3,4-Diaminotoluene 
125 AB07981614-01 1465254 N-(1-Naphthyl)ethylenediamine 2HCl 
126 AB07981816-01 569619 Basic red 9 (p-Rosaniline HCl) (C.I. 42500) 
127 AB07981842-01 87683 Hexachloro-1,3-butadiene 
128 AB07981866-01 113928 Chlorpheniramine maleate 
129 AB07985231-01 6459945 Acid red 114 (C.I. 23635) 
130 AB07985248-01 97234 2,2'-Methylenebis-(4-chlorophenol) 
131 AB07985261-01 393759 4-Chloro-3,5-dinitro-a,a,a-trifluorotoluene 
132 AB07985289-01 1675543 Bisphenol A diglycidyl ether 
133 AB07985291-01 156105 p-Nitrosodiphenylamine 
134 AB07985305-01 992596 Direct red 2 (C.I. 23500) 
135 AB07985346-01 93050 N,N-Diethyl-p-phenylenediamine 
136 AB07985386-01 133062 Captan 
137 AB07990164-01 51218 5-Fluorouracil 
138 AB07990179-01 60571 Dieldrin 
139 AB07990183-01 2213630 2,3-Dichloroquinoxaline 
140 AB07990199-01 834286 Phenformin HCl 
141 AB07990229-01 84695 Diisobutyl phthalate 
142 AB07990272-01 117102 Danthron 
143 AB07990332-01 64868 Colchicine 
144 AB07990339-01 137304 Ziram 
145 AB07990348-01 55550 N-Methyl-p-aminophenol sulfate 
146 AB07990352-01 140498 4'-(Chloracetyl)acetanilide 
147 AB07990366-01 1239458 Ethidium bromide 
148 AB08000887-01 3252435 Dibromoacetonitrile 
149 AB08001062-01 434071 Oxymetholone 
150 AB08001092-01 3524683 Pentaerythritol Triacrylate 
151 AB08001212-01 12789036 Chlordane, technical grade 
152 AB08001301-01 20562021 a-Solanine 
153 AB08001481-01 70257 N-Methyl-N'-nitro-N-nitrosoguanidine 
154 AB08001574-01 630160 1,1,1,2-Tetrabromoethane 
155 AB08002009-01 13311847 Flutamide 
156 AB08002746-01 6983795 Bixin 
157 AB08002778-01 148243 8-Hydroxyquinoline 
158 AB08002816-01 2437298 Malachite Green Oxalate 
159 AB08002895-01 1.5E+08 Saquinavir Mesylate 
160 AB08002899-01 7789120 Sodium Dichromate Dihydrate 
161 AB08003367-01 73314 Melatonin 
162 AB08003603-01 930687 2-Cyclohexen-1-one 
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163 AB08003789-01 98293 p-tert Butylcatechol 
164 AB08003879-01 598914 Dibromonitromethane 
165 AB08003920-01 13473262 D&C Red Dye 27 
166 AB08006114-01 538750 1,3-Dicyclohexylcarbodiimide 
167 AB08006121-01 115297 Endosulfan 
168 AB08006152-01 96695 4,4-Thiobis(6-t-butyl-m-cresol) 
169 AB08006174-01 1948330 t-Butylhydroquinone 
170 AB08006184-01 67209 Nitrofurantoin 
171 AB08006209-01 87661 Pyrogallol 
172 AB08006212-01 481403 1,4,5-Trihydroxynaphthalene 
173 AB08006314-01 76448 Heptachlor 
174 AB08006839-01 57976 7,12-Dimethylbenz(a)anthracene 
175 AB08006849-01 2373980 3,3'-Dihydroxybenzidine 
176 AB08007015-01 6317186 Methylene bis(thiocyanate) 
177 AB08007268-01 121540 Benzethonium chloride 
178 AB08007382-01 1402260 Cadmium acetate, dihydrate 
179 AB08007516-01 518821 Emodin (bulk) 
180 AB08007549-01 23541506 Daunomycin HCL 
181 AB08007607-01 50282 17-beta-Estradiol 
182 AB08007613-01 77474 Hexachlorocyclopentadiene 
183 AB08007614-01 6338416 5-(Hydroxymethyl)-2-furoic acid 
184 AB08007627-01 793248 n-(1,3-Dimethylbutyl)-n`-phenyl-p-phenylenediamine 
185 AB08080834-01 137268 Tetramethylthiuram disulfide 
186 AB08080836-01 95852 2-Amino-4-chlorophenol 
187 AB08080842-01 6088513 6-Hydroxy-2-naphthyl disulfide (DDD) 
188 AB08080844-01 7487947 Mercuric chloride 
189 AB08080867-01 95841 2-Amino-4-methylphenol 
190 AB08080883-01 117793 2-Aminoanthraquinone 
191 AB08080892-01 1074120 Phenyl glyoxal 
192 AB08080909-01 1271198 Titanocene dichloride 
193 AB08080916-01 6112761 6-Mercaptopurine monohydrate 
194 AB08082658-01 100276 p-Nitrophenethyl alcohol 
195 AB08082669-01 95830 4-Chloro-o-phenylenediamine 
196 AB08082688-01 762754 t-Butyl formate 
197 AB08082706-01 138896 N,N-Dimethyl-p-nitrosoaniline 
198 AB08082716-01 21829254 Nifedipine 
199 AB08082717-01 1260179 Carminic acid 
200 AB08082719-01 619238 m-Nitrobenzyl chloride 
201 AB08082743-01 612237 o-Nitrobenzyl chloride 
202 AB08097184-01 58548 Ethacrynic acid 
203 AB08548260-01 12083486 Bis(cyclopentadienyl)vanadium chloride 
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204 AB08548266-01 80159 Cumene hydroperoxide 
205 AB08548274-01 1338234 Methyl ethyl ketone peroxide 
206 AB08548279-01 1271289 Nickelocene 
207 AB08548292-01 933788 2,3,5-Trichlorophenol 
208 AB08548310-01 68268 trans-Retinol acid (Vitamin A) 
209 AB08548314-01 17831719 Tetraethylene glycol diacrylate 
210 AB08548322-01 106898 1,2-Epoxy-3-chloropropane (Epichlorohydrin) 
211 AB08548327-01 143500 Chlordecone (Kepone) 
212 AB08548342-01 101906 Diglycidyl resorcinol ether 
213 AB08548344-01 70348 1-Fluoro-2,4-dinitrobenzene 
214 AB08548348-01 101962 N,N'-Di-sec-butyl-p-phenylenediamine 
215 AB08582918-01 11024241 Digitonin 
216 AB08582919-01 6219892 4-Amino-4'-hydroxy-3-methyldiphenylamine 
217 AB08582920-01 101724 N-Isopropyl-N'-phenyl-p-phenylenediamine 
218 AB08582927-01 4901513 2,3,4,5-Tetrachlorophenol 
219 AB08582929-01 55867 Nitrogen mustard HCl 
220 AB08582931-01 97325 4-Methoxy-3-nitro-N-phenylbenzamide 
221 AB08582933-01 1421632 2'4'5'-Trihydroxybutyrophenone 
222 AB08582939-01 123773 Azodicarbonamide 
223 AB08582940-01 52417228 9-Aminoacridine HCl H2O 
224 AB08582944-01 7779308 1-(2,6,6-Trimethyl-2-cyclohexen-1-yl)-1-penten-3-one 
225 AB08582948-01 63923 Phenoxybenzamine HCl 
226 AB08582953-01 55566308 Tetrakis(hydroxymethyl)phosphonium SO4 
227 AB08582961-01 5493458 1,2-Cyclohexanedicarboxylic acid, bis(oxiranylmethyl) ester 
228 AB08582965-01 609198 3,4,5-Trichlorophenol 
229 AB08582970-01 103333 Azobenzene 
230 AB08582976-01 26530201 2-Octyl-3-isothiazolone 
231 AB08582980-01 97245 2,2'-Thiobis(4-chlorophenol) 
232 AB08582982-01 8001352 Toxaphene 
233 AB08582989-01 309002 Aldrin 
234 AB08582998-01 478433 Rhein (1,8-Dihydroxy-3-carboxylanthraquinone) 
235 AB08583000-01 633658 Berberine chloride 
236 AB13681039-01 39025235 Guggulsterones Z 
237 AB13681051-01 39025246 Guggulsterones E 
238 AB13681075-01 3155575 Dihydromethysticin 
239 AB13681076-01 18642449 Actein 
240 CONTROL 62996741 Staurosporine 
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A. ABSTRACT  
Background: Important gaps exist in our understanding of human variation in response to 
toxic environmental chemicals. Objectives: To address this critical need in next generation 
risk assessment, we tested a hypothesis that population-wide in vitro cytotoxicity screening 
has the potential to assess both the magnitude of and molecular causes for inter-individual 
genetic variability in toxicity of chemicals. Methods: We used 1086 lymphoblastoid cell 
lines, representing 9 populations from 5 continents, drawn from the 1000 Genomes Project to 
assess variation in cytotoxic responses to 179 chemicals used as phenotypes. The analysis 
included ranking of chemicals by average response and assessments of population variation 
and heritability, information that is immediately applicable to human health assessment of 
chemical toxicity. Genome-wide association mapping was also performed, with attention to 
phenotypic relevance to human exposures. Results: The extent of inter-individual variability 
in cytotoxicity was <10-fold for about 2/3 of the compounds; however, some compounds 
exhibited >100-fold range in variability. Genetic mapping suggested important roles for 
variation in membrane and trans-membrane genes with a number of chemicals showing 
association with rs13120371 in the solute carrier SLC7A11, which has been implicated in 
chemoresistance. Analysis of public RNA-sequencing profiles on the same cell lines 
provided evidence of association between basal transcription and cytotoxic response, with 
enrichment for genes with membrane localization. Conclusions: This experimental approach 
fills critical gaps of most recent large-scale toxicity testing programs by providing 
quantitative experimentally-based confidence intervals for estimating chemical hazard and 
variability, as well as generating testable hypotheses about potential mechanisms of toxicity.  
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B. INTRODUCTION  
During the last decade, considerable progress has been made in high-throughput 
approaches for toxicity testing to address the challenges posed by (i) the expense and ethical 
constraints in animal testing; (ii) uncertainties in applicability of animal models to human 
susceptibility, and (iii) a large and increasing number of chemicals, many of which have never 
been subjected to adequate toxicity testing, and to which humans are exposed.  Reports by the 
National Research Council (National Research Council 2007) and other prospective statements 
(Collins et al. 2008) have articulated a vision for the use of biochemical- and cell-based assays in 
a high throughput screening format to screen chemicals, providing an improved understanding of 
toxicity response and modes of action.  The in vitro testing of human cell lines meets human 
relevance standards (Collins et al. 2008) while serving as a bridge to targeted in vivo assessment.  
Beyond characterizing an “average” response to chemicals, another goal of next-generation 
toxicity testing is to provide an improved understanding of population variability in 
susceptibility, to identify vulnerable subpopulations, and to refine uncertainty factors used in 
regulatory risk assessment (Zeise et al. 2013). 
The Tox21 initiative (Tice et al. 2013) is conducting automated systematic screening of 
thousands of chemicals against hundreds of molecular and cellular toxicity phenotypes.  Cell-
based assays for cell viability are an established approach to prioritize chemicals for further 
evaluation or to classify into hypothesized modes of action (Huang et al. 2008).  However, for 
environmental chemicals the number of cell lines used in these assays has typically been limited 
to several dozen (Lock et al. 2012; O'Shea et al. 2011), sometimes representing multiple species 
(Xia et al. 2008).  Thus, an understanding of human population variability and, in particular, the 
role of constitutional genetic variation remains elusive.  Epidemiological approaches to these 
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questions have also been limited to a relatively few chemicals with high occupational or other 
exposure (Zeise et al. 2013), and have mainly quantified the effects of drug metabolizing 
enzymes (Ginsberg et al. 2009). Furthermore, an epidemiological approach provides little basis 
to compare directly across chemicals, including new chemicals with little to no exposure or 
potential toxicity information. 
Screening of lymphoblastoid cell lines (LCLs) is an established approach to identify 
genetic variants influencing cytotoxic response to pharmaceuticals, especially chemotherapeutic 
agents (Wheeler and Dolan 2012). Choy et al. (Choy et al. 2008) had challenged the value of 
these approaches, primarily due to potential confounding influences, including growth rates and 
batch effects. However, enrichment of human blood eQTLs has been established among weakly 
significant chemotherapeutic drug susceptibility loci (Gamazon et al. 2010).  With the advent of 
statistical methods purpose-built for cytotoxicity profiling (Brown et al. 2012a), several robust 
associations were identified (Brown et al. 2014). 
For environmental chemicals, quantifying the extent of population variation in 
cytotoxicity is of great interest, potentially providing data to inform uncertainty factors in risk 
assessment (Zeise et al. 2013).  Direct connections to human risk assessment must consider 
genetic variation in cytotoxic response at relatively low concentrations relevant to human 
exposure (Baynes 2012). This goal may conflict somewhat with maximization of power to 
identify specific genotype-susceptibility associations, as the effects of genetic variation may be 
apparent only at concentrations higher than human-relevant exposure. Furthermore, for both 
these goals, the number of cell lines used in past studies of environmental chemical cytotoxicity 
has often been inadequate to establish population variation, or to assess genetic association for 
these complex traits with small effect.   
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Here, we describe profiling 1086 LCLs for cytotoxic response to 179 chemicals, each 
assayed over a range of 8 concentrations spanning six orders of magnitude.  The compounds 
were primarily chemicals of environmental concern, cover a wide range of in vivo toxicity 
hazards, and were drawn from a larger set of 1408 compounds used for high-throughput 
screening (Lock et al. 2012; O'Shea et al. 2011; Xia et al. 2008).  The LCLs were selected from 
the 1000 Genomes Project (1000 Genomes Project Consortium et al. 2012) spanning a variety of 
ancestral populations.  Cytotoxic response was assessed using an effective concentration 10% 
(EC10) and genome-wide association mapping was performed using both EC10 and with an 
omnibus test using the entire 8-concentration profile as a multivariate vector. 
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C. MATERIALS AND METHODS  
Chemicals and cytotoxicity profiling. Chemicals were chosen as a subset of the National 
Toxicology Program’s 1408 chemical library. Chemicals were dissolved with dimethyl sulfoxide 
(DMSO) into 8 stock concentrations and were transferred into 1536-well plate format via a pin 
tool station (Kalypsys, San Diego, CA). The final concentrations ranged from 0.33 nM to 92 µM. 
The negative control was DMSO at 0.46% vol/vol; the positive control was tetra-octyl-
ammonium bromide (46 µM). The CellTiter-Glo Luminescent Cell Viability (Promega, 
Madison, WI) assay was used to assess intracellular ATP concentration, a marker for 
viability/cytotoxicity, 40 h post treatment. A ViewLux plate reader (PerkinElmer, Shelton, CT) 
was used to detect luminescent intensity in each well of the assay plates. 
Cell lines. A set of 1104 immortalized lymphoblastoid cell lines established by the HapMap 
Consortium and the 1000 Genomes Project (1000 Genomes Project Consortium et al. 2012) was 
acquired from Coriell (Camden, NJ). Out of the 1104, 401 cell lines were related individuals of 
trios (both parents and child). Cell lines were randomly divided into screening batches with equal 
distribution of populations and gender in each batch and without regard to family structure. Cells 
were cultured at 37⁰C with 5% CO2 in RPMI 1640 media (Invitrogen, Carlsbad, CA) 
supplemented with 15% fetal bovine serum (HyClone, South Logan, UT) and 100U/ml 
penicillin/100mg/ml streptomycin (Invitrogen). Media was replaced every 3 days. Cells were 
grown to a concentration of up to 10
6
 cells/ml and viability of >85% before treatment. Cells were 
plated into a tissue culture–treated 1536-well white/solid bottom assay plates (Greiner Bio-One 
North America, Monroe, NC) at 2000 cells/5 µl/well using a flying reagent dispenser 
(BioRAPTR FRD dispenser, Beckman Coulter, Carlsbad, CA). Each cell line was seeded on 
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multiple plates (1-2 plates per batch and/or between batches) so that each compound was 
screened in each cell line on 1-2 plates (all chemicals were fit to a single plate). 
Genotypes.  The primary source of genotypes was the Illumina HumanOmni2.5 platform for 
1000 Genomes (http://www.1000genomes.org  and 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20120131_omni_genotypes_and_inte
nsities), available for >90% of the samples. SNPs with a call rate below 95%, minor allele 
frequency (MAF)<0.01, or HWE p-value<1x10
-6
 were excluded.  From the original 1086 
samples, a maximal subset of 884 was chosen so as to remove first-degree relatives (‘unrelated’ 
set) using a combination of genotypes and sample annotation.  Of the 884 samples, genotyped 
SNPs from the Illumina HumanOmni2.5 platform were available for 761 samples.  The 
remaining 123 samples had been genotyped as part of the HapMap project 
(http://hapmap.ncbi.nlm.nih.gov/downloads/genotypes/hapmap3_r3/plink_format), and were 
imputed for the set of filtered Illumina SNPs using the MACH software.  A subset from a larger 
1000 Genomes set (totaling 875 samples, not restricted to these cell lines) were used as a 
reference for this genotype imputation. The final set of 1.3m SNPs were used for primary 
analysis. A further subset of 690 unrelated individuals represented Phase I individuals from 1000 
Genomes (1000 Genomes Project Consortium et al. 2012), with more complete sequencing data 
available. After applying the quality filters, a total of 12m SNPs remained. 
Cytotoxicity EC10 estimation and outlier detection. Cytotoxicity data were normalized relative 
to positive/negative controls as described. Although the primary method for association mapping 
was based on a multivariate treatment of the cytoxocity response values across the entire set of 
dose concentrations for each chemical, it is convenient for other analyses to provide a single 
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cytotoxicity dose summary per chemical and cell line.  We devised an effective concentration 
10
th
 percentile (EC10), using the logistic model  
   (
      
         
)            
with          , where   is the observed normalized signal representing proportion of surviving 
cells (which we term the “cytotoxicity value”),   is the log(concentration) for each chemical, and 
     is the mean cytotoxicity value on the logit scale for the zero concentration.       was set to 
zero, to avoid difficulties in estimating the minimum cytotoxicity value for chemicals with low 
cytotoxicity.  An exception was made for chemicals in which the cytotoxicity value at the highest 
concentration was higher than 0.4, as a very few number of plates/chemicals did not reliably 
reach maximum cytotoxicity. In those instances the cytotoxicity value was set at the observed 
cytotoxicity at the maximum concentration.  Inspection of these data revealed good fits in such 
instances according the maximum likelihood estimation. Although in principle       should 
have been 1.0, a number of plates exhibited a drift from this value, and thus the parameter was 
estimated from the data.    
Fitting for the parameters         
        proceeded by maximum likelihood using 
numerical optimization in R v2.15.  An automatic outlier detection algorithm was devised by 
considering the impact of dropping each concentration value in succession, and removing those 
values for which the maximum likelihood improved by a factor of 10 or more (example in 
Figure 3.1 and refitting the model using the non-outlying observations. 
Multivariate Association Analysis. The MAGWAS multivariate analysis of covariance model 
(Brown et al. 2012a) was used for primary association mapping. The approach allows for use of 
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the full concentration-response profile, as opposed to a univariate summary (such as EC10) as a 
single response, with the advantage of robustness and power under a wide variety of association 
patterns. The model used for association for the jth individual and genotype i for the 
chemical/SNP is 
                 
          , 
where     is the vector of responses (across the eight concentrations) for the j
th
 individual having 
genotype i,     is the design matrix of covariates, including sex, indicator variables for 
laboratory batch, and the first ten genotype principal components, and    is the eight 
concentraopn-vector of parameters modeling the effects of genotype i on the response.  The 
model assumes that the error terms are multivariate normally distributed, with mean vector 0 and 
variance-covariance matrix Σ, allowing for dependencies in the observations. P-values were 
obtained using Pillai’s trace (Pillai 1955). Because this method makes use of asymptotic theory, 
markers with fewer than 20 individuals representing any genotype were removed, leaving 
692,013 SNPs for analysis.   
Heritability. Estimation of the proportion of chemical response variation due to genetic 
variation (heritability) was first calculated for each compound using the mean of the batch 
adjusted EC10 value across the 401 related individuals belonging to the related individuals (trios).  
The Multipoint Engine for Rapid Likelihood Inference (MERLIN) (Abecasis et al. 2002) 
software package was used to estimate heritability with and without additional covariates 
including subpopulation by ethnicity (CEU, MXL and YRI) and population stratification (top 
three principal components). The covariates did not have a substantial effect on the heritability 
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estimates (results not shown). Additionally, variance component analysis and hypothesis testing 
were performed with Sequential Oligogenic Linkage Analysis Routines (Almasy and Blangero 
1998), in order to evaluate the significance and standard error for each heritability estimates per 
compound.   A false discovery threshold of 0.05 was used to ascribe significance and control for 
multiple testing.   
Using the set of 884 unrelated individuals, we also ran the GCTA package (Yang et al. 
2011) to estimate heritability, with default settings and using the 1.3m SNPs. To assess whether 
the degree of concordance between MERLIN and GCTA was at the level expected, we used the 
179-vector of MERLIN heritability estimates as a hypothetical true set of heritabilities.  These 
“true” values and associated standard errors from both MERLIN and GCTA were used to 
simulate independent normal errors to create 10,000 paired vectors of MERLIN and GCTA 
estimates, which were then compared for concordance. 
RNA-Seq data. For dataset E-GEUV-1, mapped reads were downloaded (BAM format) from 
ArrayExpress (http://www.ebi.ac.uk/arrayexpress).  IsoDOT 
(http://www.bios.unc.edu/~weisun/software/isoform.htm) was used to count reads for each non-
overlapping exon, which have been preprocessed in IsoDOT library files 
(http://www.bios.unc.edu/~weisun/software/isoform_files/). Read counts for each gene were 
obtained by summing the read count of the corresponding exons. 
Prediction of EC10 using RNA-Seq. The RNA-Seq read count data were normalized by the 
library size for each sample, and principal components were computed from these data to use as 
predictors in LASSO-based regression using the R package lars v1.2, with each chemical’s EC10 
values used in succession as a response.  Default cross-validation prediction error estimation was 
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performed within the package for each chemical. Following theoretical work on avoiding bias in 
principal component estimation (Lee et al. 2010), the entire set of principal components was 
computed once and used in the cross-validations.  
Attenuated variability estimates to account for sampling variation. To account for the 
inflationary effect of sampling variance on expected ranges of EC10 values, we considered the 
simple model:           where   is the underlying true (unknown) EC10 and   reflects 
sampling variation in the estimate.  We suppose that each chemical has an underlying true 
sampling variability   
  per observation, while observed EC10 values were, in many instances, 
averaged across multiple observations.  If an individual is measured    times,          
    .  
To conservatively estimate   
 , we identified all paired replicate instances for the chemical across 
different batched, computed the sample variance within each pair, and average across these pairs 
to obtain    ̂.  Then we computed a variance inflation factor 
    
         
   ̂         
 
where         is the average number of replicates per individual.  Finally, we consider 
individual measurements to have been inflated by √    so that, for example, the deflated inter-
susceptibility range is                     √   . 
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D. RESULTS 
Cell lines and genotypes 
An initial set of 1104 LCLs (1000 Genomes Project Consortium et al. 2012) was 
representative of 9 geographically- and ancestry-diverse populations: Utah residents with 
Northern & Western European ancestry (CEU); Han Chinese in Beijing, China (CHB); Japanese 
in Tokyo, Japan (JPT); Luhya in Webuye, Kenya (LWK); Mexican ancestry in Los Angeles, CA 
(MXL); Tuscans in Italy (TSI); Yoruban in Ibadan, Nigeria (YRI); British from England and 
Scotland (GBR); and Colombian in Medellin, Colombia (CLM). Genotypes were obtained from 
the 1000 Genomes web site.  A few cell lines (18; 1.6%) were not viable or grew very slowly, or 
had insufficiently available genotypes, and the final data analysis set consisted of 1086 cell lines.   
Due to sample size limitations in comparison with modern disease genome-wide 
association studies, and to reduce multiple comparisons, we initially focused on ~2.5 million 
markers further filtered by minor allele frequency (MAF). 172 of the individuals had not been 
genotyped on the platform, and so MaCH (Li et al. 2010) dosage imputation to these markers 
was performed using the appropriate 1000G reference population. Analyses were performed 
separately on 400 individuals belonging to parent-child trios (not all complete) in the CEU (164), 
MXL (83), and YRI (153) populations, and on a maximal set of 884 individuals in the remaining 
populations with no first-degree relationships (unrelateds).  Association analyses were performed 
using both the Omni 2.5 set with MAF>0.05 (~1.3m) and a larger set (~12m) of typed SNPs 
available from the sequencing data, as described below. 
Figure 3.2a shows the distribution of populations and continental ancestry.  LCLs were 
randomly divided into screening batches with equal distribution of populations and sex in each 
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batch, without regard to family structure.  The major HapMap/1000G continental ancestry 
populations were represented, as well as admixed populations from the Americas (Figure 3.2b). 
Cytotoxicity profiling 
Figure 3.3 shows a flow chart of cytotoxicity profiling across 8 concentrations ranging 
from 0.33 nM to 92 µM.  Logistic curve fitting with outlier detection (Figure 3.1) was used to 
obtain EC10 values, which were batch-corrected and averaged across replicates for each cell line. 
To place the current study in context with other cell line cytotoxicity genetic mapping 
studies, we reviewed comparable studies, identifying 18 reports (Lock et al. 2012; O'Shea et al. 
2011; Gamazon et al. 2010; Wheeler et al. 2013; Innocenti et al. 2009; Stark et al. 2010; Aksoy 
et al. 2009; O'Donnell et al. 2010; Li et al. 2009; Peters et al. 2011; Huang et al. 2011; Wheeler 
et al. 2011; Kulkarni et al. 2012; Brown et al. 2012b). These studies had (i) more than one 
chemical (except (Brown et al. 2012b)), and (ii) at least 50 cell lines. Figure 3.4a depicts a 
heatmap of our cytotoxicity measurements across cell lines and chemicals.  The figure also 
depicts, to scale, the size of the other 18 studies in terms of cell lines X chemicals/drugs.  In 
these terms, the size of the study reported here is an order of magnitude greater than any single 
previous study, and several times larger than the other reports combined. 
For the ~700 cell lines for which there was at least one replicate plate, Figure 3.4b 
depicts the EC10 values for replicates (r=0.90).  Nine of the chemicals were assayed in duplicate 
on the each plate, and duplicate chemicals showed similar median EC10 and range of variability 
across cell lines (Figure 3.4c). The entire range of EC10 values across all chemicals exhibited 
remarkable variation in cytotoxicity (Figure 3.4d).  Only one other report has been of similar 
scale in chemicals represented (240 chemicals investigated in (Lock et al. 2012)).  However, our 
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comparisons across chemicals are much more definitive in the ability to rank and prioritize 
compounds by cytotoxic activity, due to the large number of cell lines profiled (n=1086 in the 
current report, vs. n=81 in (Lock et al. 2012)).   
Figure 3.5a shows the results of EC10 estimation for all cell lines for an illustrative 
chemical, as well as the results from the logistic fit applied to the pooled data (similar to (Lock et 
al. 2012)). The histogram depicts the individual EC10 estimates, showing variation of more than 
an order of magnitude. To quantify “susceptible” subgroups in the population, we recorded the 
5
th
 and 95
th
 percentiles of EC10 values for each chemical, and the quantile difference q95-q05 on 
the log scale represents a fold-range of population variability. Figure 3.5b shows the fold-range 
across the 179 chemicals, as a histogram and as a function of mean EC10 values (inset).  The 
fold-range is low for the chemicals at the high and low extremes due to measurement constraints 
at the extremes. Overall, the measured fold-ranges are expected to be inflated due to technical 
sampling variation, and the figure also shows an estimate of the true underlying distribution after 
removing this source of variation. The majority (166; 92.7%) of the chemicals show a shrunken 
fold-range less than 10. For a few chemicals, the estimated fold-range in cytotoxicity is much 
greater than 10, and may be as great as 100 or more (Table 3.1).  
For each population, we produced a profile of EC10 values across the 179 chemicals by 
averaging for each chemical across the individuals within the population.  Hierarchical clustering 
of the averaged profiles (Figure 3.5c) showed general assortment by continental ancestry, 
although variation within populations was generally greater than across populations.  While a 
large number of chemicals showed significant EC10 variation across populations or by sex (false 
discovery rate q<0.05, Table 3.2), this variation tended to be modest (two examples in Figure 
3.5d). 
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Heritability and mapping 
Trio-based analysis provided significant evidence of additive heritability for 22 chemicals 
(q<0.05), with significant h
2
 ranging from ~0.25 to ~0.5 (Figure 3.5e). This analysis was 
augmented by essentially independent heritability estimation using GCTA (Yang et al. 2011) 
performed using the maximal set of 884 unrelated individuals. GCTA-based h
2
 ranged from ~0.4 
to 0.8 for 34 significant chemicals (Figures 3.5a-b).   
Estimation of the EC10 as a phenotype was motivated by relevance to human health 
assessment practices (Baynes 2012); however, elucidation of the underlying genetic mechanisms 
may be more powerful without assumptions about the point-of-departure.  Moreover, the EC10 is 
not sensitive to genetic influences that are apparent only at high concentrations. We thus adopted 
a three-stage approach to mapping, using ten genotype principal components and sex as 
covariates.  For the primary analysis, using the set of unrelated individuals, we applied the 
multivariate MAGWAS approach (Brown et al. 2012a), which is sensitive to any pattern of 
variation of cytotoxicity measurements due to genotype. Second, for the same individuals, we 
used EC10 values as a quantitative phenotype in regression analysis for an additive model of SNP 
allele effects, using the larger set of 1.3m SNPs (chr1-X).  At the level of individual SNPs, this 
analysis was used to identify significant associations that might have been missed by MAGWAS 
and to investigate pathway-based associations (Schaid et al. 2012). Finally, in order to capture a 
larger number of SNPs and variants with lower MAF (Gamazon et al. 2012), we applied the EC10 
regression approach to 690 of the unrelated individuals who were part of 1000 Genomes Phase I 
(1000 Genomes Project Consortium et al. 2012), and used ~12.4m variants with MAF>0.01.  
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Preliminary examination of the last analysis indicated phenotype outlier effects causing spurious 
significant findings due to the lower MAF threshold, and so after applying an initial filter of 
association P<5×10
-8
, the (chemical)×(SNP) analyses were recomputed after applying an inverse 
quantile normalization to the EC10 values.  
For the primary analyses, each chemical is deemed worthy of separate investigation.  
Thus, we reasoned that a balanced approach to multiple comparisons was to apply per-chemical 
false discovery control, following proposals that SNPs with FDR q<0.10 be declared significant 
(van den Oord and Sullivan 2003).  Table 3.3 shows these 48 chemical-SNP associations, after 
removing redundant regional findings within +1Mb.  The nearest gene is reported, along with 
partial R
2
, the portion of variance explained in the MAGWAS model across the entire 8 
concentrations after considering covariates.  The most significant MAGWAS findings tend to 
have larger partial R
2
, but the relationship to P-values is complex (Figure 3.6).  
Table 3.3 is presented for each chemical, but a re-ranking by P-values reveals that the top 
10 significant associations includes three solute carriers (SLC7A11 for 2-amino-4-methylphenol, 
SLC39A14 for 1,3-dicyclohexylcarbodiimide, and SLCO3A1 for titanocene dichloride), the 
transmembrane protein TMEM196 for N-isopropyl-N'-phenyl-p-phenylen, and NFAT5 for o-
aminophenol, a gene which activates several solute carriers in response to osmotic stress 
(Halterman et al. 2012).  These findings suggest a major role for membrane proteins and solute 
carrier transporters in mediating cytotoxicity, as has been reported for the chemotherapeutic 
agent paclitaxel (Njiaju et al. 2012).   
The most significant MAGWAS association (P=8.4×10
-10
) was for 2-amino-4-
methylphenol at rs13120371 in the 3’ UTR of SLC7A11, a cystine and glutamate transporter also 
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known as xCT.  The result was highly significant on a per-chemical basis (q=0.0006), and at the 
significance threshold for multiple comparison correction for the entire set of SNPs X chemicals 
combined (q=0.10).  Figure 3.7a shows the corresponding MAGWAS Manhattan plot, with a 
regional plot (Figure 3.7b).  The same SNP also appeared with q<0.10 for methyl mercuric 
chloride and N-methyl-p-aminophenol sulfate (Table 3.3).  Comparative curves for 2-amino-4-
methylphenol and the three genotypes show that the difference in cytotoxic response appears 
mainly at the highest concentration (Figure 3.7c). The plot illustrates the contrast between EC10, 
which does not differ significantly by genotype, and the multivariate MAGWAS finding, which 
is sensitive to concentration-response variation.   
For the secondary analysis using regression of EC10 on SNP genotype, we computed the 
genomic control value (Devlin and Roeder 1999). The mean  (+s.d.) across chemicals was 
0.988+0.017 suggesting that population stratification was well-controlled.  Table 3.4 shows 
results from the EC10 regression analyses, with all significant findings (per-chemical q<0.10) 
shown after removing redundant regional findings (63 unique chemicals, 260 unique nearest 
gene assignments).  For many chemicals, the effects of genotype are observable both for EC10 
and across the multivariate response, and the two approaches provide similar evidence (Figure 
3.8). At the false discovery rate (Storey and Tibshirani 2003) of <0.1 only ~18 unique chemicals 
would be expected to appear in the table.  SNPs in four genes appear in the table for three or 
more chemicals: GRIP1 (Glutamate receptor interacting protein 1), which directs localization of 
transmembrane proteins (Setou et al. 2002); FMN2, a component of p21-based cell cycle arrest 
(Yamada et al. 2013); DNER, a transmembrane protein associated with glioblastoma propagation 
(Sun et al. 2009); and the cell membrane cadherin CDH13, which acts as an epithelial tumor 
suppressor (Chan et al. 2008). As with the MAGWAS results, membrane localized proteins 
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appear to play an important role.  Because EC10 were available for 179 chemicals, we could also 
illustrate that GCTA-based heritability estimates are largely reflected in a tendency toward small 
association P-values, a phenomenon that is difficult to discern for single-trait GWAS studies 
(Figure 3.9c). Table 3.5 shows the significant associations for the analysis of the larger number 
(12.4m) of sequenced SNPs.  
With regards to rs13120371 in SLC7A11, we hypothesized that it may modify resistance 
to a larger number of chemicals.  We examined the EC10 P-values for rs13120371 across all 179 
chemicals, observing a clear excess of small P-values (Figure 3.7d).  Using a standard false-
discovery computation (Storey and Tibshirani 2003), we estimated the proportion of true 
discoveries for the SNP across the chemicals as 0.25, a significant trend that remained even after 
removal of the three top MAGWAS-identified chemicals. The estimated number of true 
discoveries, corresponding to an estimated 44 chemicals showing true cytotoxicity association 
with rs13120371, is subject to considerable sampling variation.   Nonetheless, the data indicate 
that SLC7A11 may be a cytotoxicity mediator, and a role for SLC7A11 has been proposed in 
glutathione-mediated chemotherapeutic resistance (Huang et al. 2005).   
“Pathway” association analysis of gene sets/ontologies was performed for EC10 
phenotypes and the 1.3m Omni 2.5 SNPs using gene set scan (Schaid et al. 2012) which 
computes significance of SNPs, genes, and ontologies (KEGG and Gene Ontologies).  Eleven 
chemicals had significant pathways, and several chemicals showed significant associations with 
immune-response pathways and ontologies (Table 3.6) at family-wise error rate (FWER) <0.05. 
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RNA-Seq analysis 
For 344 cell lines in the study, RNA-Seq expression data on 36,142 genes was available 
(Lappalainen et al. 2013).  We performed association analyses of normalized expression vs. EC10 
values for each of the 179 chemicals, with per-chemical false discovery q<0.1. A total of 260 
genes met the threshold for at least one of 52 chemicals (Figure 3.10a).   
Analysis of these genes by DAVID/EASE (Dennis et al. 2003) suggested enrichment for 
ribosomal proteins and those involved with actin binding and nucleotide binding.   However, the 
use of such “gene-list” methods has been shown to greatly increase false-positive rates due to 
gene-gene correlations (Gatti et al. 2010). Accordingly, we performed analysis of Gene Ontology 
Cellular Components terms using the safeExpress, which accounts for correlation structures in 
gene expression (Zhou et al. 2013).  Figure 3.10b shows the results for 22 chemicals and 33 
terms, with at least one significant per-chemical finding at q<0.1.  Several chemicals exhibit 
enrichment of genes with protein localization to the cell membrane, in addition to other 
localizations.  
The RNA-Seq findings support the underlying theme that genes with cell membrane 
localization are important to cytotoxic susceptibility, with transcription acting as a mediator to 
genetic variation.  However, the ability to jointly model the effects of transcriptomic and genetic 
variation is hampered by sample size limitations, and the overall association of EC10 with 
expression is relatively modest.  Using the entire expression dataset to predict EC10 for each 
chemical using a penalized prediction procedure, only three chemicals exhibited more than 5% 
explained variation (Table 3.7). The explained variation among these few chemicals may be 
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exaggerated due to winner’s curse inflation, and the average explained variation across the 
chemicals was less than 1%.  
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E. DISCUSSION 
Our study, with a large number of environmental chemicals interrogated on a much larger 
sample than previous datasets, demonstrates the feasibility of addressing the challenge of 
assessing the individual variability in next-generation risk assessments (Zeise et al. 2013). 
Despite concerns over the ability to map meaningful drug response traits in cell lines (Choy et al. 
2008), our results suggest that large sample sizes, on the order necessary for mapping human 
complex traits (Goldstein 2009), can overcome the challenges.  Importantly, these data are also a 
useful resource for future investigation. Our results generated dozens of associations about the 
mechanism of toxicity for hundreds of chemicals that can be used to generate testable 
hypotheses.  
Although we present results as a survey across the 179 chemicals, the results for 
population variation and association for each chemical will be useful for future targeted 
investigations.  Moreover, the use of a common protocol and automated system enabled 
comparisons across chemicals in a manner that is difficult to perform across separate studies of 
individual chemicals. Cytotoxicity in LCLs is just one among multiple criteria that may be used 
in prioritization and to refine uncertainty factors (Zeise et al. 2013), but fills a great need for 
additional data on population variation (Collins et al. 2008). 
Beyond the immediate utility of such data for context-specific decisions in human health 
assessment of chemicals, we were able to discover important biological associations. We have 
observed that genes with protein localization to cell membranes, including solute carriers, are 
enriched in a subset of chemicals, both in genetic association and RNA-Seq association analyses.  
Solute carrier transporters have been investigated as potential mediators of cytotoxicity for 
chemotherapeutic agents (DeGorter et al. 2012), with specific genes investigated for paclitaxel 
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(Njiaju et al. 2012), oxaliplatin (Zhang et al. 2006), gemcitabine (Marce et al. 2006). These 
genes control cellular influx and efflux of drugs and toxicants, and thus are a plausible source of 
genetically-induced variation in susceptibility.  Moreover, several families of solute carriers are 
important mediators of toxicity in liver and kidney (DeGorter et al. 2012), which are the primary 
relevant organs for a large number of the chemical studies.  To our knowledge, our study is the 
first to highlight membrane transporters as potentially important in a wider range of chemical 
compounds, beyond the cancer chemotherapeutic agents that have been the subject of most LCL 
mapping studies. 
The significant association results for rs13120371 in SLC7A11 were interesting, and 
supported by a growing literature on the direct and indirect importance of SLC7A11 in 
chemoresistance (Lo et al. 2008). Small interfering SLC7A11 RNA, including x(c)(-) inhibitors, 
have been shown to increase sensitivity to various agents in various cancer cell lines (Pham et al. 
2010). Expression of SLC7A11 is altered in drug-resistant ovarian cancer cell lines (Januchowski 
et al. 2013), is downregulated in response to thymoquinone in breast cancer cells (Motaghed et 
al. 2014), and is clinically predictive of poor survival in hepatocellular carcinoma and 
glioblastoma (Kinoshita et al. 2013).  Also, SLC7A11 was shown to be inversely correlated with 
clinical outcome in bladder cancer, and to be negatively regulated by the micro RNA miRNA-27a 
for cisplatin-resistant cell lines (Drayton et al. 2014). 
 
Conclusions: This study provides an example of how a large-scale systems biology experiment 
(toxicity phenotyping, genetic mapping, and correlation with basal gene expression data) can aid 
in translation to public health protection. Testing human cell lines that represent various 
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populations and identify sensitive subpopulations can substantially improve any risk assessment 
paradigm where decision making will be relied on actual estimated variability rather than mere 
statistical assumptions that may or may not be satisfied.   Traditional GWAS studies are 
concerned with uncovering genetic modifiers that may underpin a person’s susceptibility to a 
particular disease. At the same time, little information on how much inter-individual variability 
may exist in the population for a particular chemical-associated adverse health outcome, even 
though current risk assessment practices favor data-driven estimation. The use of genetically-
defined/-diverse models in chemical safety/toxicity testing is uncommon primarily because of 
the complexity of such studies.  Although the risk assessment process is shifting toward greater 
reliance on in vitro data, none of the in vitro assays in Tox21, ToxCast, or other large-scale 
screening programs is designed to address individual variability (Rusyn and Daston 2010). The 
availability of the genetically-diverse, genetically-defined renewable source of human cells, such 
as LCLs from the HapMap and 1000 Genomes, opens an opportunity for in vitro toxicity testing 
at the population scale. Our heritability estimates show that genetic variation may have a 
profound effect on differences between individual cell lines, and that such variability can be 
quantified and used to generate testable hypotheses about the mechanisms of toxicity.  
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FIGURES 
 
 
Figure 3.1. Illustrative Fits for Cytotoxicity Estimation. The fits and EC10 point estimate 
(vertical lines) shown in grey. The top and bottom rows show instances of cytotoxic compounds.  
The middle panels show compounds that are non-cytotoxic for the range of concentrations, and 
EC10 was fixed at the maximum concentration.  Points marked in red were excluded on the basis 
of the likelihood ratio criterion described in Online Methods, providing new fits and EC10 
values shown in green. 
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Figure 3.2. Distributions of the LCLS among the 9 Populations  (a) Distribution of the LCLs 
among the 9 populations used in this study. Abbreviations follow the 1000 Genomes 
nomenclature (see text). Outer boundaries show continental/ancestral origin. (b) Scatter plot for 
the 1st and 2nd principal components for genotypes across all cell lines, colored by population.  
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Figure 3.3 Flow Chart of Data Processing to Obtain Cytotoxicity Response Values and 
EC10. 
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Figure 3.4 Comparison of the Current Study to Other Comparable LCL cell line/screening 
studies and Reproducibility (a) Comparison of the current study to other comparable LCL cell 
line/screening studies, in terms of the number of cell lines and chemicals screened.  EC10 values 
are shown in the heatmap, while the area of each depicted report is in proportion to the current 
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study. Published studies with at least 2 compounds (except for the largest single drug study, Ref. 
28), and with at least 50 cell lines, are used for comparison. (b) Intra-experimental 
reproducibility of EC10 values for randomly selected pairs of within-batch replicate plates for all 
chemicals and cell lines. (c) Side-by-side boxplots show 9 compounds that were assayed in two 
independent sets of wells on each plate. (d) Boxplots of cytotoxicity EC10 values for the 179 
chemicals (arranged by mean activity) across the 1086 cell lines. 
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Figure 3.5. Magnitude of Inter-Individual Variability Across Chemicals and Populations 
(a) Modeling in vitro quantitative high-throughput screening data, using β-nitrostyrene as an 
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example chemical. Logistic dose-response modeling was performed for each individual (plate) to 
the values shown in gray, providing individual 10% effect concentration estimates (EC10, 
histogram). The fit of the logistic model to the pooled data is also shown as a dashed curve, and 
EC10 estimation based on this curve is similar to the average of the individual EC10 values). (b) 
A histogram (blue bars) of EC10 fold-range (q95-q05) for 179 compounds across 1086 cell lines. 
The red curve shows the same distribution when values are shrunken to account for technical 
variability. The inset shows the relationship between fold-range and mean estimated EC10 for 
each chemical. (c) Hierarchical clustering for the 179-length profiles of mean EC10, computed 
within each population. The upper bar’s color depicts continental ancestral origin of each 
population. (d) Boxplot of EC10 values by population for 2 example chemicals with different 
potency levels, which showed significant population differences by ANOVA (cycloheximide, 
P=6.0×10
-6
 and triamterene, P=3.6×10
-4
). (e) Trio-based heritability estimates (h2) for 
compounds with significant additive heritability (q<0.05, 22 out of 179 compounds tested).  
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Figure 3.6 P-values vs. partial R2. A plot of the most significant genetic variant for each 
chemical, with black dots depicting the -log10 p-values for the association, and red dots showing 
the maximum partial R-squared across all 8 concentrations. 
 
 
 
 
 108 
 
 
 
 
Figure 3.7. Genotype-Cytotoxicity Associations (a) Manhattan plot of MAGWAS -log10(P) vs. 
genomic position, for association of genotype and cytotoxicity to 2-amino-4-methylphenol.  The 
line of suggestive association (expected once per genome scan) is in green, and Bonferroni-
corrected significance for a single chemical in black. (b) LocusZoom plot of the most significant 
region.  SNP rs13120371 was the most significant (P=8.4×10
-10
), while the nearby rs7674870 
was used for comparison of linkage disequilibrium patterns in the region. (c) Average 
concentration-response profiles of cytotoxicity of 2-amino-4-methylphenol plotted separately for 
each rs13120371 genotype. Genotype effects appear only for the highest concentrations. (d) 
Histogram of EC10-based P-values for all 179 chemicals for rs13120371 shows an excess of 
small P-values. 
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Figure 3.8 MAGWAS vs. PLINK for an example chemical/region. LocusZoom plots of the 
most significant SNP (rs504504, chr1p22) associated with cytotoxicity of dieldrin from (a) 
MAGWAS (a) and (b) PLINK regression analyses, using EC10 as a quantitative phenotype. 
(a) 
(b) 
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Figure 3.9. Heritability of EC10 (a) Histogram of GCTA heritability (h2) estimates for EC10. 
(b)  Heritability estimates for each chemical vs. GCTA -log10(P-values).  For GCTA heritability, 
34 chemicals with false discovery rate q<0.05 are shown in green.  (c ) The estimated proportion 
of true discoveries (among 1.3M SNPs) vs. GCTA heritability estimates for EC10 (r=0.96). 
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Figure 3.10 Heatmaps of Gene- and Pathway-Chemical Associations (a) Heatmap of -
log10(q) for 260 genes and 52 chemicals, in which q<0.1 for at least one gene-chemical 
combination.  (b) Heatmap of -log10(q) for 33 Gene Ontology Cellular Component pathways and 
22 chemicals, in which q<0.1 for at least one pathway-chemical combinations. 
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Table 3.1. Average EC10 Cytotoxicity Values and Fold-Ranges  
Drug Name CAS# Mean
a
 Median
b
 SD q05
c
 q95 Fold 
Range 
q95- q05 
Shrunk
en Fold 
Range 
Estimat
e
d
 
Daunomycin HCL 23541-50-6 -2.467 -2.562 0.317 -3.116 -1.344 59.198 7.422 
Colchicine 64-86-8 -2.232 -2.215 0.214 -2.699 -1.531 14.726 1.710 
Colchicine 64-86-8 -2.228 -2.199 0.212 -2.651 -1.668 9.603 2.679 
Malachite green oxalate 2437-29-8 -1.492 -1.473 0.242 -2.114 -0.795 20.842 3.718 
Tetramethylthiouram disulfide 137-26-8 -1.347 -1.362 0.403 -1.991 -0.635 22.655 7.521 
Cycloheximide 66-81-9 -1.357 -1.357 0.290 -1.909 -0.870 10.944 2.565 
Digoxin 20830-75-5 -1.303 -1.302 0.222 -1.839 -0.691 14.052 3.229 
Ziram 137-30-4 -1.264 -1.296 0.557 -2.217 0.081 199.014 50.632 
Cycloheximide 66-81-9 -1.208 -1.204 0.294 -1.853 -0.606 17.683 5.106 
Phenylmercuric acetate 62-38-4 -1.183 -1.195 0.345 -1.846 -0.517 21.363 8.569 
Zinc pyrithione 13463-41-7 -1.100 -1.140 0.463 -1.815 0.041 71.802 22.069 
Mercuric chloride 7487-94-7 -0.946 -1.024 0.678 -2.053 0.181 171.242 42.958 
6-Thioguanine (6-TG) 154-42-7 -0.803 -0.863 0.786 -2.233 0.542 595.493 91.906 
Hexamethyl-p-rosaniline 
chloride 
548-62-9 -0.774 -0.746 0.262 -1.232 -0.287 8.809 3.668 
Methyl mercuric (II) chloride 115-09-3 -0.554 -0.544 0.373 -1.398 0.140 34.552 13.299 
6-Mercaptopurine monohydrate 6112-76-1 -0.348 -0.524 0.973 -1.674 1.701 2368.405 201.289 
5-Fluorouracil 51-21-8 -0.152 -0.188 0.613 -1.141 0.949 123.005 25.675 
Azathioprine 446-86-6 -0.021 -0.187 0.835 -1.177 1.333 323.460 75.384 
Chloranil 118-75-2 -0.116 -0.145 0.442 -0.908 0.844 56.582 8.202 
tetra-N-Octylammonium 
bromide 
14866-33-2 -0.135 -0.109 0.291 -0.636 0.537 14.911 6.379 
Ethidium bromide 1239-45-8 0.019 -0.006 0.322 -0.657 0.747 25.357 10.620 
p-Nitrosodiphenylamine 156-10-5 0.024 0.052 0.341 -0.500 0.597 12.493 6.943 
N,N-Dimethyl-p-nitrosoaniline 138-89-6 0.023 0.062 0.330 -0.634 0.511 13.984 5.040 
Cetylpyridinium bromide 140-72-7 0.080 0.072 0.332 -0.470 0.708 15.086 7.573 
Sodium dichromate dihydrate 
(VI) 
7789-12-0 0.109 0.112 0.348 -0.467 0.729 15.685 5.277 
Nitrogen mustard hydrochloride 55-86-7 0.114 0.113 0.507 -0.643 0.990 42.993 16.172 
Pentaerythritol triacrylate 3524-68-3 0.101 0.152 0.297 -0.461 0.538 9.977 4.039 
Potassium dichromate 7778-50-9 0.157 0.168 0.315 -0.470 0.810 19.050 6.706 
Pyrimethamine 58-14-0 0.189 0.173 0.571 -0.765 1.249 103.396 11.847 
Sodium dichromate dihydrate 
(VI) 
7789-12-0 0.181 0.197 0.369 -0.590 0.851 27.615 9.685 
2-Octyl-3-isothiazolone 26530-20-1 0.200 0.231 0.291 -0.418 0.673 12.335 4.571 
Chlorambucil 305-03-3 0.267 0.277 0.276 -0.213 0.763 9.465 3.480 
Diglycidyl resorcinol ether 
(DGRE) 
101-90-6 0.304 0.308 0.362 -0.381 0.966 22.269 7.881 
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9-Aminoacridine, 
monohydrochloride, 
monohydrate 
52417-22-8 0.326 0.330 0.249 -0.166 0.735 7.972 4.079 
1,3,5-Triglycidyl isocyanurate 2451-62-9 0.319 0.337 0.329 -0.360 1.044 25.305 8.179 
Fumaronitrile 764-42-1 0.413 0.371 0.330 -0.063 0.972 10.847 3.021 
o-Phenanthroline 66-71-7 0.369 0.372 0.198 0.026 0.752 5.328 2.200 
N,N'-Di-sec-butyl-p-
phenyldiamine 
101-96-2 0.384 0.394 0.207 0.003 0.734 5.384 3.496 
Hexachlorophene 70-30-4 0.387 0.399 0.295 -0.275 1.046 20.979 6.739 
Chlorhexidine 55-56-1 0.389 0.425 0.353 -0.549 1.085 43.071 9.064 
Tetraethylene glycol diacrylate 17831-71-9 0.438 0.447 0.275 -0.039 0.878 8.259 2.915 
Methylene bis(thiocyanate) 6317-18-6 0.487 0.472 0.256 0.115 0.942 6.714 3.793 
Catechol 120-80-9 0.477 0.486 0.304 -0.101 0.978 11.997 5.334 
beta-Nitrostyrene 5153-67-3 0.539 0.509 0.270 0.137 1.037 7.954 3.195 
Benzethonium chloride 121-54-0 0.554 0.542 0.168 0.276 0.877 3.990 2.138 
N-Methyl-p-aminophenol 
sulfate 
55-55-0 0.584 0.593 0.258 0.152 1.032 7.600 4.078 
Ergotamine tartrate 379-79-3 0.621 0.623 0.361 -0.097 1.214 20.464 3.631 
Domiphen bromide 538-71-6 0.614 0.633 0.239 0.229 0.967 5.466 2.947 
1,1,1,2-Tetrabromoethane 630-16-0 0.612 0.647 0.266 -0.022 1.027 11.189 5.288 
Nitazoxanide 55981-09-4 0.700 0.705 0.276 0.152 1.209 11.412 4.428 
2,2',4'-Trichloroacetophenone 4252-78-2 0.705 0.706 0.236 0.245 1.157 8.167 1.456 
2,4-Difluoronitrobenzene 446-35-5 0.700 0.715 0.680 -0.514 1.915 268.741 20.770 
Iodochlorohydroxyquinoline 130-26-7 0.739 0.755 0.253 0.134 1.178 11.082 3.679 
Diethylene glycol diacrylate 4074-88-8 0.735 0.770 0.278 0.091 1.195 12.700 6.164 
2-Amino-4-chlorophenol 95-85-2 0.749 0.776 0.526 -0.357 1.579 86.417 9.579 
Turmeric (>98% curcurmin) 458-37-7 0.790 0.805 0.208 0.370 1.163 6.198 2.313 
1-Methyl-3-nitro-1-nitroso-
guanidine 
70-25-7 0.857 0.826 0.320 0.174 1.396 16.668 7.219 
Tetraethylene glycol diacrylate 17831-71-9 0.825 0.829 0.209 0.345 1.292 8.861 3.413 
Dibromonitromethane (water 
disinfection byproducts) 
598-91-4 0.865 0.869 0.235 0.319 1.290 9.351 4.609 
1,8-Dihydroxy-4,5-
dinitroanthraquinone 
81-55-0 0.834 0.871 0.221 0.261 1.209 8.863 4.152 
Dexamethazone 50-02-2 0.792 0.898 0.966 -1.049 2.000 1119.682 43.483 
1,6-Hexamethylene diacrylate 13048-33-4 0.906 0.928 0.184 0.615 1.108 3.111 1.382 
1,3-Diiminobenz (f)-isoindoline 65558-69-2 0.931 0.939 0.180 0.318 1.266 8.873 2.115 
4-Amino-4'-hydroxy-3-methyl-
diphenylamine 
6219-89-2 0.927 0.942 0.207 0.449 1.393 8.779 3.345 
1,3-Dicyclohexylcarbodiimide 538-75-0 0.962 0.947 0.257 0.517 1.453 8.632 4.137 
Guggulsterones E 39025-24-6 0.942 0.966 0.301 0.386 1.383 9.913 3.755 
2,3,4,5-Tetrachloronitrobenzene 879-39-0 0.956 0.980 0.322 0.355 1.432 11.957 2.319 
Dieldrin 60-57-1 0.978 0.982 0.325 0.276 1.476 15.869 6.769 
3-Chloro-4-(dichloromethyl)-5-
hydroxy-2(5H)-furanone(MX) 
77439-76-0 0.959 0.990 0.212 0.443 1.258 6.542 2.034 
17beta-Estradiol 50-28-2 0.947 0.994 0.326 0.384 1.370 9.672 1.422 
Aldrin 309-00-2 0.977 0.997 0.402 0.262 1.573 20.474 4.223 
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t-Butylhydroquinone 1948-33-0 0.943 0.998 0.435 -0.057 1.479 34.406 4.193 
Acetochlor 34256-82-1 1.002 1.007 0.206 0.702 1.309 4.048 2.302 
4,4-Thiobis(6-tert-butyl-m-
cresol) 
96-69-5 1.002 1.012 0.143 0.681 1.251 3.712 2.085 
Hydroquinone 123-31-9 0.988 1.013 0.362 0.369 1.535 14.663 7.213 
2-Amino-4-methylphenol 95-84-1 0.973 1.016 0.291 0.463 1.325 7.283 3.983 
N-Isopropyl-N'-phenyl-p-
phenylenediamine 
101-72-4 0.994 1.018 0.196 0.514 1.268 5.677 1.661 
p-Quinone 106-51-4 0.996 1.018 0.231 0.527 1.348 6.627 1.580 
Triamterene 396-01-0 1.035 1.020 0.370 0.367 1.727 22.859 10.261 
Amiloride hydrochloride 2016-88-8 1.008 1.043 0.392 0.256 1.591 21.661 1.968 
Tamoxifen citrate 54965-24-1 1.060 1.059 0.159 0.647 1.327 4.787 1.243 
N,N,N',N'-Tetramethyl-p-
phenylenediamine 
100-22-1 1.048 1.066 0.387 0.418 1.635 16.503 2.355 
Aflatoxin B1 from Aspergillus 
flavus 
1162-65-8 1.033 1.068 0.415 0.357 1.649 19.589 5.202 
t-Butylhydroquinone 1948-33-0 1.053 1.069 0.248 0.646 1.428 6.049 3.112 
Hematoxylin 517-28-2 1.055 1.073 0.249 0.514 1.412 7.909 1.575 
Retinal 116-31-4 1.073 1.086 0.189 0.665 1.353 4.874 2.904 
p-tert-Butylcatechol 98-29-3 1.086 1.089 0.198 0.753 1.481 5.353 3.450 
Reserpine 50-55-5 1.085 1.090 0.163 0.783 1.319 3.438 1.375 
o-Nitrobenzyl chloride 612-23-7 1.056 1.093 0.512 0.035 1.924 77.577 6.760 
Captan 133-06-2 1.087 1.100 0.194 0.633 1.399 5.838 2.406 
Melatonin 73-31-4 1.108 1.116 0.330 0.551 1.600 11.199 6.378 
Chlordecone (kepone) 143-50-0 1.119 1.129 0.124 0.916 1.297 2.408 1.179 
4-Chloro-o-phenylenediamine 95-83-0 1.084 1.130 0.496 0.238 1.875 43.388 6.949 
Saquinavir mesylate (AIDS 
Initiative) 
149845-06-7 1.128 1.138 0.167 0.804 1.379 3.764 1.304 
Captan 133-06-2 1.114 1.141 0.218 0.640 1.389 5.613 1.892 
Progesterone 57-83-0 1.145 1.151 0.197 0.866 1.431 3.678 1.838 
7,12-Dimethylbenzanthracene 57-97-6 1.123 1.157 0.381 0.514 1.669 14.291 1.420 
8-Hydroxyquinoline 148-24-3 1.142 1.172 0.325 0.465 1.684 16.551 7.506 
N-(1,3-Dimethylbutyl)-N'-
phenyl-p-phenylenediamine 
793-24-8 1.169 1.173 0.129 0.989 1.350 2.300 1.481 
HC blue 2 33229-34-4 1.137 1.174 0.292 0.584 1.552 9.285 1.833 
Toxaphene 8001-35-2 1.187 1.176 0.129 0.980 1.412 2.704 1.798 
Titanocene dichloride 1271-19-8 1.157 1.176 0.262 0.723 1.569 7.019 2.756 
Chlordane (technical grade) 12789-03-6 1.149 1.188 0.353 0.566 1.547 9.576 2.009 
Progesterone 57-83-0 1.200 1.200 0.171 0.900 1.466 3.679 1.807 
p-Aminophenol 123-30-8 1.208 1.201 0.192 0.976 1.503 3.364 1.332 
Dazomet 533-74-4 1.200 1.202 0.301 0.650 1.789 13.792 7.957 
dichloroacetonitrile 3018-12-0 1.191 1.203 0.291 0.750 1.598 7.034 2.769 
Amitriptyline HCl 549-18-8 1.200 1.205 0.189 0.883 1.492 4.058 1.545 
Ethacrynic acid 58-54-8 1.209 1.206 0.216 0.843 1.554 5.140 1.973 
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Dibromoacetonitrile 3252-43-5 1.219 1.212 0.221 0.849 1.639 6.173 2.679 
2,2'-Thiobis(4,6-dichlorophenol) 97-18-7 1.207 1.213 0.243 0.487 1.670 15.248 3.791 
N-(1-Naphthyl)ethylenediamine 
dihydrochloride 
1465-25-4 1.231 1.222 0.110 1.066 1.420 2.260 1.595 
Endosulfan 115-29-7 1.212 1.224 0.237 0.840 1.548 5.113 2.521 
N,N'-Diphenyl-p-
phenylenediamine 
74-31-7 1.205 1.224 0.354 0.609 1.754 13.991 1.556 
Tetrachlorvinphos 961-11-5 1.219 1.234 0.285 0.620 1.649 10.689 1.723 
2,4-Decadienal 25152-84-5 1.269 1.242 0.229 0.576 1.860 19.229 7.996 
13-cis-Retinal 472-86-6 1.262 1.247 0.168 1.062 1.583 3.316 1.625 
Bisphenol A diglycidyl ether 1675-54-3 1.231 1.250 0.291 0.831 1.678 7.024 2.548 
Cadmium chloride 10108-64-2 1.273 1.259 0.225 0.908 1.656 5.591 3.115 
N,N-Diethyl-p-
phenylenediamine 
93-05-0 1.278 1.260 0.201 1.019 1.720 5.022 3.012 
Vitamin D3 67-97-0 1.336 1.263 0.254 1.036 1.893 7.202 4.846 
2,3,4,5-Tetrachlorophenol 4901-51-3 1.254 1.265 0.186 0.977 1.528 3.552 1.361 
Chlordecone (kepone) 143-50-0 1.289 1.284 0.143 0.990 1.649 4.563 2.838 
Ethyl linolenate 1191-41-9 1.307 1.288 0.164 1.086 1.630 3.504 1.634 
Bis(cyclopentadienyl)vanadium 
chloride 
12083-48-6 1.282 1.296 0.288 0.647 1.770 13.261 4.582 
Retinol acetate 127-47-9 1.321 1.299 0.194 1.054 1.712 4.547 1.323 
p-Benzoquinone dioxime 105-11-3 1.305 1.319 0.297 0.831 1.765 8.589 2.301 
p-n-Nonylphenol 104-40-5 1.291 1.321 0.346 0.712 1.830 13.136 3.046 
Chlorpheniramine maleate 113-92-8 1.241 1.322 0.505 0.368 1.893 33.512 3.510 
4-(Chloroacetyl)acetanilide 140-49-8 1.295 1.323 0.340 0.739 1.785 11.119 3.698 
Flutamide (pubertal study) 13311-84-7 1.319 1.357 0.369 0.733 1.789 11.391 4.921 
p-Nitrophenethyl alcohol 100-27-6 1.267 1.359 0.606 0.097 2.000 80.068 2.231 
Glutaraldehyde 111-30-8 1.382 1.365 0.171 1.123 1.705 3.820 1.912 
1-Naphthylamine 134-32-7 1.290 1.366 0.554 0.186 2.000 65.228 13.509 
Oxymetholone 434-07-1 1.356 1.369 0.197 0.901 1.743 6.951 2.337 
Cadmium acetatedihydrate 4/4/5743 1.391 1.381 0.245 0.832 1.827 9.868 3.891 
2-Biphenylamine 90-41-5 1.321 1.409 0.589 0.234 2.000 58.342 4.916 
2-Chloroacetophenone (CN) 532-27-4 1.426 1.422 0.218 1.062 1.761 5.004 2.494 
2-Pivalyl-1,3-indandione 83-26-1 1.430 1.433 0.259 1.019 1.845 6.693 4.470 
8-Hydroxyquinoline 148-24-3 1.393 1.457 0.350 0.613 1.824 16.237 6.894 
o-Phenylenediamine 95-54-5 1.451 1.468 0.369 0.779 1.994 16.406 4.867 
2,4-Hexadienal 142-83-6 1.481 1.471 0.209 1.166 1.850 4.833 2.308 
m-Nitrobenzyl chloride 619-23-8 1.416 1.478 0.427 0.641 2.000 22.878 3.445 
3,4-Diaminotoluene 496-72-0 1.457 1.480 0.370 0.768 2.000 17.068 5.441 
3,4-Dinitrotoluene 610-39-9 1.466 1.487 0.344 0.922 2.000 11.962 3.184 
2,3,5-Trichlorophenol 933-78-8 1.534 1.538 0.323 1.024 2.000 9.472 1.817 
2',4',5'-
Trihydroxybutyrophenone 
1421-63-2 1.502 1.552 0.337 0.916 1.961 11.117 4.527 
Ninhydrin 485-47-2 1.549 1.570 0.234 1.122 2.000 7.544 4.182 
cis-Dichlorodiamine platinum 15663-27-1 1.561 1.620 0.351 0.887 2.000 12.978 3.574 
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Propiconazole 60207-90-1 1.648 1.674 0.215 1.254 1.923 4.662 1.245 
Rhein (1,8-dihydroxy-3-carboxyl 
anthraquinone) 
478-43-3 1.637 1.690 0.318 1.098 2.000 7.980 4.135 
o-Aminophenol 95-55-6 1.633 1.703 0.346 0.978 2.000 10.513 2.559 
Nifedipine 21829-25-4 1.679 1.719 0.218 1.153 2.000 7.026 2.466 
Di(2-ethylhexyl) phthalate 117-81-7 1.684 1.723 0.286 0.735 2.000 18.405 6.967 
Alizarin Yellow R, free acid 2243-76-7 1.642 1.723 0.346 0.969 2.000 10.730 1.874 
Verapamil HCl 152-11-4 1.662 1.727 0.283 1.142 2.000 7.219 1.468 
Sulfathiazole 72-14-0 1.601 1.813 0.489 0.564 2.000 27.262 5.784 
Phenformin hydrochloride 834-28-6 1.765 1.820 0.224 1.241 2.000 5.745 3.414 
Dichlorvos (Vapona) 62-73-7 1.810 1.862 0.203 1.422 2.000 3.785 2.203 
Danthron 117-10-2 1.761 1.865 0.259 1.308 2.000 4.916 2.561 
dimethyldipropylene-triamine 10563-29-8 1.810 1.895 0.244 1.323 2.000 4.752 1.392 
Systhane 88671-89-0 1.870 1.942 0.221 1.506 2.000 3.118 1.907 
Azobenzene 103-33-3 1.827 1.943 0.263 1.351 2.000 4.459 1.554 
1-(2,6,6-Trimethyl-2-
cyclohexene-1-yl)-1-penten-3-
one 
7779-30-8 1.913 1.954 0.141 1.585 2.000 2.603 1.669 
Diisobutyl phthalate 84-69-5 1.937 1.965 0.167 1.573 2.000 2.671 2.303 
4-Methoxy-3-nitro-N-
phenylbenzamide 
97-32-5 1.957 1.972 0.124 1.737 2.000 1.832 2.041 
Ethoxyquin 91-53-2 1.871 1.972 0.281 1.456 2.000 3.497 1.823 
t-Butyl formate 762-75-4 1.930 1.989 0.217 1.576 2.000 2.652 3.165 
Aldicarb 116-06-3 1.976 1.993 0.123 1.894 2.000 1.277 1.126 
permethrin 52645-53-1 1.974 1.995 0.088 1.864 2.000 1.367 1.176 
4-Chloro-3,5-dinitro-a,a,a-
trifluorotoluene 
393-75-9 1.957 1.998 0.196 1.744 2.000 1.803 1.259 
3,4-Dichlorophenyl isocyanate 102-36-3 1.978 1.998 0.108 1.855 2.000 1.395 1.172 
Styrene 100-42-5 1.993 1.999 0.053 2.000 2.000 1.000 1.000 
5-(Hydroxymethyl)-2-furoic acid 6338-41-6 1.996 2.000 0.044 2.000 2.000 1.000 1.000 
trans-1,4-dichloro-2-butene 110-57-6 1.965 2.001 0.143 1.795 2.000 1.602 1.168 
Hexachloro-1,3-butadiene 87-68-3 1.990 2.001 0.079 1.986 2.000 1.034 1.016 
Mono(2-ethylhexyl)phthalate 4376-20-9 1.986 2.001 0.079 1.947 2.000 1.131 1.163 
Methacrylonitrile 126-98-7 1.981 2.002 0.146 1.990 2.000 1.024 1.009 
1,2-Epoxy-3-chloropropane 
(Epichlorohydrin) 
106-89-8 1.985 2.003 0.095 1.995 2.000 1.012 1.018 
aValues are log10(molar concentration). 
b Table entries are sorted by the median.  c 5th percentile. d 
See Online Methods for the shrinkage procedure, which estimates the fold-range after removing the 
effect of technical sampling variation. 
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Table 3.2. Chemicals showing significant EC10 variation across populations or by sex 
Drug Name CAS# P population 
differences 
q population 
differences 
P sex 
difference
s 
q sex 
differenc
es 
Azathioprine 446-86-
6 
3.8E-13 6.8E-11 0.228 0.506 
5-Fluorouracil 51-21-8 9.3E-13 8.3E-11 0.003 0.078 
1,3,5-Triglycidyl isocyanurate 2451-
62-9 
7.4E-10 4.4E-08 0.223 0.504 
Diglycidyl resorcinol ether 
(DGRE) 
101-90-
6 
1.6E-09 7.0E-08 0.042 0.217 
6-Thioguanine (6-TG) 154-42-
7 
2.4E-09 8.4E-08 0.804 0.882 
6-Mercaptopurine 
monohydrate 
6112-
76-1 
8.1E-09 2.4E-07 0.898 0.918 
Turmeric (>98% curcurmin) 458-37-
7 
2.1E-08 5.5E-07 0.031 0.196 
Phenformin hydrochloride 834-28-
6 
8.1E-08 1.8E-06 0.289 0.556 
Tetrachlorvinphos 961-11-
5 
3.4E-06 6.7E-05 0.517 0.735 
Cycloheximide 66-81-9 6.0E-06 1.1E-04 0.778 0.882 
N,N-Dimethyl-p-nitrosoaniline 138-89-
6 
8.9E-06 1.4E-04 0.018 0.162 
Hematoxylin 517-28-
2 
1.1E-05 1.6E-04 0.643 0.822 
Diethylene glycol diacrylate 4074-
88-8 
1.2E-05 1.6E-04 0.012 0.131 
Cadmium acetatedihydrate 4--4--
5743 
1.4E-05 1.8E-04 0.757 0.882 
Sodium dichromate dihydrate 
(VI) 
7789-
12-0 
1.6E-05 1.9E-04 0.050 0.218 
beta-Nitrostyrene 5153-
67-3 
1.8E-05 2.0E-04 0.229 0.506 
N-Methyl-p-aminophenol 
sulfate 
55-55-0 2.1E-05 2.2E-04 0.051 0.219 
Tetraethylene glycol 
diacrylate 
17831-
71-9 
3.8E-05 3.8E-04 0.023 0.180 
Tetraethylene glycol 
diacrylate 
17831-
71-9 
4.6E-05 4.4E-04 0.050 0.218 
1,1,1,2-Tetrabromoethane 630-16-
0 
5.8E-05 0.001 0.368 0.609 
Pyrimethamine 58-14-0 7.1E-05 0.001 0.650 0.826 
2,2',4'-Trichloroacetophenone 4252-
78-2 
6.9E-05 0.001 0.746 0.879 
Malachite green oxalate 2437-
29-8 
6.7E-05 0.001 0.567 0.774 
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Retinal 116-31-
4 
7.6E-05 0.001 0.880 0.906 
t-Butylhydroquinone 1948-
33-0 
1.2E-04 0.001 0.070 0.249 
Methyl mercuric (II) chloride 115-09-
3 
1.2E-04 0.001 0.067 0.247 
Dieldrin 60-57-1 1.2E-04 0.001 0.007 0.121 
Sodium dichromate dihydrate 
(VI) 
7789-
12-0 
1.1E-04 0.001 0.027 0.196 
2-Amino-4-chlorophenol 95-85-2 1.7E-04 0.001 0.808 0.882 
Nitrogen mustard 
hydrochloride 
55-86-7 2.0E-04 0.001 0.077 0.251 
Verapamil HCl 152-11-
4 
2.4E-04 0.001 0.425 0.661 
Triamterene 396-01-
0 
3.6E-04 0.002 0.486 0.722 
N-Isopropyl-N'-phenyl-p-
phenylenediamine 
101-72-
4 
3.6E-04 0.002 0.359 0.601 
Cycloheximide 66-81-9 3.8E-04 0.002 0.880 0.906 
Alizarin Yellow R, free acid 2243-
76-7 
4.0E-04 0.002 0.061 0.239 
Benzethonium chloride 121-54-
0 
0.001 0.003 0.076 0.251 
9-Aminoacridine, 
monohydrochloride, 
monohydrate 
52417-
22-8 
0.001 0.003 0.604 0.795 
Dexamethazone 50-02-2 0.001 0.003 0.571 0.774 
3,4-Dinitrotoluene 610-39-
9 
0.001 0.003 0.008 0.121 
Retinol acetate 127-47-
9 
0.001 0.004 0.094 0.295 
p-Nitrosodiphenylamine 156-10-
5 
0.001 0.004 0.022 0.180 
Glutaraldehyde 111-30-
8 
0.001 0.004 0.131 0.392 
trans-1,4-dichloro-2-butene 110-57-
6 
0.001 0.004 0.177 0.441 
Hexachlorophene 70-30-4 0.001 0.005 0.856 0.902 
Acetochlor 34256-
82-1 
0.001 0.005 0.257 0.548 
Titanocene dichloride 1271-
19-8 
0.001 0.005 0.849 0.902 
Chlordecone (kepone) 143-50-
0 
0.001 0.005 0.046 0.218 
Nifedipine 21829-
25-4 
0.002 0.006 0.000 0.022 
Saquinavir mesylate (AIDS 149845- 0.002 0.006 0.141 0.395 
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Initiative) 06-7 
Chlordecone (kepone) 143-50-
0 
0.002 0.006 0.010 0.128 
dimethyldipropylene-triamine 10563-
29-8 
0.002 0.006 0.308 0.562 
Zinc pyrithione 13463-
41-7 
0.002 0.007 0.275 0.556 
1-Methyl-3-nitro-1-nitroso-
guanidine 
70-25-7 0.003 0.009 0.015 0.150 
Cetylpyridinium bromide 140-72-
7 
0.003 0.011 0.010 0.128 
8-Hydroxyquinoline 148-24-
3 
0.004 0.012 0.193 0.474 
Potassium dichromate 7778-
50-9 
0.004 0.013 0.067 0.247 
2,4-Difluoronitrobenzene 446-35-
5 
0.004 0.013 0.163 0.418 
p-tert-Butylcatechol 98-29-3 0.004 0.013 0.618 0.802 
t-Butylhydroquinone 1948-
33-0 
0.004 0.013 0.702 0.861 
p-n-Nonylphenol 104-40-
5 
0.005 0.015 0.143 0.395 
Amiloride hydrochloride 2016-
88-8 
0.006 0.016 0.011 0.128 
17beta-Estradiol 50-28-2 0.006 0.016 0.154 0.399 
Ethyl linolenate 1191-
41-9 
0.006 0.016 0.045 0.218 
Pentaerythritol triacrylate 3524-
68-3 
0.008 0.023 0.001 0.050 
Di(2-ethylhexyl) phthalate 117-81-
7 
0.008 0.023 0.216 0.499 
Bis(cyclopentadienyl)vanadiu
m chloride 
12083-
48-6 
0.008 0.023 0.720 0.871 
Dichlorvos (Vapona) 62-73-7 0.009 0.025 0.282 0.556 
1,6-Hexamethylene diacrylate 13048-
33-4 
0.010 0.025 0.002 0.073 
N,N-Diethyl-p-
phenylenediamine 
93-05-0 0.010 0.027 0.303 0.562 
8-Hydroxyquinoline 148-24-
3 
0.011 0.027 0.280 0.556 
Ethidium bromide 1239-
45-8 
0.011 0.027 0.787 0.882 
4-Methoxy-3-nitro-N-
phenylbenzamide 
97-32-5 0.013 0.033 0.558 0.768 
Dibromoacetonitrile 3252-
43-5 
0.015 0.038 0.248 0.535 
4-Amino-4'-hydroxy-3-methyl- 6219- 0.017 0.042 0.786 0.882 
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diphenylamine 89-2 
Hexamethyl-p-rosaniline 
chloride 
548-62-
9 
0.018 0.043 0.864 0.902 
4,4-Thiobis(6-tert-butyl-m-
cresol) 
96-69-5 0.019 0.044 0.345 0.600 
2-Chloroacetophenone (CN) 532-27-
4 
0.020 0.046 0.071 0.249 
2-Amino-4-methylphenol 95-84-1 0.021 0.047 0.594 0.794 
Ninhydrin 485-47-
2 
0.022 0.050 0.389 0.627 
o-Phenanthroline 66-71-7 0.022 0.050 0.075 0.251 
Phenylmercuric acetate 62-38-4 0.169 0.237 0.000 0.037 
P-values were obtained by running analyses of variance on log10(EC10) with subpopulation or sex as a 
categorical variable. q-values were obtained after Benjamini-Hochberg false discovery rate correction 
per chemical.  
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Table 3.3. MAGWAS Multivariate Association Results. 
Chemicala CAS # SNP bpb Chrom Gene Pc qvalued Explained R2 
e 
2-Amino-4-methylphenol 95-84-1 rs13120371 139092719 4 SLC7A11 8.42E-10 0.0006 0.0723 
Methyl mercuric (II) chloride 115-09-3 rs13120371 139092719 4 SLC7A11 8.89E-08 0.0632 0.0414 
N-Methyl-p-aminophenol 
sulfate 
55-55-0 rs13120371 139092719 4 SLC7A11 4.88E-08 0.0347 0.0395 
N-Isopropyl-N'-phenyl-p-
phenylenediamine 
101-72-4 rs1159874 19916619 7 TMEM196 2.71E-09 0.0019 0.0264 
rs6430301 148953669 2 MBD5 2.84E-07 0.0674 0.0262 
rs3935192 75878841 17 FLJ45079 5.44E-07 0.0968 0.0281 
2-Amino-4-methylphenol 95-84-1 rs57046479 99635548 9 ZNF782 3.25E-07 0.0769 0.0181 
rs6446632 4355380 4 ZBTB49 6.15E-07 0.0875 0.0340 
o-Aminophenol 95-55-6 rs1800566 69745145 16 NFAT5 4.32E-09 0.0031 0.0554 
rs4244032 142794725 5 NR3C1 3.79E-07 0.0430 0.0210 
rs8073076 63454129 17 AXIN2 1.10E-06 0.0784 0.0193 
rs11062381 2954423 12 FKBP4 1.46E-06 0.0945 0.0337 
Titanocene dichloride 1271-19-8 rs62009303 92805261 15 SLCO3A1 1.97E-08 0.0140 0.0222 
rs62189869 162922728 2 LOC151171 1.82E-07 0.0431 0.0197 
rs12902246 49274274 15 SECISBP2L 4.62E-07 0.0657 0.0311 
rs1906308 104333651 11 PDGFD 7.90E-07 0.0703 0.0261 
13-cis-Retinal 472-86-6 rs541217 106564400 6 PRDM1 1.23E-08 0.0087 0.0205 
rs4532252 12397379 4 RAB28 3.72E-07 0.0715 0.0329 
N,N-Diethyl-p-
phenylenediamine 
93-05-0 rs6691053 173868955 1 DARS2 2.82E-08 0.0200 0.0194 
rs61879371 19852683 11 NAV2 1.39E-07 0.0494 0.0181 
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CAS # SNP bpb Chrom Gene Pc qvalued Explained R2 
e 
2,4-Decadienal 25152-84-
5 
rs1194596 154238383 1 C1orf43 3.60E-08 0.0207 0.0282 
rs4689451 6458552 4 PPP2R2C 9.97E-08 0.0236 0.0211 
Malachite green oxalate 2437-29-8 rs3742522 24906534 14 KHNYN 5.53E-08 0.0062 0.0388 
rs10772306 10677140 12 KLRAP1 3.59E-07 0.0283 0.0169 
rs717818 141830833 4 RNF150 1.40E-06 0.0908 0.0180 
Fumaronitrile 764-42-1 rs11048994 27530778 12 ARNTL2 7.08E-08 0.0504 0.0136 
rs12962668 444687 18 COLEC12 2.64E-07 0.0940 0.0262 
Retinal 116-31-4 rs11590090 113313563 1 FAM19A3 9.91E-08 0.0508 0.0198 
rs34835780 3842112 1 LOC100133612 2.14E-07 0.0508 0.0143 
Permethrin 52645-53-
1 
rs2408151 5912100 8 MCPH1 1.04E-07 0.0740 0.0211 
rs2598 47241618 20 PREX1 2.26E-07 0.0805 0.0197 
1,3-Dicyclohexylcarbodiimide 538-75-0 rs28437300 22224506 8 SLC39A14 4.25E-09 0.0030 0.0245 
Dieldrin 60-57-1 rs504504 85420044 1 MCOLN2 1.64E-08 0.0116 0.0517 
Flutamide (pubertal study) 13311-84-
7 
rs17186961 103630028 8 KLF10 1.83E-08 0.0130 0.0283 
Aldrin 309-00-2 rs340251 158599864 3 MFSD1 2.37E-08 0.0118 0.0271 
2,3,4,5-Tetrachlorophenol 4901-51-3 rs7879360 88236251 X CPXCR1 3.95E-08 0.0281 0.0181 
Colchicine 64-86-8 rs7777880 48275852 7 ABCA13 4.34E-08 0.0308 0.0244 
Sulfathiazole 72-14-0 rs1796415 121543011 12 P2RX7 4.94E-08 0.0351 0.0416 
Reserpine 50-55-5 rs13143102 131264117 4 C4orf33 5.05E-08 0.0359 0.0388 
Dichlorvos (Vapona) 62-73-7 rs1037353 83525588 11 DLG2 6.73E-08 0.0479 0.0165 
1,2-Epoxy-3-chloropropane 106-89-8 rs3130884 72228285 X PABPC1L2B 6.97E-08 0.0496 0.0182 
Cycloheximide 66-81-9 rs8053118 79168698 16 WWOX 7.66E-08 0.0545 0.0189 
Benzethonium chloride 121-54-0 rs62496173 9309398 8 TNKS 9.07E-08 0.0645 0.0220 
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Chemicala CAS # SNP bpb Chrom Gene Pc qvalued Explained R2 
e 
Tetrachlorvinphos 961-11-5 rs7642013 32638632 3 DYNC1LI1 9.38E-08 0.0667 0.0208 
Mono(2-ethylhexyl)phthalate 4376-20-9 rs1204399 99886830 X TNMD 9.79E-08 0.0577 0.0285 
7,12-Dimethylbenzanthracene 57-97-6 rs9932935 16247471 16 ABCC1 9.84E-08 0.0700 0.0338 
Phenylmercuric acetate 62-38-4 rs12899102 40495067 15 BUB1B 1.41E-07 0.0522 0.0233 
o-Phenanthroline 66-71-7 rs11716740 182831688 3 MCCC1 1.98E-07 0.0740 0.0238 
aThe first three entries highlight that rs13120371 in SLC7A11 was observed with FDR q<0.10 for three chemicals.  Remaining entries are sorted 
first by chemical, and then P-value. bNCBI build 37.  cMAGWAS P-value.  d FDR q-value obtained per chemical, using ~700K SNPs analyzed by 
MAGWAS. ePartial R2 attributable to variation in genotype. 
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Table 3.4 Significant EC10 –SNP associations among set of 1.3m SNPs 
Chemical CAS # SNP bpa Chro
m 
gene Pb q-
valuec 
Chlordecone (kepone) 143-50-0 rs28502033 714403
92 
7 CALN1 1.29
E-10 
2E-04 
Tetramethylthiouram disulfide 137-26-8 rs74487456 877081
46 
15 AGBL1 3.13
E-10 
4E-04 
2,2'-Thiobis(4,6-dichlorophenol) 97-18-7 rs78022668 220093
749 
1 SLC30A1
0 
3.28
E-10 
4E-04 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX)droxy-2(5H)-furanone(MX) 
77439-
76-0 
rs11414767
1 
806998
99 
16 CDYL2 1.23
E-09 
0.002 
2,4-Hexadienal 142-83-6 rs499384 335820
90 
6 BAK1 1.93
E-09 
0.003 
1,3-Diiminobenz (f)-isoindoline 65558-
69-2 
rs11813930 214294
32 
10 C10orf1
13 
2.13
E-09 
0.003 
2,3,4,5-Tetrachlorophenol 4901-51-
3 
rs61732507 381289
32 
21 HLCS 2.35
E-09 
0.003 
N-Methyl-p-aminophenol sulfate 55-55-0 rs13120371 139092
719 
4 SLC7A11 3.97
E-09 
0.005 
4-Amino-4’-hydroxy-3-methyl-diphenylamineenylamine 6219-89-
2 
rs75523194 863169
69 
7 GRM3 6.78
E-09 
0.009 
1,8-Dihydroxy-4,5-dinitroanthraquinoneuinone 81-55-0 rs75198473 241641
98 
10 KIAA121
7 
7.92
E-09 
0.011 
cis-Dichlorodiamine platinum 15663-
27-1 
rs6461533 210829
86 
7 SP8 8.25
E-09 
0.011 
dichloroacetonitrile 3018-12-
0 
rs75207133 123195
84 
9 TYRP1 8.74
E-09 
0.012 
Amiloride hydrochloride 2016-88-
8 
rs74631305 667728
43 
12 GRIP1 9.18
E-09 
0.012 
Domiphen bromide 538-71-6 rs78468118 827006
51 
16 CDH13 9.24
E-09 
0.009 
o-Phenylenediamine 95-54-5 rs28473317 100407
305 
15 ADAMTS
17 
9.34
E-09 
0.009 
t-Butyl formate 762-75-4 rs17044941 234331
91 
2 KLHL29 9.43
E-09 
0.013 
N,N,N’,N’-Tetramethyl-p-phenylenediamineediamine 100-22-1 rs9825285 171722
475 
3 TMEM2
12 
9.50
E-09 
0.013 
Cycloheximide 66-81-9 rs75192401 107761
225 
11 RAB39 1.02
E-08 
0.014 
Progesterone 57-83-0 rs60732724 153798
056 
5 GALNT1
0 
1.14
E-08 
0.015 
Domiphen bromide 538-71-6 rs75611658 103934
813 
13 SLC10A2 1.29
E-08 
0.009 
o-Phenylenediamine 95-54-5 rs11301912
0 
291965
46 
13 SLC46A3 1.39
E-08 
0.009 
1,2-Epoxy-3-chloropropane (Epichlorohydrin) 106-89-8 rs74422342 128543
398 
7 KCP 1.53
E-08 
0.015 
Alizarin Yellow R, free acid 2243-76-
7 
rs78618741 168250
523 
2 XIRP2 1.59
E-08 
0.021 
17beta-Estradiol 50-28-2 rs76341199 739328
70 
6 KHDC1L 1.90
E-08 
0.025 
Aflatoxin B1 from Aspergillus flavusavus 1162-65-
8 
rs73277691 354953
26 
20 C20orf1
18 
1.96
E-08 
0.017 
1,1,1,2-Tetrabromoethane 630-16-0 rs73737933 801557
5 
5 MTRR 2.07
E-08 
0.015 
2',4',5'-Trihydroxybutyrophenone 1421-63-
2 
rs10213832 172302
409 
5 ERGIC1 2.10
E-08 
0.028 
Diethylene glycol diacrylate 4074-88-
8 
rs75191956 516398
20 
15 GLDN 2.11
E-08 
0.028 
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8-Hydroxyquinoline 148-24-3 rs9477330 171350
67 
6 RBM24 2.20
E-08 
0.021 
1,2-Epoxy-3-chloropropane (Epichlorohydrin) 106-89-8 rs73109015 637907
27 
5 RGS7BP 2.28
E-08 
0.015 
Mercuric chloride 7487-94-
7 
rs5963392 381443
23 
X RPGR 2.30
E-08 
0.031 
1,3-Diiminobenz (f)-isoindoline 65558-
69-2 
rs11444823
5 
101178
035 
12 ANO4 2.43
E-08 
0.016 
Melatonin 73-31-4 rs6473423 841340
51 
8 SNX16 2.55
E-08 
0.034 
2-Octyl-3-isothiazolone 26530-
20-1 
rs57831318 154355
658 
3 GPR149 2.58
E-08 
0.020 
Chlordane (technical grade) 12789-
03-6 
rs4531541 756681
92 
12 CAPS2 2.67
E-08 
0.035 
N-(1,3-Dimethylbutyl)-N’-phenyl-p-phenylenediamine 793-24-8 rs17173040 144146
779 
7 NOBOX 2.67
E-08 
0.031 
2-Chloroacetophenone (CN) 532-27-4 rs7262054 566213
12 
20 ANKRD6
0 
2.86
E-08 
0.038 
Iodochlorohydroxyquinoline 130-26-7 rs2122382 623264
84 
2 COMMD
1 
2.88
E-08 
0.019 
1-Naphthylamine 134-32-7 rs11418175
7 
341515
15 
14 NPAS3 3.01
E-08 
0.04 
dichloroacetonitrile 3018-12-
0 
rs78571529 543504
74 
2 ACYP2 3.11
E-08 
0.018 
Guggulsterones E 39025-
24-6 
rs11249990
8 
127825
897 
12 TMEM1
32C 
3.13
E-08 
0.042 
Zinc pyrithione 13463-
41-7 
rs531928 165901
231 
1 UCK2 3.14
E-08 
0.042 
2,2'-Thiobis(4,6-dichlorophenol) 97-18-7 rs11658045
1 
231391
030 
1 GNPAT 3.18
E-08 
0.021 
8-Hydroxyquinoline 148-24-3 rs4721944 207907
67 
7 ABCB5 3.23
E-08 
0.021 
1,1,1,2-Tetrabromoethane 630-16-0 rs4566162 513227
20 
16 SALL1 3.37
E-08 
0.015 
N-(1-Naphthyl)ethylenediamine dihydrochloride 1465-25-
4 
rs74706294 918492
17 
6 BACH2 3.39
E-08 
0.025 
Acetochlor 34256-
82-1 
rs11523761
8 
800406
82 
2 CTNNA2 3.40
E-08 
0.045 
Nitazoxanide 55981-
09-4 
rs182482 160710
20 
16 ABCC1 3.44
E-08 
0.026 
Colchicine 64-86-8 rs9419276 134798
249 
10 C10orf9
3 
3.53
E-08 
0.047 
Cycloheximide 66-81-9 rs78272463 955130
38 
8 KIAA142
9 
3.74
E-08 
0.023 
dichloroacetonitrile 3018-12-
0 
rs72894316 743786
60 
3 CNTN3 3.96
E-08 
0.018 
Bisphenol A diglycidyl ether 1675-54-
3 
rs7708761 118856
707 
5 HSD17B
4 
4.01
E-08 
0.032 
N,N-Dimethyl-p-nitrosoaniline 138-89-6 rs11523761
8 
800406
82 
2 CTNNA2 4.02
E-08 
0.041 
Aflatoxin B1 from Aspergillus flavus 1162-65-
8 
rs78373020 986730
48 
1 DPYD 4.09
E-08 
0.017 
Captan 133-06-2 rs9533891 450992
24 
13 TSC22D1 4.11
E-08 
0.055 
7,12-Dimethylbenzanthracene 57-97-6 rs7051976 786578
92 
X ITM2A 4.26
E-08 
0.046 
Aflatoxin B1 from Aspergillus flavus 1162-65-
8 
rs73892641 267573
2 
20 EBF4 4.31
E-08 
0.017 
m-Nitrobenzyl chloride 619-23-8 rs11656302
7 
107358
795 
4 AIMP1 4.37
E-08 
0.037 
1,1,1,2-Tetrabromoethane 630-16-0 rs80050627 165228
913 
1 LMX1A 4.48
E-08 
0.015 
1,2-Epoxy-3-chloropropane (Epichlorohydrin) 106-89-8 rs10175753 230503
892 
2 DNER 4.53
E-08 
0.020 
t-Butylhydroquinone 1948-33-
0 
rs76069668 101975
867 
2 CREG2 4.78
E-08 
0.063 
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17beta-Estradiol 50-28-2 rs79788122 907598
26 
13 GPC5 4.78
E-08 
0.028 
N-(1-Naphthyl)ethylenediamine dihydrochloride 1465-25-
4 
rs3736146 334576
97 
17 NLE1 4.81
E-08 
0.025 
Bisphenol A diglycidyl ether 1675-54-
3 
rs7699080 728858
99 
4 NPFFR2 4.83
E-08 
0.032 
Toxaphene 8001-35-
2 
rs60756373 249105
34 
22 UPB1 4.84
E-08 
0.036 
Aflatoxin B1 from Aspergillus flavus 1162-65-
8 
rs19089932
6 
244197
75 
21 NCAM2 5.04
E-08 
0.017 
4-Amino-4’-hydroxy-3-methyl-diphenylamine 6219-89-
2 
rs78933262 867603
40 
16 FOXL1 5.06
E-08 
0.034 
Cycloheximide 66-81-9 rs11221963
8 
894582
22 
14 EML5 5.06
E-08 
0.023 
Hexachloro-1,3-butadiene 87-68-3 rs72774515 294911 2 ACP1 5.22
E-08 
0.069 
N,N,N’,N’-Tetramethyl-p-phenylenediamine 100-22-1 rs74706317 150228
076 
2 LYPD6 5.32
E-08 
0.035 
Systhane 88671-
89-0 
rs74798209 770383
27 
15 SCAPER 5.36
E-08 
0.036 
2,3,4,5-Tetrachlorophenol 4901-51-
3 
rs1904540 670454
72 
12 GRIP1 5.39
E-08 
0.036 
1,8-Dihydroxy-4,5-dinitroanthraquinone 81-55-0 rs58733988 374005
97 
4 KIAA123
9 
5.60
E-08 
0.025 
Cadmium chloride 10108-
64-2 
rs4751095 131322
781 
10 MGMT 5.61
E-08 
0.074 
m-Nitrobenzyl chloride 619-23-8 rs2570981 121765
728 
5 SNCAIP 5.63
E-08 
0.037 
N-(1-Naphthyl)ethylenediamine dihydrochloride 1465-25-
4 
rs55681361 472988
54 
21 PCBP3 5.71
E-08 
0.025 
Cycloheximide 66-81-9 rs5974707 136862
247 
X GPR101 5.72
E-08 
0.038 
Chlordecone (kepone) 143-50-0 rs34098910 497209
32 
12 TROAP 5.97
E-08 
0.040 
p-Nitrosodiphenylamine 156-10-5 rs236356 368011
88 
6 CPNE5 6.00
E-08 
0.059 
Domiphen bromide 538-71-6 rs8057753 561752
42 
16 LOC2838
56 
6.14
E-08 
0.027 
Titanocene dichloride 1271-19-
8 
rs10521479 555833
83 
X FOXR2 6.16
E-08 
0.082 
N,N-Dimethyl-p-nitrosoaniline 138-89-6 rs11305997
5 
194701
443 
3 C3orf21 6.23
E-08 
0.041 
Saquinavir mesylate (AIDS Initiative) 149845-
06-7 
rs80233769 917429
37 
15 SV2B 6.24
E-08 
0.083 
Nitazoxanide 55981-
09-4 
rs7522764 147001
029 
1 BCL9 6.41
E-08 
0.028 
4-Chloro-o-phenylenediamine 95-83-0 rs11943865 148650
93 
4 CC2D2A 6.41
E-08 
0.059 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX)droxy-2(5H)-furanone(MX) 
77439-
76-0 
rs11338951
1 
143441
17 
16 MKL2 6.43
E-08 
0.020 
17beta-Estradiol 50-28-2 rs78468118 827006
51 
16 CDH13 6.54
E-08 
0.028 
1-Naphthylamine 134-32-7 rs11618649
9 
668004
64 
3 LRIG1 6.55
E-08 
0.044 
Acetochlor 34256-
82-1 
rs16839696 138609
221 
2 HNMT 6.72
E-08 
0.045 
Dazomet 533-74-4 rs11481148
4 
140314
947 
2 LRP1B 6.79
E-08 
0.085 
N,N'-Diphenyl-p-phenylenediamine 74-31-7 rs9523298 919535
23 
13 MIR17H
G 
6.79
E-08 
0.045 
dichloroacetonitrile 3018-12-
0 
rs74598282 871158
33 
9 KLF4 6.97
E-08 
0.021 
7,12-Dimethylbenzanthracene 57-97-6 rs6681688 818812
12 
1 LPHN2 7.00
E-08 
0.046 
Ziram 137-30-4 rs6696727 214422
475 
1 SMYD2 7.16
E-08 
0.095 
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Styrene 100-42-5 rs73154933 694486
2 
2 CMPK2 7.33
E-08 
0.097 
Aflatoxin B1 from Aspergillus flavus 1162-65-
8 
rs57916829 672786
17 
18 DOK6 7.44
E-08 
0.020 
permethrin 52645-
53-1 
rs12547834 103661
811 
8 KLF10 7.66
E-08 
0.067 
N-(1,3-Dimethylbutyl)-N’-phenyl-p-phenylenediamine 793-24-8 rs11891305 379473
8 
2 ALLC 7.75
E-08 
0.031 
dichloroacetonitrile 3018-12-
0 
rs11620259
2 
118722
702 
8 EXT1 8.06
E-08 
0.021 
1,3-Diiminobenz (f)-isoindoline 65558-
69-2 
rs11579730
2 
715790
45 
5 MRPS27 8.89
E-08 
0.034 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX) 
77439-
76-0 
rs11307345
8 
883482
09 
3 C3orf38 9.27
E-08 
0.021 
Amiloride hydrochloride 2016-88-
8 
rs9805629 110688
370 
13 COL4A1 9.30
E-08 
0.062 
Captan 133-06-2 rs7144942 306995
18 
14 PRKD1 9.43
E-08 
0.042 
2,3,4,5-Tetrachlorophenol 4901-51-
3 
rs28483005 888327
41 
7 ZNF804B 9.81
E-08 
0.043 
2-Amino-4-chlorophenol 95-85-2 rs7871969 667346
5 
9 GLDC 9.95
E-08 
0.057 
Systhane 88671-
89-0 
rs75774128 535059
43 
13 PCDH8 9.99
E-08 
0.044 
17beta-Estradiol 50-28-2 rs36022476 766737
85 
15 SCAPER 1.03
E-07 
0.028 
1,3-Diiminobenz (f)-isoindoline 65558-
69-2 
rs75108342 186491
772 
4 SORBS2 1.03
E-07 
0.034 
Triamterene 396-01-0 rs75524003 811778 9 DMRT1 1.04
E-07 
0.075 
p-Nitrosodiphenylamine 156-10-5 rs11278084
7 
991209
81 
7 ZKSCAN
5 
1.06
E-07 
0.059 
2,4-Hexadienal 142-83-6 rs76209455 838786 17 NXN 1.07
E-07 
0.071 
Toxaphene 8001-35-
2 
rs11216844
3 
233419
69 
6 HDGFL1 1.07
E-07 
0.036 
Colchicine 64-86-8 rs60118770 914432
59 
8 TMEM6
4 
1.11
E-07 
0.074 
Nitazoxanide 55981-
09-4 
rs10187279 228612
202 
2 SLC19A3 1.12
E-07 
0.037 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX) 
77439-
76-0 
rs11216844
3 
233419
69 
6 HDGFL1 1.15
E-07 
0.022 
Captan 133-06-2 rs1793170 118150
205 
11 MPZL3 1.17
E-07 
0.042 
2-Amino-4-chlorophenol 95-85-2 rs75408210 676088
38 
2 ETAA1 1.18
E-07 
0.057 
Chlordecone (kepone) 143-50-0 rs9933397 553966
53 
16 IRX6 1.20
E-07 
0.047 
4-Amino-4’-hydroxy-3-methyl-diphenylamine 6219-89-
2 
rs76662197 142805
555 
4 IL15 1.20
E-07 
0.053 
Captan 133-06-2 rs35333194 123412
290 
6 CLVS2 1.27
E-07 
0.042 
2-Amino-4-chlorophenol 95-85-2 rs77766744 400234
74 
12 C12orf4
0 
1.31
E-07 
0.057 
17beta-Estradiol 50-28-2 rs14698611
8 
968950
44 
X DIAPH2 1.33
E-07 
0.028 
p-Nitrosodiphenylamine 156-10-5 rs11462131
3 
216531
001 
2 LOC6463
24 
1.33
E-07 
0.059 
Triamterene 396-01-0 rs74000350 239858
614 
2 HDAC4 1.41
E-07 
0.075 
17beta-Estradiol 50-28-2 rs77203508 174412
976 
2 ZAK 1.42
E-07 
0.028 
1,2-Epoxy-3-chloropropane (Epichlorohydrin) 106-89-8 rs77143142 104926
726 
12 CHST11 1.43
E-07 
0.047 
N-(1,3-Dimethylbutyl)-N’-phenyl-p-phenylenediamine 793-24-8 rs11487255
2 
716542
41 
17 SDK2 1.45
E-07 
0.031 
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2,3,4,5-Tetrachlorophenol 4901-51-
3 
rs74444408 277966
16 
14 NOVA1 1.51
E-07 
0.050 
o-Aminophenol 95-55-6 rs11476573
0 
156894
511 
6 ARID1B 1.53
E-07 
0.088 
N-(1,3-Dimethylbutyl)-N’-phenyl-p-phenylenediamine 793-24-8 rs74831443 543568
52 
2 ACYP2 1.53
E-07 
0.031 
Hexachloro-1,3-butadiene 87-68-3 rs72661424 103823
726 
13 SLC10A2 1.61
E-07 
0.071 
dichloroacetonitrile 3018-12-
0 
rs11215989 116407
490 
11 BUD13 1.62
E-07 
0.036 
8-Hydroxyquinoline 148-24-3 rs2705858 148972
62 
2 NBAS 1.63
E-07 
0.066 
1,1,1,2-Tetrabromoethane 630-16-0 rs80184146 539670
78 
7 POM121
L12 
1.64
E-07 
0.043 
17beta-Estradiol 50-28-2 rs77023555 415187
15 
8 MIR486 1.67
E-07 
0.028 
1,3-Diiminobenz (f)-isoindoline 65558-
69-2 
rs79099303 178107
512 
5 ZNF354A 1.68
E-07 
0.045 
4-Chloro-o-phenylenediamine 95-83-0 rs1863773 171861
497 
2 TLK1 1.68
E-07 
0.059 
Triamterene 396-01-0 rs80124975 551711
50 
7 EGFR 1.69
E-07 
0.075 
N-(1,3-Dimethylbutyl)-N’-phenyl-p-phenylenediamine 793-24-8 rs73077728 396662
23 
5 DAB2 1.70
E-07 
0.031 
Cycloheximide 66-81-9 rs938729 127996
472 
9 RABEPK 1.70
E-07 
0.045 
2-Amino-4-chlorophenol 95-85-2 rs74445911 991882
02 
3 COL8A1 1.71
E-07 
0.057 
Acetochlor 34256-
82-1 
rs75608771 181458
496 
4 ODZ3 1.73
E-07 
0.051 
N,N'-Diphenyl-p-phenylenediamine 74-31-7 rs852350 468281
60 
20 PREX1 1.73
E-07 
0.057 
Systhane 88671-
89-0 
rs76341199 739328
70 
6 KHDC1L 1.73
E-07 
0.057 
Aflatoxin B1 from Aspergillus flavus 1162-65-
8 
rs73946114 115126
665 
2 ACTR3 1.73
E-07 
0.038 
permethrin 52645-
53-1 
SNP2-
19172082 
193086
01 
2 OSR1 1.73
E-07 
0.067 
4-Chloro-o-phenylenediamine 95-83-0 rs35972823 127572
550 
9 OLFML2
A 
1.76
E-07 
0.059 
o-Aminophenol 95-55-6 rs73367814 144496
350 
8 MAFA 1.86
E-07 
0.088 
Acetochlor 34256-
82-1 
rs11585057
9 
108846
714 
12 FICD 1.91
E-07 
0.051 
dichloroacetonitrile 3018-12-
0 
rs35516880 497040
23 
19 TRPM4 1.97
E-07 
0.037 
o-Aminophenol 95-55-6 rs11621481
4 
145659
037 
1 RNF115 1.98
E-07 
0.088 
Aflatoxin B1 from Aspergillus flavus 1162-65-
8 
rs16863051 222617
754 
2 EPHA4 1.99
E-07 
0.038 
permethrin 52645-
53-1 
rs11879047 485350
12 
19 CABP5 2.00
E-07 
0.067 
4-Chloro-o-phenylenediamine 95-83-0 rs915258 996540
01 
X PCDH19 2.01
E-07 
0.059 
1,3-Diiminobenz (f)-isoindoline 65558-
69-2 
rs78119276 408794
72 
13 FOXO1 2.05
E-07 
0.045 
Chlordecone (kepone) 143-50-0 rs73490735 783961
6 
16 A2BP1 2.12
E-07 
0.047 
p-Nitrosodiphenylamine 156-10-5 rs2697819 140737
05 
11 SPON1 2.12
E-07 
0.07 
7,12-Dimethylbenzanthracene 57-97-6 rs77953084 130557
966 
3 ATP2C1 2.22
E-07 
0.074 
Domiphen bromide 538-71-6 rs11110500 101123
449 
12 GAS2L3 2.23
E-07 
0.054 
4-Chloro-o-phenylenediamine 95-83-0 rs16886866 122678
03 
4 HS3ST1 2.23
E-07 
0.059 
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Toxaphene 8001-35-
2 
rs74822199 920159
24 
1 CDC7 2.25
E-07 
0.047 
dichloroacetonitrile 3018-12-
0 
rs78443892 101205
305 
12 ANO4 2.34
E-07 
0.039 
17beta-Estradiol 50-28-2 rs76272767 313212
04 
3 STT3B 2.39
E-07 
0.035 
Domiphen bromide 538-71-6 rs77606067 123572
01 
2 LPIN1 2.41
E-07 
0.054 
8-Hydroxyquinoline 148-24-3 rs78767283 135001
510 
5 CXCL14 2.42
E-07 
0.066 
Domiphen bromide 538-71-6 rs77635386 979414
84 
14 VRK1 2.43
E-07 
0.054 
1,8-Dihydroxy-4,5-dinitroanthraquinone 81-55-0 rs61749065 379214
24 
1 LOC7284
31 
2.48
E-07 
0.064 
2-Amino-4-chlorophenol 95-85-2 rs10980588 113609
826 
9 MUSK 2.49
E-07 
0.066 
Chlordecone (kepone) 143-50-0 rs13229 411658
78 
17 IFI35 2.52
E-07 
0.047 
N-Methyl-p-aminophenol sulfate 55-55-0 rs523638 234658
886 
1 TARBP1 2.54
E-07 
0.067 
Cycloheximide 66-81-9 rs11456102
4 
888699
7 
6 SLC35B3 2.61
E-07 
0.058 
2,3,4,5-Tetrachlorophenol 4901-51-
3 
rs16930149 296015
08 
10 LYZL1 2.67
E-07 
0.057 
p-Nitrosodiphenylamine 156-10-5 rs72884793 597428
33 
3 FHIT 2.76
E-07 
0.073 
Toxaphene 8001-35-
2 
rs11640971
3 
167134
776 
5 ODZ2 2.76
E-07 
0.047 
Toxaphene 8001-35-
2 
rs9660010 240588
502 
1 FMN2 2.82
E-07 
0.047 
Acetochlor 34256-
82-1 
rs11475202
3 
498972
38 
2 FSHR 2.86
E-07 
0.063 
2,3,4,5-Tetrachlorophenol 4901-51-
3 
SNP5-
131756739 
131728
840 
5 SLC22A5 2.95
E-07 
0.057 
17beta-Estradiol 50-28-2 rs58049330 906111
55 
9 CDK20 2.96
E-07 
0.039 
2,3,4,5-Tetrachlorophenol 4901-51-
3 
rs1052179 712670
10 
10 TSPAN1
5 
3.01
E-07 
0.057 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX) 
77439-
76-0 
rs11437715
6 
230451
029 
2 DNER 3.05
E-07 
0.038 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX) 
77439-
76-0 
rs72984722 140332
059 
2 LRP1B 3.10
E-07 
0.038 
1-Naphthylamine 134-32-7 rs73742862 547634
62 
6 FAM83B 3.14
E-07 
0.095 
Nitazoxanide 55981-
09-4 
rs74060294 701782
04 
14 KIAA024
7 
3.15
E-07 
0.084 
Chlordecone (kepone) 143-50-0 rs1154879 428144
17 
14 LRFN5 3.16
E-07 
0.047 
Chlordecone (kepone) 143-50-0 rs74424738 194716
032 
3 C3orf21 3.17
E-07 
0.047 
8-Hydroxyquinoline 148-24-3 rs45507700 307823
57 
13 KATNAL
1 
3.18
E-07 
0.066 
Domiphen bromide 538-71-6 rs11568403 869555
35 
9 SLC28A3 3.20
E-07 
0.061 
dichloroacetonitrile 3018-12-
0 
rs11556738
6 
845377
93 
1 TTLL7 3.25
E-07 
0.043 
o-Phenylenediamine 95-54-5 rs11455769
1 
161583
86 
6 MYLIP 3.34
E-07 
0.087 
1,3-Diiminobenz (f)-isoindoline 65558-
69-2 
rs79150690 231473
11 
9 ELAVL2 3.39
E-07 
0.064 
Cycloheximide 66-81-9 rs28679586 311884
01 
17 MYO1D 3.39
E-07 
0.064 
8-Hydroxyquinoline 148-24-3 rs12311965 131268
403 
12 STX2 3.49
E-07 
0.066 
Progesterone 57-83-0 rs77458047 980052
27 
8 PGCP 3.54
E-07 
0.060 
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Progesterone 57-83-0 rs11214105 112037
653 
11 TEX12 3.64
E-07 
0.060 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX) 
77439-
76-0 
rs73460084 801736
64 
9 GNA14 3.67
E-07 
0.038 
Chlordecone (kepone) 143-50-0 rs15087363
3 
145799
41 
20 MACRO
D2 
3.70
E-07 
0.049 
2,3,4,5-Tetrachlorophenol 4901-51-
3 
rs7734259 120522
6 
5 SLC6A19 3.78
E-07 
0.063 
Cycloheximide 66-81-9 rs7263958 124846
78 
20 SPTLC3 3.86
E-07 
0.064 
Domiphen bromide 538-71-6 rs11437715
6 
230451
029 
2 DNER 3.87
E-07 
0.062 
17beta-Estradiol 50-28-2 rs16893110 240929
18 
5 PRDM9 3.89
E-07 
0.047 
4-Chloro-o-phenylenediamine 95-83-0 rs75858454 782004
96 
9 MIR548
H3 
4.42
E-07 
0.093 
1,1,1,2-Tetrabromoethane 630-16-0 rs74053705 917148
8 
1 GPR157 4.48
E-07 
0.085 
p-Nitrosodiphenylamine 156-10-5 rs13390320 631649
2 
2 SOX11 4.49
E-07 
0.099 
Domiphen bromide 538-71-6 rs1587323 251591
33 
15 SNRPN 4.54
E-07 
0.062 
Progesterone 57-83-0 rs11702590 425246
28 
21 BACE2 4.55
E-07 
0.06 
o-Phenylenediamine 95-54-5 rs76475950 540566
15 
2 GPR75-
ASB3 
4.56
E-07 
0.087 
o-Phenylenediamine 95-54-5 rs16925298 708167
4 
9 KDM4C 4.58
E-07 
0.087 
Cycloheximide 66-81-9 rs78767283 135001
510 
5 CXCL14 4.59
E-07 
0.068 
Nitazoxanide 55981-
09-4 
rs12346608 280620 9 DOCK8 4.63
E-07 
0.088 
Domiphen bromide 538-71-6 rs56708270 279254
85 
X DCAF8L1 4.66
E-07 
0.062 
1,8-Dihydroxy-4,5-dinitroanthraquinone 81-55-0 rs11860817 553886
44 
16 IRX6 4.76
E-07 
0.079 
17beta-Estradiol 50-28-2 rs10076309 927706
38 
5 FLJ4270
9 
4.80
E-07 
0.052 
4-Chloro-o-phenylenediamine 95-83-0 rs3211770 113793
849 
13 F10 4.93
E-07 
0.093 
1-Naphthylamine 134-32-7 rs11481811
8 
791433
99 
7 MAGI2 5.02
E-07 
0.095 
1-Naphthylamine 134-32-7 rs59993949 129924
957 
12 TMEM1
32D 
5.07
E-07 
0.095 
Acetochlor 34256-
82-1 
rs73235161 207897
38 
2 HS1BP3 5.16
E-07 
0.078 
1-Naphthylamine 134-32-7 rs6468813 103139
683 
8 NCALD 5.29
E-07 
0.095 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX) 
77439-
76-0 
rs78748755 665034
51 
11 C11orf8
0 
5.32
E-07 
0.047 
dichloroacetonitrile 3018-12-
0 
rs77088325 898513
2 
20 PLCB1 5.33
E-07 
0.059 
Progesterone 57-83-0 rs7059570 264216
97 
X MAGEB6 5.43
E-07 
0.060 
1-Naphthylamine 134-32-7 SNP14-
50902158 
518324
08 
14 TMX1 5.49
E-07 
0.095 
Acetochlor 34256-
82-1 
rs74088312 965979
17 
14 BDKRB2 5.51
E-07 
0.078 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX) 
77439-
76-0 
rs6540459 208369
736 
1 PLXNA2 5.64
E-07 
0.047 
Domiphen bromide 538-71-6 rs4237673 393670
04 
11 LRRC4C 5.66
E-07 
0.068 
Chlordecone (kepone) 143-50-0 rs73833731 568396
49 
3 ARHGEF
3 
5.79
E-07 
0.064 
1,8-Dihydroxy-4,5-dinitroanthraquinone 81-55-0 rs9567646 467630
28 
13 LCP1 5.93
E-07 
0.087 
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Cycloheximide 66-81-9 rs11178293
8 
265287
64 
1 CATSPER
4 
6.04
E-07 
0.076 
Aflatoxin B1 from Aspergillus flavus 1162-65-
8 
rs76487712 352452
96 
2 CRIM1 6.11
E-07 
0.075 
Acetochlor 34256-
82-1 
rs11110500 101123
449 
12 GAS2L3 6.47
E-07 
0.078 
Acetochlor 34256-
82-1 
rs74059988 888060
6 
12 RIMKLB 6.48
E-07 
0.078 
Nitazoxanide 55981-
09-4 
rs9313437 168395
192 
5 SLIT3 6.55
E-07 
0.097 
Domiphen bromide 538-71-6 rs6028580 382824
21 
20 DHX35 6.56
E-07 
0.073 
17beta-Estradiol 50-28-2 rs75555706 960157
92 
8 C8orf38 6.57
E-07 
0.058 
Chlordecone (kepone) 143-50-0 rs11481699
3 
634234
82 
8 NKAIN3 6.63
E-07 
0.064 
Chlordecone (kepone) 143-50-0 rs73126926 536966
07 
5 HSPB3 6.73
E-07 
0.064 
1,3-Diiminobenz (f)-isoindoline 65558-
69-2 
rs12813380 118296
931 
12 KSR2 6.95
E-07 
0.097 
1-Naphthylamine 134-32-7 rs73200328 148782
22 
2 NBAS 7.05
E-07 
0.095 
N-(1,3-Dimethylbutyl)-N’-phenyl-p-phenylenediamine 793-24-8 rs724997 173708
117 
2 RAPGEF
4 
7.08
E-07 
0.083 
Cycloheximide 66-81-9 rs11130253 506811
58 
3 MAPKAP
K3 
7.08
E-07 
0.076 
1-Naphthylamine 134-32-7 rs76046261 165773
65 
11 C11orf5
8 
7.10
E-07 
0.095 
Aflatoxin B1 from Aspergillus flavus 1162-65-
8 
rs11552184
7 
149101
485 
3 TM4SF1 7.12
E-07 
0.075 
1-Naphthylamine 134-32-7 rs55711976 423009
80 
19 CEACAM
3 
7.16
E-07 
0.095 
N-(1,3-Dimethylbutyl)-N’-phenyl-p-phenylenediamine 793-24-8 rs4427625 401826
06 
12 SLC2A13 7.17
E-07 
0.083 
1,3-Diiminobenz (f)-isoindoline 65558-
69-2 
rs4077144 127622
908 
2 LOC3397
60 
7.22
E-07 
0.097 
Aflatoxin B1 from Aspergillus flavus 1162-65-
8 
rs62016193 633930
9 
16 RBFOX1 7.31
E-07 
0.075 
N-(1,3-Dimethylbutyl)-N’-phenyl-p-phenylenediamine 793-24-8 SNP16-
62118696 
635611
95 
16 CDH11 7.38
E-07 
0.083 
N-(1,3-Dimethylbutyl)-N’-phenyl-p-phenylenediamine 793-24-8 rs17015753 251111
28 
3 TOP2B 7.46
E-07 
0.083 
Chlordecone (kepone) 143-50-0 rs35972823 127572
550 
9 OLFML2
A 
7.90
E-07 
0.07 
Cycloheximide 66-81-9 rs77828608 295429
70 
22 KREMEN
1 
8.32
E-07 
0.076 
17beta-Estradiol 50-28-2 rs74631305 667728
43 
12 GRIP1 8.51
E-07 
0.071 
Progesterone 57-83-0 rs11009601 342371
66 
10 PARD3 8.57
E-07 
0.071 
Aflatoxin B1 from Aspergillus flavus 1162-65-
8 
rs281886 131785
132 
7 PLXNA4 8.65
E-07 
0.082 
Cycloheximide 66-81-9 rs11444203
4 
161596
15 
7 ISPD 8.90
E-07 
0.076 
Cycloheximide 66-81-9 rs11531755
0 
247693
6 
17 KIAA066
4 
9.15
E-07 
0.076 
Chlordecone (kepone) 143-50-0 rs9540605 664864
29 
13 PCDH9 9.26
E-07 
0.070 
N-(1,3-Dimethylbutyl)-N’-phenyl-p-phenylenediamine 793-24-8 rs599023 601723
44 
13 DIAPH3 9.86
E-07 
0.094 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX) 
77439-
76-0 
rs74444408 277966
16 
14 NOVA1 9.96
E-07 
0.075 
Acetochlor 34256-
82-1 
rs947213 105682
496 
6 PREP 1.01
E-06 
0.100 
Chlordecone (kepone) 143-50-0 rs9660010 240588
502 
1 FMN2 1.10
E-06 
0.070 
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Chlordecone (kepone) 143-50-0 rs11836196 163919
99 
12 SLC15A5 1.10
E-06 
0.070 
Chlordecone (kepone) 143-50-0 rs6076084 235285
36 
20 CST9L 1.10
E-06 
0.070 
Chlordecone (kepone) 143-50-0 rs78571529 543504
74 
2 ACYP2 1.11
E-06 
0.07 
N-(1,3-Dimethylbutyl)-N’-phenyl-p-phenylenediamine 793-24-8 rs77953084 130557
966 
3 ATP2C1 1.13
E-06 
0.094 
Acetochlor 34256-
82-1 
rs76289940 949003
17 
12 TMCC3 1.15
E-06 
0.100 
Progesterone 57-83-0 rs77697536 199224
99 
2 TTC32 1.16
E-06 
0.071 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX) 
77439-
76-0 
rs77746073 117912
00 
12 ETV6 1.17
E-06 
0.080 
Chlordecone (kepone) 143-50-0 rs2697819 140737
05 
11 SPON1 1.18
E-06 
0.071 
Acetochlor 34256-
82-1 
rs56922398 552184
60 
6 GFRAL 1.19
E-06 
0.100 
Chlordecone (kepone) 143-50-0 rs79304881 164845
251 
4 1-Mar 1.23
E-06 
0.071 
Progesterone 57-83-0 rs292582 134882
680 
7 WDR91 1.25
E-06 
0.071 
Acetochlor 34256-
82-1 
rs79450652 180881
757 
2 CWC22 1.25
E-06 
0.100 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX) 
77439-
76-0 
rs74631305 667728
43 
12 GRIP1 1.31
E-06 
0.083 
Acetochlor 34256-
82-1 
rs58612427 687863
70 
2 APLF 1.35
E-06 
0.100 
Acetochlor 34256-
82-1 
rs73432502 224269
49 
13 FGF9 1.35
E-06 
0.100 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX) 
77439-
76-0 
rs1545116 589932
26 
16 GOT2 1.44
E-06 
0.083 
Chlordecone (kepone) 143-50-0 rs35315427 87179 17 RPH3AL 1.56
E-06 
0.084 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX) 
77439-
76-0 
rs77635386 979414
84 
14 VRK1 1.69
E-06 
0.090 
Progesterone 57-83-0 rs4758204 761904
1 
11 PPFIBP2 1.73
E-06 
0.084 
Chlordecone (kepone) 143-50-0 rs28539080 599446
06 
20 CDH4 1.75
E-06 
0.087 
Progesterone 57-83-0 rs8044956 704970
86 
16 FUK 1.84
E-06 
0.084 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX) 
77439-
76-0 
rs78468118 827006
51 
16 CDH13 1.90
E-06 
0.093 
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone(MX) 
77439-
76-0 
rs78297143 436043
13 
14 LRFN5 2.14
E-06 
0.098 
Chlordecone (kepone) 143-50-0 rs9931421 779260
21 
16 VAT1L 2.19
E-06 
0.098 
Chlordecone (kepone) 143-50-0 rs7868175 665808
0 
9 GLDC 2.56
E-06 
0.098 
Chlordecone (kepone) 143-50-0 rs2012691 105453
745 
7 ATXN7L1 2.62
E-06 
0.098 
Chlordecone (kepone) 143-50-0 rs74059988 888060
6 
12 RIMKLB 2.71
E-06 
0.098 
Chlordecone (kepone) 143-50-0 rs73808311 334980
9 
3 CRBN 2.75
E-06 
0.098 
Chlordecone (kepone) 143-50-0 rs61214761 114039
909 
7 FOXP2 2.75
E-06 
0.098 
Chlordecone (kepone) 143-50-0 rs56381502 258459
22 
5 CDH9 2.97
E-06 
0.098 
Chlordecone (kepone) 143-50-0 rs79494514 341223
46 
13 STARD1
3 
2.97
E-06 
0.098 
Chlordecone (kepone) 143-50-0 rs79843432 239514
826 
1 FMN2 2.99
E-06 
0.098 
Chlordecone (kepone) 143-50-0 rs73145960 519209
9 
2 SOX11 3.02
E-06 
0.098 
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aNCBI build 37 .  b P-value.  c FDR q-value obtained per chemical.  
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Table 3.5. Significant EC10 –SNP associations among larger set of 12m SNPs 
Chemical CAS # SNP bp Chrom gene P q_value 
Vitamin D3 67-97-0 rs75591162 179520663 3 PEX5L 2.79E-
14 
3.47E-
07 
Amiloride hydrochloride 2016-88-
8 
rs149885464 114388490 X LRCH2 9.75E-
14 
1.21E-
06 
Systhane 88671-
89-0 
rs114097262 57530631 20 TH1L 2.22E-
12 
2.76E-
05 
Cycloheximide 66-81-9 rs112895158 143565653 3 C3orf58 3.19E-
12 
3.96E-
05 
Hexachlorophene 70-30-4 rs149041648 4081594 7 SDK1 3.88E-
12 
4.82E-
05 
17beta-Estradiol 50-28-2 rs148557261 85025463 X CHM 4.44E-
12 
2.76E-
05 
1,8-Dihydroxy-4,5-
dinitroanthraquinone 
81-55-0 rs115918434 70712674 6 COL19A1 5.56E-
12 
6.90E-
05 
o-Nitrobenzyl chloride 612-23-7 rs9966852 20953234 18 C18orf45 9.72E-
12 
1.00E-
04 
Cycloheximide 66-81-9 rs116560380 53916956 16 FTO 1.70E-
11 
1.00E-
04 
1,3-Diiminobenz (f)-
isoindoline 
65558-
69-2 
rs150407211 204994131 1 NFASC 1.82E-
11 
2.00E-
04 
N-Methyl-p-aminophenol 
sulfate 
55-55-0 rs139684082 55659431 20 BMP7 1.88E-
11 
2.00E-
04 
2,2'-Thiobis(4,6-
dichlorophenol) 
97-18-7 rs78022668 220093749 1 EPRS 2.19E-
11 
9.06E-
05 
17beta-Estradiol 50-28-2 rs114097262 57530631 20 TH1L 2.90E-
11 
6.86E-
05 
1,1,1,2-Tetrabromoethane 630-16-0 rs116253534 7734317 3 GRM7 3.24E-
11 
4.00E-
04 
Saquinavir mesylate (AIDS 
Initiative) 
149845-
06-7 
rs77326389 27959745 15 OCA2 3.77E-
11 
5.00E-
04 
Nitazoxanide 55981-
09-4 
rs116345917 38690860 5 LIFR 4.41E-
11 
3.91E-
05 
Dichlorvos (Vapona) 62-73-7 rs5915692 4004014 X PRKX 5.19E-
11 
6.00E-
04 
17beta-Estradiol 50-28-2 rs77919593 178511146 2 PDE11A 5.52E-
11 
6.86E-
05 
Ziram 137-30-4 rs114456684 89021170 13 SLITRK5 6.92E-
11 
9.00E-
04 
cis-Dichlorodiamine platinum 15663-
27-1 
rs13236745 21072550 7 SP8 7.19E-
11 
3.00E-
04 
Nitazoxanide 55981-
09-4 
rs114256919 106718263 14 LOC100288568 7.81E-
11 
6.06E-
05 
1,6-Hexamethylene 
diacrylate 
13048-
33-4 
rs62231930 24939620 22 C22orf13 7.91E-
11 
0.001 
N,N,N',N'-Tetramethyl-p-
phenylenediamine 
100-22-1 rs111412077 92398645 11 FAT3 9.36E-
11 
5.00E-
04 
p-Nitrosodiphenylamine 156-10-5 rs78789459 188016223 4 FAT1 1.04E-
10 
7.00E-
04 
Hexachlorophene 70-30-4 rs185960291 107817291 11 RAB39 1.11E-
10 
7.00E-
04 
p-Nitrosodiphenylamine 156-10-5 rs185480677 214584272 1 PTPN14 1.14E-
10 
7.00E-
04 
17beta-Estradiol 50-28-2 rs77023555 41518715 8 ANK1 1.20E-
10 
1.00E-
04 
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1-Methyl-3-nitro-1-nitroso-
guanidine 
81-55-0 rs139598440 89777354 X TGIF2LX 1.22E-
10 
5.00E-
04 
1,8-Dihydroxy-4,5-
dinitroanthraquinone 
70-25-7 rs115531561 69465188 2 ANTXR1 1.22E-
10 
0.002 
o-Aminophenol 95-55-6 rs182028010 230236320 1 GALNT2 1.26E-
10 
0.002 
1,3-Diiminobenz (f)-
isoindoline 
65558-
69-2 
rs146270840 194601175 3 FAM43A 1.56E-
10 
6.00E-
04 
Glutaraldehyde 111-30-8 rs7992282 31601586 13 C13orf26 1.58E-
10 
0.002 
Nitazoxanide 55981-
09-4 
rs182761810 47129104 X USP11 1.59E-
10 
1.00E-
04 
4-Chloro-o-
phenylenediamine 
95-83-0 rs146160738 103390555 X MCART6 1.68E-
10 
0.002 
Systhane 88671-
89-0 
rs111763750 53503234 13 PCDH8 1.72E-
10 
3.00E-
04 
6-Thioguanine (6-TG) 154-42-7 rs72484656 73259654 9 TRPM3 1.99E-
10 
0.003 
1,3-Diiminobenz (f)-
isoindoline 
65558-
69-2 
rs148557261 85025463 X CHM 2.02E-
10 
6.00E-
04 
Vitamin D3 67-97-0 rs79427953 155449132 5 SGCD 2.31E-
10 
9.00E-
04 
p-Quinone 106-51-4 rs140356758 96472953 13 UGGT2 2.35E-
10 
0.003 
Vitamin D3 67-97-0 rs73001915 180641510 4 LOC285501 2.47E-
10 
9.00E-
04 
4-Chloro-o-
phenylenediamine 
95-83-0 rs61790870 34693156 4 ARAP2 2.53E-
10 
0.002 
17beta-Estradiol 50-28-2 rs138873795 93861771 15 RGMA 2.59E-
10 
3.00E-
04 
Retinal 116-31-4 rs61741388 114156579 9 KIAA0368 3.11E-
10 
0.002 
17beta-Estradiol 50-28-2 rs9957628 57478543 18 PMAIP1 3.18E-
10 
3.00E-
04 
1,2-Epoxy-3-chloropropane 
(Epichlorohydrin) 
106-89-8 rs114097262 57530631 20 TH1L 3.35E-
10 
0.004 
Vitamin D3 67-97-0 rs77571603 29323478 10 LYZL1 3.37E-
10 
9.00E-
04 
Chlordecone (kepone) 143-50-0 rs6834412 4731136 4 MSX1 3.58E-
10 
0.003 
Cycloheximide 66-81-9 rs4075856 127996778 9 RABEPK 3.66E-
10 
8.00E-
04 
N,N,N',N'-Tetramethyl-p-
phenylenediamine 
100-22-1 rs139345780 35242366 2 CRIM1 3.73E-
10 
0.001 
Vitamin D3 67-97-0 rs140124941 58119464 12 AGAP2 3.75E-
10 
9.00E-
04 
Sodium dichromate 
dihydrate (VI) 
7789-12-
0 
rs144044660 175439270 4 HPGD 3.76E-
10 
0.005 
Systhane 88671-
89-0 
rs182761810 47129104 X USP11 3.79E-
10 
5.00E-
04 
Azathioprine 446-86-6 rs72625563 30966462 X TAB3 3.90E-
10 
0.004 
2',4',5'-
Trihydroxybutyrophenone 
1421-63-
2 
rs77671255 18038964 7 PRPS1L1 4.15E-
10 
0.005 
Retinol acetate 127-47-9 rs115240733 83143062 8 SNX16 4.28E-
10 
0.005 
N,N'-Diphenyl-p-
phenylenediamine 
74-31-7 rs150553218 180241673 4 LOC285501 4.57E-
10 
5.00E-
04 
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1,3-Diiminobenz (f)-
isoindoline 
65558-
69-2 
rs79373644 68284871 17 KCNJ2 4.60E-
10 
0.001 
N,N-Diethyl-p-
phenylenediamine 
93-05-0 rs184971028 23937090 9 ELAVL2 4.63E-
10 
0.006 
Nifedipine 21829-
25-4 
rs74383932 211608006 2 CPS1 4.76E-
10 
0.002 
o-Nitrobenzyl chloride 612-23-7 rs75820586 88320786 14 GALC 4.89E-
10 
0.003 
17beta-Estradiol 50-28-2 rs114750717 143943362 X SPANXN1 4.99E-
10 
4.00E-
04 
Guggulsterones E 39025-
24-6 
rs74929760 146457160 4 MMAA 5.00E-
10 
0.006 
Hydroquinone 123-31-9 rs78268501 7128396 4 SORCS2 5.03E-
10 
0.006 
Endosulfan 115-29-7 rs75512317 132143171 X USP26 5.16E-
10 
0.006 
2,2'-Thiobis(4,6-
dichlorophenol) 
97-18-7 rs76656117 24217993 10 KIAA1217 5.29E-
10 
0.002 
Nifedipine 21829-
25-4 
rs187575156 33840771 16 ZNF267 5.51E-
10 
0.002 
Hexachlorophene 70-30-4 rs188272213 38447642 5 EGFLAM 5.59E-
10 
0.002 
Nitazoxanide 55981-
09-4 
rs115715858 88034425 15 AGBL1 6.03E-
10 
3.00E-
04 
Rhein (1,8-dihydroxy-3-
carboxyl anthraquinone) 
478-43-3 rs181686881 28901928 15 GOLGA8F 6.04E-
10 
0.008 
Mercuric chloride 7487-94-
7 
rs115872305 65584758 5 SFRS12 6.05E-
10 
0.008 
Saquinavir mesylate (AIDS 
Initiative) 
50-28-2 rs115129751 102066268 14 DIO3 6.16E-
10 
5.00E-
04 
17beta-Estradiol 149845-
06-7 
rs28712763 38664057 5 LIFR 6.16E-
10 
0.002 
Chlordecone (kepone) 143-50-0 rs28502033 71440392 7 WBSCR17 6.28E-
10 
0.003 
1,8-Dihydroxy-4,5-
dinitroanthraquinone 
81-55-0 rs186751172 137938171 X FGF13 7.36E-
10 
0.001 
1-Naphthylamine 134-32-7 rs56166709 26718141 16 JMJD5 7.81E-
10 
0.002 
Oxymetholone 434-07-1 rs118085300 72050372 10 NPFFR1 7.90E-
10 
0.010 
1-Naphthylamine 134-32-7 rs148976999 89292543 2 EIF2AK3 7.96E-
10 
0.002 
Fumaronitrile 764-42-1 rs112841261 95693291 8 ESRP1 8.09E-
10 
0.010 
Nitazoxanide 55981-
09-4 
rs139729800 176909149 1 ASTN1 8.33E-
10 
3.00E-
04 
Pentaerythritol triacrylate 3524-68-
3 
rs12263759 127748420 10 ADAM12 8.37E-
10 
0.007 
Cycloheximide 66-81-9 rs2774024 21573881 1 ECE1 8.42E-
10 
9.00E-
04 
Saquinavir mesylate (AIDS 
Initiative) 
149845-
06-7 
rs115362446 59318384 10 IPMK 8.50E-
10 
0.002 
9-Aminoacridine, 
monohydrochloride, 
monohydrate 
52417-
22-8 
rs148846460 115474911 X SLC6A14 8.52E-
10 
0.011 
Saquinavir mesylate (AIDS 
Initiative) 
149845-
06-7 
rs140911187 32806643 11 CCDC73 8.61E-
10 
0.002 
p-Nitrosodiphenylamine 156-10-5 rs115484855 116269294 10 ABLIM1 8.63E- 0.002 
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10 
2,2',4'-
Trichloroacetophenone 
4252-78-
2 
rs73371185 3098435 18 MYOM1 8.84E-
10 
0.011 
Sodium dichromate 
dihydrate (VI) 
7789-12-
0 
rs117147263 3894712 12 PARP11 9.07E-
10 
0.006 
1,1,1,2-Tetrabromoethane 630-16-0 rs73561088 87780267 13 SLITRK5 9.11E-
10 
0.002 
Azathioprine 446-86-6 rs191755607 40475255 X ATP6AP2 9.13E-
10 
0.004 
Retinal 116-31-4 rs113516752 106955309 14 LOC100288568 9.20E-
10 
0.002 
Retinal 116-31-4 rs115605961 36196063 3 STAC 9.46E-
10 
0.002 
o-Phenylenediamine 95-54-5 rs78961197 55949853 19 SHISA7 9.46E-
10 
0.006 
p-Aminophenol 123-30-8 rs113103160 107838962 11 RAB39 9.50E-
10 
0.007 
2,4-Hexadienal 142-83-6 rs79177535 114025195 11 ZBTB16 9.74E-
10 
0.012 
Ziram 137-30-4 rs116855907 21587330 16 METTL9 1.00E-
09 
0.006 
Diethylene glycol diacrylate 4074-88-
8 
rs78140462 110470359 12 ANKRD13A 1.02E-
09 
0.013 
Cetylpyridinium bromide 140-72-7 rs80257852 23561114 9 ELAVL2 1.03E-
09 
0.013 
Azathioprine 3018-12-
0 
rs28365025 183643255 3 ABCC5 1.06E-
09 
0.003 
dichloroacetonitrile 446-86-6 rs117910051 164141498 6 PACRG 1.06E-
09 
0.004 
1,1,1,2-Tetrabromoethane 630-16-0 rs142817312 110092992 10 SORCS1 1.09E-
09 
0.002 
Saquinavir mesylate (AIDS 
Initiative) 
149845-
06-7 
rs145544371 6472066 X VCX3A 1.10E-
09 
0.002 
Colchicine 64-86-8 rs80328096 19803987 3 EFHB 1.11E-
09 
0.002 
Pentaerythritol triacrylate 3524-68-
3 
rs192972674 72721640 X PABPC1L2A 1.11E-
09 
0.007 
2,3,4,5-
Tetrachloronitrobenzene 
879-39-0 rs115782131 85339219 2 TCF7L1 1.13E-
09 
0.014 
p-Nitrosodiphenylamine 50-28-2 rs12087685 23727348 1 TCEA3 1.15E-
09 
8.00E-
04 
17beta-Estradiol 156-10-5 rs193048198 243945733 1 ZNF238 1.15E-
09 
0.002 
Phenformin hydrochloride 834-28-6 rs140883532 53503005 20 CYP24A1 1.16E-
09 
0.014 
Azathioprine 446-86-6 rs146213067 136068920 X GPR101 1.17E-
09 
0.004 
p-Aminophenol 123-30-8 rs57325800 10214905 1 UBE4B 1.19E-
09 
0.007 
1,3,5-Triglycidyl isocyanurate 2451-62-
9 
rs150927141 11429085 1 UBIAD1 1.19E-
09 
0.007 
Tetramethylthiouram 
disulfide 
100-27-6 rs140556470 48843069 X GRIPAP1 1.20E-
09 
0.004 
p-Nitrophenethyl alcohol 137-26-8 rs142624309 58608899 1 OMA1 1.20E-
09 
0.012 
Progesterone 143-50-0 rs185665429 129727410 8 MYC 1.22E-
09 
0.003 
Chlordecone (kepone) 57-83-0 rs73285294 153826706 5 SAP30L 1.22E- 0.015 
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09 
17beta-Estradiol 50-28-2 rs76191860 116013224 12 MED13L 1.24E-
09 
8.00E-
04 
Retinol acetate 127-47-9 rs7838214 118761053 8 EXT1 1.29E-
09 
0.008 
1,2-Epoxy-3-chloropropane 
(Epichlorohydrin) 
106-89-8 rs77143142 104926726 12 TXNRD1 1.32E-
09 
0.005 
o-Phenylenediamine 88671-
89-0 
rs11917950 8725408 3 C3orf32 1.37E-
09 
0.002 
Systhane 95-54-5 rs138701165 33431943 X DMD 1.37E-
09 
0.006 
1,1,1,2-Tetrabromoethane 630-16-0 rs113917611 145680395 5 RBM27 1.41E-
09 
0.002 
Ergotamine tartrate 379-79-3 rs78908092 91139027 8 CALB1 1.42E-
09 
0.002 
Nitrogen mustard 
hydrochloride 
55-86-7 rs185629858 72754141 9 MAMDC2 1.44E-
09 
0.009 
Nitrogen mustard 
hydrochloride 
55-86-7 rs150079115 229475297 1 C1orf96 1.46E-
09 
0.009 
Triamterene 396-01-0 rs116253534 7734317 3 GRM7 1.47E-
09 
0.018 
t-Butylhydroquinone 1948-33-
0 
rs78839292 4302598 6 PECI 1.48E-
09 
0.018 
Pyrimethamine 58-14-0 rs150650924 19223048 16 SYT17 1.53E-
09 
0.019 
1,2-Epoxy-3-chloropropane 
(Epichlorohydrin) 
106-89-8 rs73380687 33444259 15 FMN1 1.56E-
09 
0.005 
dichloroacetonitrile 3018-12-
0 
rs116561096 173810265 4 GALNT7 1.57E-
09 
0.004 
Chlordecone (kepone) 143-50-0 rs189105020 53254392 X IQSEC2 1.60E-
09 
0.003 
1,1,1,2-Tetrabromoethane 630-16-0 rs113557926 37267705 2 HEATR5B 1.61E-
09 
0.002 
2-Chloroacetophenone (CN) 532-27-4 rs138236656 17144946 17 FLCN 1.63E-
09 
0.020 
p-Nitrophenethyl alcohol 100-27-6 rs74821785 180732042 4 LOC285501 1.65E-
09 
0.004 
Diisobutyl phthalate 84-69-5 rs59163027 3618869 8 CSMD1 1.71E-
09 
0.021 
Systhane 88671-
89-0 
rs114062278 67964362 5 PIK3R1 1.75E-
09 
0.002 
Chlordecone (kepone) 143-50-0 rs147841840 121413130 12 HNF1A 1.76E-
09 
0.003 
Toxaphene 8001-35-
2 
rs2232859 24890981 22 UPB1 1.77E-
09 
0.021 
Dexamethazone 50-02-2 rs148291248 94417682 1 ABCA4 1.77E-
09 
0.022 
2-Octyl-3-isothiazolone 26530-
20-1 
rs114113654 104765328 2 POU3F3 1.83E-
09 
0.023 
Vitamin D3 67-97-0 rs115033986 35362684 2 CRIM1 1.87E-
09 
0.002 
Vitamin D3 67-97-0 rs76371158 87850932 11 RAB38 1.90E-
09 
0.002 
Amiloride hydrochloride 2016-88-
8 
rs138475390 144438110 X SPANXN1 1.94E-
09 
0.008 
3,4-Diaminotoluene 496-72-0 rs187884265 30037137 X MAGEB2 1.94E-
09 
0.024 
Endosulfan 115-29-7 rs141860023 147034359 X FMR1 1.98E- 0.012 
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09 
Tetramethylthiouram 
disulfide 
137-26-8 rs189210853 100196239 1 FRRS1 1.98E-
09 
0.012 
2',4',5'-
Trihydroxybutyrophenone 
1421-63-
2 
rs10213832 172302409 5 ERGIC1 1.98E-
09 
0.012 
Diethylene glycol diacrylate 149845-
06-7 
rs76663109 219066443 1 LYPLAL1 2.01E-
09 
0.004 
Saquinavir mesylate (AIDS 
Initiative) 
4074-88-
8 
rs34600565 51549528 15 CYP19A1 2.01E-
09 
0.013 
1,3-Diiminobenz (f)-
isoindoline 
65558-
69-2 
rs184897828 23101302 7 KLHL7 2.02E-
09 
0.003 
Hydroquinone 123-31-9 rs259613 238432583 1 ZP4 2.05E-
09 
0.013 
Systhane 88671-
89-0 
rs115987646 17518759 21 USP25 2.08E-
09 
0.002 
Vitamin D3 67-97-0 rs114742274 78274036 9 PCSK5 2.11E-
09 
0.002 
Hexachlorophene 70-30-4 rs4599696 72213159 7 TYW1B 2.16E-
09 
0.007 
p-Nitrosodiphenylamine 156-10-5 rs76022962 57713812 16 GPR97 2.19E-
09 
0.003 
1-Naphthylamine 143-50-0 rs79365910 127437542 5 SLC12A2 2.28E-
09 
0.003 
Chlordecone (kepone) 134-32-7 rs73982303 20719652 17 CCDC144NL 2.28E-
09 
0.003 
Fumaronitrile 764-42-1 rs150469316 38260872 15 TMCO5A 2.33E-
09 
0.015 
13-cis-Retinal 472-86-6 rs141310758 57507867 20 GNAS 2.35E-
09 
0.004 
N,N-Diethyl-p-
phenylenediamine 
93-05-0 rs141821443 78500126 16 WWOX 2.36E-
09 
0.015 
Sulfathiazole 72-14-0 rs192596112 18253562 17 SHMT1 2.37E-
09 
0.023 
Malachite green oxalate 2437-29-
8 
rs77904586 3698213 3 LRRN1 2.38E-
09 
0.018 
Dibromonitromethane 
(water disinfection 
byproducts) 
598-91-4 rs139080195 33110833 6 COL11A2 2.51E-
09 
0.005 
Pentaerythritol triacrylate 3524-68-
3 
rs114097262 57530631 20 TH1L 2.56E-
09 
0.011 
Aldicarb 116-06-3 rs117120562 76067201 7 ZP3 2.59E-
09 
0.032 
Melatonin 472-86-6 rs5030075 186456754 3 KNG1 2.63E-
09 
0.004 
13-cis-Retinal 73-31-4 rs146412275 190261780 3 TMEM207 2.63E-
09 
0.033 
Retinol acetate 127-47-9 rs112136721 76923060 1 ST6GALNAC3 2.71E-
09 
0.008 
Captan 133-06-2 rs80260839 55452081 11 OR4C6 2.72E-
09 
0.018 
Nitazoxanide 55981-
09-4 
rs112047343 25684936 6 SCGN 2.75E-
09 
9.00E-
04 
Vitamin D3 67-97-0 rs16908781 122453569 9 DBC1 2.76E-
09 
0.002 
Chlorhexidine 55-56-1 rs2069493 99967186 14 CCNK 2.78E-
09 
0.035 
2-Amino-4-chlorophenol 95-85-2 rs149669986 188717980 4 TRIML2 2.82E-
09 
0.032 
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Flutamide (pubertal study) 13311-
84-7 
rs147788105 36895798 14 SFTA3 2.92E-
09 
0.036 
8-Hydroxyquinoline 148-24-3 rs190163116 14927274 2 NBAS 2.93E-
09 
0.036 
p-Nitrosodiphenylamine 156-10-5 rs142249979 22127356 3 ZNF385D 2.96E-
09 
0.003 
p-Nitrosodiphenylamine 156-10-5 rs139756912 53520212 19 ZNF160 3.02E-
09 
0.003 
13-cis-Retinal 472-86-6 rs112109406 41635317 19 CYP2F1 3.06E-
09 
0.004 
Mono(2-ethylhexyl)phthalate 4376-20-
9 
rs142849625 87323965 X KLHL4 3.08E-
09 
0.038 
o-Phenylenediamine 95-54-5 rs78673081 159546875 6 FNDC1 3.14E-
09 
0.006 
2-Chloroacetophenone (CN) 532-27-4 rs7885074 79470548 X TBX22 3.15E-
09 
0.020 
Nitazoxanide 55981-
09-4 
rs147784707 39731980 19 IL28B 3.22E-
09 
0.001 
1,2-Epoxy-3-chloropropane 
(Epichlorohydrin) 
106-89-8 rs113130251 16684250 8 FGF20 3.24E-
09 
0.008 
dichloroacetonitrile 3018-12-
0 
rs17517181 132048205 9 C9orf106 3.25E-
09 
0.004 
dichloroacetonitrile 3018-12-
0 
rs116202592 118722702 8 EXT1 3.25E-
09 
0.004 
Retinal 116-31-4 rs75551402 144924136 6 UTRN 3.25E-
09 
0.005 
Hydroquinone 123-31-9 rs141081361 12301484 6 EDN1 3.36E-
09 
0.014 
Mercuric chloride 7487-94-
7 
rs114980796 146855180 7 CNTNAP2 3.44E-
09 
0.012 
1,1,1,2-Tetrabromoethane 630-16-0 rs76616047 165230707 1 LMX1A 3.49E-
09 
0.003 
Chlordecone (kepone) 143-50-0 rs117340306 159702181 6 FNDC1 3.49E-
09 
0.041 
Cycloheximide 74-31-7 rs140838976 42607192 2 EML4 3.50E-
09 
0.001 
N,N'-Diphenyl-p-
phenylenediamine 
66-81-9 rs141347833 95509996 8 KIAA1429 3.50E-
09 
0.003 
1,3-Diiminobenz (f)-
isoindoline 
65558-
69-2 
rs115797302 71579045 5 MRPS27 3.56E-
09 
0.003 
Nitazoxanide 55981-
09-4 
rs9587366 108038145 13 FAM155A 3.58E-
09 
0.001 
Nitazoxanide 55981-
09-4 
rs112507751 13672142 7 ETV1 3.59E-
09 
0.001 
1,2-Epoxy-3-chloropropane 
(Epichlorohydrin) 
106-89-8 rs143124581 127508299 2 GYPC 3.66E-
09 
0.008 
Chlordecone (kepone) 143-50-0 rs9305010 23959373 19 ZNF681 3.69E-
09 
0.003 
Chlorambucil 100-22-1 rs73477286 10512356 X CLCN4 3.73E-
09 
0.008 
N,N,N',N'-Tetramethyl-p-
phenylenediamine 
305-03-3 rs148476652 230219445 2 DNER 3.73E-
09 
0.024 
HC blue 2 33229-
34-4 
rs150501661 80565923 2 CTNNA2 3.78E-
09 
0.047 
Cycloheximide 66-81-9 rs77426543 23327356 14 MMP14 3.86E-
09 
0.003 
p-Nitrophenethyl alcohol 100-27-6 rs7235815 42824095 18 SETBP1 3.91E-
09 
0.008 
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Methylene bis(thiocyanate) 6317-18-
6 
rs111371582 200201474 1 FAM58B 3.94E-
09 
0.049 
Azathioprine 446-86-6 rs145504708 104046255 14 C14orf153 3.97E-
09 
0.008 
1,8-Dihydroxy-4,5-
dinitroanthraquinone 
81-55-0 rs58965029 55366235 7 LANCL2 4.02E-
09 
0.002 
2,2',4'-
Trichloroacetophenone 
4252-78-
2 
rs149411402 24732313 X POLA1 4.05E-
09 
0.025 
Retinol acetate 127-47-9 rs7220141 8596496 17 CCDC42 4.18E-
09 
0.008 
Glutaraldehyde 111-30-8 rs17080050 179587743 5 RASGEF1C 4.22E-
09 
0.005 
9-Aminoacridine, 
monohydrochloride, 
monohydrate 
52417-
22-8 
rs143574721 71726068 4 GRSF1 4.23E-
09 
0.019 
dichloroacetonitrile 3018-12-
0 
rs116306510 9045458 20 PLCB1 4.25E-
09 
0.004 
Saquinavir mesylate (AIDS 
Initiative) 
149845-
06-7 
rs148557261 85025463 X CHM 4.30E-
09 
0.005 
1,3-Diiminobenz (f)-
isoindoline 
65558-
69-2 
rs1937167 121239310 X GLUD2 4.32E-
09 
0.003 
4-Chloro-3,5-dinitro-a,a,a-
trifluorotoluene 
393-75-9 rs6784365 16264220 3 GALNTL2 4.37E-
09 
0.009 
Phenylmercuric acetate 62-38-4 rs183322569 144144565 X SPANXN1 4.38E-
09 
0.054 
1,3-Dicyclohexylcarbodiimide 538-75-0 rs185941966 48916163 X CCDC120 4.42E-
09 
0.055 
Ergotamine tartrate 379-79-3 rs7060812 143883587 X SPANXN1 4.45E-
09 
0.002 
1-Naphthylamine 134-32-7 rs76224072 66811251 3 KBTBD8 4.45E-
09 
0.005 
Captan 133-06-2 rs117766494 134786971 10 C10orf93 4.55E-
09 
0.029 
Vitamin D3 67-97-0 rs852471 5679853 7 FSCN1 4.61E-
09 
0.003 
1,1,1,2-Tetrabromoethane 630-16-0 rs75201540 107697197 3 CD47 4.63E-
09 
0.003 
9-Aminoacridine, 
monohydrochloride, 
monohydrate 
52417-
22-8 
rs150993793 107634677 6 PDSS2 4.64E-
09 
0.019 
Captan 133-06-2 rs143629216 108864949 X KCNE1L 4.69E-
09 
0.029 
Saquinavir mesylate (AIDS 
Initiative) 
149845-
06-7 
rs77216777 7737628 16 A2BP1 4.74E-
09 
0.005 
Sodium dichromate 
dihydrate (VI) 
7789-12-
0 
rs76202242 77000874 15 SCAPER 4.80E-
09 
0.020 
p-Nitrosodiphenylamine 156-10-5 rs13390320 6316492 2 SOX11 4.87E-
09 
0.004 
2-Amino-4-chlorophenol 95-85-2 rs114488597 6692895 9 GLDC 5.09E-
09 
0.032 
Tamoxifen citrate 54965-
24-1 
rs73418488 39876321 22 MGAT3 5.11E-
09 
0.017 
Chlordecone (kepone) 143-50-0 rs7604210 220464122 2 STK11IP 5.14E-
09 
0.004 
17beta-Estradiol 50-28-2 rs73515607 12081555 16 TNFRSF17 5.16E-
09 
0.002 
Nitazoxanide 55981-
09-4 
rs142350989 11163875 18 FAM38B 5.18E-
09 
0.002 
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Glutaraldehyde 111-30-8 rs145788790 76706431 3 ZNF717 5.26E-
09 
0.005 
o-Phenylenediamine 95-54-5 rs10487606 24377991 7 NPY 5.27E-
09 
0.008 
Tetrachlorvinphos 961-11-5 rs17037561 108142257 4 DKK2 5.40E-
09 
0.065 
Endosulfan 115-29-7 rs77954654 28003512 7 JAZF1 5.42E-
09 
0.022 
Turmeric (>98% curcurmin) 458-37-7 rs151050814 3717523 2 ALLC 5.47E-
09 
0.068 
Chlordecone (kepone) 143-50-0 rs114366607 9548336 11 ZNF143 5.48E-
09 
0.004 
17beta-Estradiol 50-28-2 rs78044298 13282331 17 HS3ST3A1 5.61E-
09 
0.002 
17beta-Estradiol 50-28-2 rs73400780 100613871 7 MUC12 5.62E-
09 
0.002 
p-Nitrosodiphenylamine 156-10-5 rs8056610 80414263 16 DYNLRB2 5.69E-
09 
0.004 
1,1,1,2-Tetrabromoethane 630-16-0 rs114472896 51352245 16 SALL1 5.70E-
09 
0.004 
Azobenzene 103-33-3 rs8034597 50564358 15 HDC 5.81E-
09 
0.022 
Catechol 120-80-9 rs5970515 150169694 X HMGB3 6.01E-
09 
0.044 
Dichlorvos (Vapona) 62-73-7 rs147257714 119289133 4 PRSS12 6.07E-
09 
0.025 
Alizarin Yellow R, free acid 2243-76-
7 
rs9484620 142617993 6 GPR126 6.08E-
09 
0.076 
p-Benzoquinone dioxime 105-11-3 rs116199788 14629043 9 ZDHHC21 6.09E-
09 
0.025 
Digoxin 20830-
75-5 
rs4668546 7802776 2 RNF144A 6.17E-
09 
0.033 
Retinol acetate 127-47-9 rs77518266 16948889 9 CNTLN 6.18E-
09 
0.008 
Vitamin D3 67-97-0 rs147712607 131033194 12 RIMBP2 6.21E-
09 
0.003 
o-Phenylenediamine 95-54-5 rs10197500 6314210 2 SOX11 6.24E-
09 
0.009 
Tamoxifen citrate 54965-
24-1 
rs140206324 162533710 3 OTOL1 6.24E-
09 
0.017 
1,3-Diiminobenz (f)-
isoindoline 
65558-
69-2 
rs111425337 45991437 20 ZMYND8 6.25E-
09 
0.003 
4-Chloro-3,5-dinitro-a,a,a-
trifluorotoluene 
393-75-9 rs73317253 111956225 8 KCNV1 6.27E-
09 
0.009 
Vitamin D3 67-97-0 rs114278053 41810548 14 LRFN5 6.28E-
09 
0.003 
p-Nitrophenethyl alcohol 100-27-6 rs114585626 6905318 16 A2BP1 6.28E-
09 
0.009 
1-Naphthylamine 134-32-7 rs116257974 83616924 7 SEMA3A 6.31E-
09 
0.005 
Nitazoxanide 55981-
09-4 
rs16887170 55652860 6 BMP5 6.34E-
09 
0.002 
Mono(2-ethylhexyl)phthalate 4376-20-
9 
rs140233380 150658923 X PASD1 6.35E-
09 
0.039 
1,1,1,2-Tetrabromoethane 630-16-0 rs112605190 74299348 17 QRICH2 6.48E-
09 
0.004 
Bisphenol A diglycidyl ether 1675-54-
3 
rs189546210 89544224 2 EIF2AK3 6.52E-
09 
0.077 
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Cycloheximide 66-81-9 rs59128236 187624402 3 BCL6 6.60E-
09 
0.003 
1,1,1,2-Tetrabromoethane 630-16-0 rs77326389 27959745 15 OCA2 6.70E-
09 
0.004 
Rhein (1,8-dihydroxy-3-
carboxyl anthraquinone) 
478-43-3 rs80120215 119009775 1 SPAG17 6.70E-
09 
0.042 
Nifedipine 21829-
25-4 
rs148079596 74646587 13 KLF12 6.73E-
09 
0.017 
Cetylpyridinium bromide 140-72-7 rs192455865 77187063 5 AP3B1 6.73E-
09 
0.030 
1,8-Dihydroxy-4,5-
dinitroanthraquinone 
81-55-0 rs190416563 40716108 20 PTPRT 6.74E-
09 
0.003 
1,3-Diiminobenz (f)-
isoindoline 
65558-
69-2 
rs7214324 75241094 17 SEC14L1 6.74E-
09 
0.003 
Methyl mercuric (II) chloride 115-09-3 rs140638640 3157831 X MXRA5 6.96E-
09 
0.059 
1,3-Diiminobenz (f)-
isoindoline 
65558-
69-2 
rs114723141 71915908 18 CYB5A 7.06E-
09 
0.003 
1,2-Epoxy-3-chloropropane 
(Epichlorohydrin) 
3018-12-
0 
rs16958628 11860133 16 ZC3H7A 7.08E-
09 
0.004 
dichloroacetonitrile 106-89-8 rs148108647 388033 7 FAM20C 7.08E-
09 
0.011 
Captan 133-06-2 rs143336822 79139911 15 MORF4L1 7.10E-
09 
0.018 
Catechol 120-80-9 rs75909882 186181894 3 CRYGS 7.16E-
09 
0.044 
Saquinavir mesylate (AIDS 
Initiative) 
149845-
06-7 
rs139792645 69525002 14 DCAF5 7.20E-
09 
0.006 
Flutamide (pubertal study) 13311-
84-7 
rs75591162 179520663 3 PEX5L 7.30E-
09 
0.039 
4-Chloro-3,5-dinitro-a,a,a-
trifluorotoluene 
393-75-9 rs140966476 1185683 19 STK11 7.32E-
09 
0.009 
4-Chloro-o-
phenylenediamine 
95-83-0 rs114170015 8036026 3 GRM7 7.42E-
09 
0.023 
Aldicarb 116-06-3 rs77630313 67951530 2 C1D 7.43E-
09 
0.046 
2,3,5-Trichlorophenol 933-78-8 rs72743494 210497480 1 HHAT 7.50E-
09 
0.093 
Retinol acetate 127-47-9 rs75201540 107697197 3 CD47 7.51E-
09 
0.008 
Triamterene 396-01-0 rs61880875 7924360 11 OR10A6 7.54E-
09 
0.047 
4-Chloro-3,5-dinitro-a,a,a-
trifluorotoluene 
393-75-9 rs146080764 49534816 11 FOLH1 7.58E-
09 
0.009 
o-Nitrobenzyl chloride 612-23-7 rs113423597 53897175 4 SCFD2 7.59E-
09 
0.030 
Vitamin D3 67-97-0 rs75048966 28220491 1 C1orf38 7.70E-
09 
0.004 
1,1,1,2-Tetrabromoethane 630-16-0 rs190646915 1410097 X CSF2RA 7.71E-
09 
0.004 
Fumaronitrile 764-42-1 rs6575909 102802858 14 ZNF839 7.72E-
09 
0.022 
t-Butyl formate 66-81-9 rs62389351 163302180 5 MAT2B 7.92E-
09 
0.003 
Cycloheximide 762-75-4 rs116857952 69222338 6 BAI3 7.92E-
09 
0.098 
Amiloride hydrochloride 2016-88-
8 
rs45477793 88470954 12 CEP290 7.98E-
09 
0.017 
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dichloroacetonitrile 3018-12-
0 
rs114922911 186024997 4 SLC25A4 8.06E-
09 
0.004 
p-Benzoquinone dioxime 105-11-3 rs116331855 182768941 2 SSFA2 8.08E-
09 
0.025 
Vitamin D3 67-97-0 rs78073324 63616070 1 FOXD3 8.16E-
09 
0.004 
1,8-Dihydroxy-4,5-
dinitroanthraquinone 
81-55-0 rs113434813 143835690 X SPANXN1 8.24E-
09 
0.003 
Nitazoxanide 55981-
09-4 
rs112997343 74356986 17 SPHK1 8.26E-
09 
0.002 
Ergotamine tartrate 55981-
09-4 
rs4263901 50758525 X BMP15 8.39E-
09 
0.002 
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Table 3.6. SNP set pathway      
Chemical CAS # Set Name No. Genes Zscorea FWER-
controlled Pb 
1,1,1,2-Tetrabromoethane 630-16-0 KEGG Allograft rejection 30 4.31 0.002 
KEGG Graft-versus-host disease 31 4.06 0.003 
KEGG Asthma 25 3.31 0.019 
2,2',4'-Trichloroacetophenone 4252-78-2 KEGG Autoimmune thyroid disease 45 3.71 0.007 
HC blue 2 33229-34-4 KEGG Butirosin and neomycin biosynthesis 5 3.51 0.008 
13-cis-Retinal 472-86-6 KEGG Butirosin and neomycin biosynthesis 5 3.67 0.010 
N-(1,3-Dimethylbutyl)-N'-
phenyl-p-phenylenediamine 
793-24-8 KEGG Asthma 25 3.49 0.010 
KEGG Allograft rejection 30 3.47 0.011 
Azathioprine 446-86-6 GO.MF transforming growth factor beta receptor, 
pathway-specific cytoplasmic mediator activity 
5 5.19 0.015 
2,3,4,5-Tetrachlorophenol 4901-51-3 KEGG Natural killer cell mediated cytotoxicity 131 3.36 0.016 
KEGG Antigen processing and presentation 63 3.15 0.022 
Ziram 137-30-4 GO.BP Regulation of chronic inflammatory response 7 5.26 0.017 
8-Hydroxyquinoline 148-24-3 KEGG Mismatch repair 23 3.26 0.018 
KEGG Steroid hormone biosynthesis 52 3.24 0.020 
KEGG Porphyrin and chlorophyll metabolism 39 3.04 0.038 
Chlordane (technical grade) 12789-03-6 GO.CC Central element 5 4.34 0.034 
Permethrin 52645-53-1 GO.BP Regulation of interleukin-2 production 34 5.08 0.037 
aZ-score computed by the gene_set_scan software.  bFamily-wise error controlled by resampling per chemical for each pathway type 
investigated. 
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Table 3.7.  LASSO prediction accuracy of expression vs. EC10 for chemicals with 
proportion of variance explained R2>0.01.Prediction accuracy of expression vs. EC10. 
Drug_Name CAS # R2 
Iodochlorohydroxyquinoline 130-26-7 0.058 
Dieldrin 60-57-1 0.055 
Triamterene 396-01-0 0.052 
2,3,5-Trichlorophenol 933-78-8 0.048 
m-Nitrobenzyl chloride 619-23-8 0.042 
Azathioprine 446-86-6 0.040 
Dexamethazone 50-02-2 0.038 
Cadmium acetatedihydrate 4-4-5743 0.038 
Diethylene glycol diacrylate 4074-88-8 0.034 
Chlordecone (kepone) 143-50-0 0.029 
Potassium dichromate 7778-50-9 0.028 
Dichlorvos (Vapona) 62-73-7 0.026 
Ethidium bromide 1239-45-8 0.024 
Daunomycin HCL 23541-50-6 0.023 
Diisobutyl phthalate 84-69-5 0.022 
Mercuric chloride 7487-94-7 0.021 
HC blue 2 33229-34-4 0.021 
Sodium dichromate dihydrate (VI) 7789-12-0 0.020 
N,N-Dimethyl-p-nitrosoaniline 138-89-6 0.020 
Methylene bis(thiocyanate) 6317-18-6 0.019 
Hexachlorophene 70-30-4 0.019 
Di(2-ethylhexyl) phthalate 117-81-7 0.019 
Systhane 88671-89-0 0.018 
3,4-Diaminotoluene 496-72-0 0.018 
N-(1,3-Dimethylbutyl)-N'-phenyl- 793-24-8 0.018 
Colchicine 64-86-8 0.016 
Ethacrynic acid 58-54-8 0.015 
Azobenzene 103-33-3 0.014 
t-Butylhydroquinone 1948-33-0 0.014 
6-Mercaptopurine monohydrate 6112-76-1 0.014 
Tamoxifen citrate 54965-24-1 0.014 
4,4-Thiobis(6-tert-butyl-m-creso 96-69-5 0.013 
Zinc pyrithione 13463-41-7 0.011 
Methacrylonitrile 126-98-7 0.011 
Domiphen bromide 538-71-6 0.010 
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CHAPTER 4: IN VITRO SCREENING FOR INTER-INDIVIDUAL AND POPULATION 
VARIABILITY IN TOXICITY OF PESTICIDE MIXTURES 
 
A. ABSTRACT 
Population-based human in vitro models offer exceptional opportunities for evaluating 
the potential hazard and mode of action of chemicals, as well as variability in response. 
Challenges remain that require further assessment to increase the utility of the information 
obtained from in vitro models. This study was designed to address the potential challenges of 
screening and assessing the cytotoxicity of complex mixtures. We selected 146 lymphoblast cell 
lines from 4 ancestrally and geographically diverse populations based on the availability of 
genome sequence and basal RNA-seq data.  Cells were exposed to two pesticide mixtures (an 
organochlorine pesticide environmental mixture extracted from a passive surface water sampling 
device, and a mixture of 36 currently used pesticides) at 8 concentrations and were then 
evaluated for cytotoxicity. qHTS screening in the genetically-defined populations produced 
robust and reproducible results. On average, the two mixtures exhibited a similar range of in 
vitro cytotoxicity and showed considerable inter-individual variability across the screened cell 
lines. However, in vitro-to-in vivo extrapolation (IVIVE), which was performed by reverse 
pharmacokinetics, suggested a significantly lower oral equivalent dose for the chlorinated 
pesticide mixture compared to the current-use pesticide mixture. Multivariate genome-wide 
association mapping revealed an association between the current use-pesticide mixture and a
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polymorphism in rs1947825 in C17orf54. Moreover, genetic pathway analysis showed a 
significant association between metabolism pathways and the cytotoxicity of the chlorinated 
pesticide mixture. We concluded that, together with IVIVE, an efficient in vitro experimental 
design that incorporates population variability and comparative population genomics can 
effectively enable the quantification of human health hazard in the most sensitive individuals to 
environmental mixtures. Additionally, such approaches can lead to generation of testable 
hypotheses regarding potential toxicity mechanisms.  
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B. INTRODUCTION 
Pesticides are compounds that are used to kill, repel, or control certain forms of plant or 
animal life that are considered to be pests (Krieger 2011). Adverse health effects of pesticides 
can range from mild skin and mucous membrane irritation to more severe outcomes such as 
neurotoxicity and cancer (Rother 2014; Bassil et al. 2007; Sanborn et al. 2007). Moreover, 
sensitivity to exposure is higher among relatively vulnerable populations, including women, 
children, the elderly, the immune-compromised and the malnourished (Perry et al. 2014; 
Jurewicz and Hanke 2008). There are several challenges in the evaluation of the human health 
hazard of pesticides.  First, pesticides have variable Modes of Action (MOA) dependent on use 
and activity, and are meant to be harmful and toxic to pests, but not humans. Second, because 
they are widely used in agricultural and household settings, people are frequently exposed to 
pesticide residues. Third, pesticides can be dispersed as mixtures, creating complexity in hazard 
evaluation (Manikkam et al. 2012).   
While safety testing of the individual pesticides is conducted according to established 
regulatory guidelines, evaluation of the toxicity of mixtures is less structured (OPP, 2002). The 
cumulative risk assessment approach is conducted for individual chemicals with common 
mechanisms of toxicity, even though the data is usually available only for individual chemicals 
(OPP 2002). Indeed, current toxicity testing paradigms have been questioned for their failure to 
consider commonly occurring co-exposures to environmental agents and the magnitude of 
human population variability in response to chemicals (National Research Council 2009).  
Whole animal testing is difficult to employ for testing chemical mixtures. In contrast, in 
vitro testing could allow grouping of chemicals according to their effects on key biologic 
pathways or their real human co-exposures over a broad range of concentrations in a rapid and 
 155 
 
inexpensive manner (Andersen and Krewski 2009). The resulting data could enable an informed 
and focused approach to the problem of assessing risk in human populations exposed to 
mixtures. Furthermore, with an experimental in vitro design that represents a human population, 
we are allowed to not only explore the hazard, but also the intrinsic variability that is associated 
with it across different dose ranges (Lock et al. 2012; O'Shea et al. 2010). Such information 
would be valuable to inform regulatory decisions that could more fully protect public health and 
sensitive subpopulations (National Research Council 2009). 
In the present study, we addressed the hypothesis that comparative population genomics 
with efficient in vitro experimental design can be used for evaluation of the potential for hazard, 
mode of action, and the extent of population variability in responses to chemical mixtures. We 
screened 146 lymphoblast cell lines (LCLs) from four ancestrally and geographically diverse 
populations with publicly available genotypes and sequencing data from the 1000 Genomes 
Project (1000 Genomes Project Consortium 2010). Cells were exposed to two pesticide mixtures 
(organochlorine pesticide environmental mixture extracted from a passive surface water 
sampling device, and a mixture of 36 currently used pesticides) at 8 concentrations. Cell viability 
was evaluated with CellTiter-Glo® (Promega) assay which evaluates ATP production in a 96-
well plate format. Cytotoxic response was assessed using an effective concentration  threshold of 
10% (EC10) (Abdo et al., in preparation), designed to be relevant to the dose-response evaluation 
commonly used in quantitative risk assessment practice and to meaningfully capture ranges of 
variation in response across chemicals. Genome-wide association mapping, gene set scan, and 
pathway analyses were performed to evaluate the genetic determinants of susceptibility. 
Furthermore, in vitro-to-in-vivo extrapolation by reverse pharmacokinetics and real cumulative 
exposures were utilized to predict xenobiotic steady state pharmacokinetics. 
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C. MATERIALS AND METHODS 
Experimental Design 
Cell lines. A set of 146 immortalized LCLs was acquired from Coriell Cell Repositories 
(Camden, NJ). The 146 cell lines represent 4 ancestrally and geographically diverse populations: 
Utah residents with Northern & European ancestry (CEU); Tuscan in Italy (TSI); Yoruban in 
Ibadan, Nigeria (YRI); and British from England & Scotland (GBR) (see table 4.1 for number 
and percent of each population and gender). The cell lines were chosen based on the availability 
of dense genotyping information and RNA-Seq expression data. Screening was conducted in two 
batches, and cell lines were randomly divided into the batches without regard to family structure 
but with equal representation of population and gender in each batch. Cells were suspended in 
flasks in an  upright position in RPMI 1640 media (Gibco, Carlsbad, CA) supplemented with 
15% fetal bovine serum (HyClone, South Logan, UT) and 1% penicillin-streptomycin (Gibco) 
and cultured at 37°C with 5% CO2. Media was changed every 3 days. Cell count and viability 
were assessed once a day for five days for all cell lines using Cellometer Auto T4 Plus 
(Nexcelem Bioscience, Lawrence, MA). Cells were grown to a concentration up to 10
6
 cells/ml, 
volume of at least 100 ml, and viability of > 85% before treatment. After centrifugation, the cells 
were resuspended in fresh media. Cells (100 μl containing 104 cells) were aliquoted to each well 
in a 96-well treatment plate (following the addition of the chemicals) and mixed using the 
Biomek 3000 robot. Plates were incubated for 24 h after treatment at 37°C and 0.5% CO2.To 
increase the robustness of the data and to evaluate reproducibility, each cell line was seeded in at 
least two plates so that each compound would be screened in each cell line on 2 or more plates. 
Chemical Mixtures. Cells were exposed to two extracts of environmental chemical mixtures: the 
first mixture, Chlorinated Pesticide Mixture (CPM), a real environmental sample obtained from a 
 157 
 
universal passive sampling device deployed for 30 days in surface water next to a chlorinated 
pesticide storage facility (10 pesticides were present in detectable quantities in the post-
collection laboratory analysis) (see table 4.2 for complete list of pesticide chemicals identified by 
mass spectrometry); and the second mixture, Current-Use Pesticide Mixture (CUPM), being a 
mixture of 36 currently used pesticides that mimics real exposure amounts of eastern North 
Carolina (see table 4.2 for complete list of pesticide chemicals). Chemicals were dissolved with 
dimethyl sulfoxide (DMSO) into 8 different stock concentrations. Final concentrations ranged 
from 0.032 to 370.4 µM for current-use pesticide mixture and from 0.022 to 65.7 µM for 
chlorinated pesticide mixture. The mixtures were aliquoted to 96-well plate format using the 
Biomek 3000 robot. The negative control was DMSO at 0.5% vol/vol; the positive control was 
tetra-octyl ammonium bromide at 46 µM. 
Cytotoxicity profiling. The CellTiter-Glo Luminescent Cell Viability (Promega Corporation, 
Madison, WI) assay was used to assess intracellular ATP concentration, a marker for 
cytotoxicity, 40 h post treatment. Time points were selected based on previous experiments at the 
National Institutes of Health Chemical Genomics Center (Xia et al. 2008). A ViewLux plate 
reader (PerkinElmer, Shelton, CT) was used to detect luminescent intensity in each well of the 
assay plates.  
 
Data Processing 
Cytotoxicity EC10 estimation and outlier detection. Cytotoxicity data were normalized relative 
to positive/negative controls as described elsewhere (Xia et al. 2008). We derived and effective 
concentration 10
th
 percentile (EC10) to provide a single cytotoxicity dose summary per chemical 
and cell line. The derivation of EC10 was based on the logistic model: 
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   (
      
         
)            
with          , where   is the observed normalized signal representing proportion of surviving 
cells (which we term the “cytotoxicity value”),   is the log(concentration) for each chemical, 
and      is the mean cytotoxicity value on the logit scale for the zero concentration.       was 
set to zero, to avoid difficulties in estimating the minimum cytotoxicity value for chemicals with 
low cytotoxicity.  An exception was made for chemicals in which the cytotoxicity value at the 
highest concentration was higher than 0.4, as a very few number of plates/chemicals did not 
reliably reach maximum cytotoxicity. In those instances the cytotoxicity value was set at the 
observed cytotoxicity at the maximum concentration.  Inspection of these data revealed good fits 
in such instances. Although in principle       should have been 1.0, a number of plates 
exhibited a drift from this value, and thus the parameter was estimated from the data.    
Fitting for the parameters         
        proceeded by maximum likelihood using numerical 
optimization in R v2.15.  An automatic outlier detection algorithm was devised by considering 
the impact of dropping each concentration value in succession, and removing those values for 
which the maximum likelihood improved by a factor of 10 or more and refitting the model using 
the non-outlying observations. 
Normalizing batch effects. Batch effects were evaluated by running principal component 
analysis. EC10 values were adjusted for batch effect using the ComBat method (Johnson et al. 
2007). 
Concentration response for populations and individuals. For each pesticide mixture, the three-
parametric logistic regression described above in EC10 estimation was fit to concentration-
response data for each cell line. The variation in the EC10 estimates was used as illustrative of 
population variation in true EC10 values, although additional sampling variation underlies each 
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EC10 estimate. An overall logistic concentration-response curve was fit to the aggregated data 
across all individuals. See Figure 4.1 
Reproducibility and correlation between mixtures. Pearson and Spearman correlation 
coefficients (r) between pairs of replicate plates were used to assess experimental reproducibility 
and the correlation between the two mixtures. For this analysis, the two replicate plates were 
selected for each mixture and cell line pair. See Figure 4.1 
Chemical/Mixture Specific Adjustment Factor (CSAF). Variability in response for each 
mixture across the 146 cell lines was obtained by obtaining the ratio of the 50
th
 percentile to the 
5
th
 percentile. The WHO CSAF guideline for toxicokinetics study is to obtain the ratio of the 95
th
 
to the 50
th
 percentile as the uncertainty factor for human variability in toxicokinetics. Both of our 
mixtures were skewed to the left. To be on the conservative side, we obtained the uncertainty 
factor for human variability in toxicodynamics as 50
th
percentile/5
th
percentile or the bigger tail 
(WHO 2005).   
Chemical descriptors. Chemical descriptors were calculated using Dragon version 5.5. Constant 
and near constant descriptors as well as highly correlated descriptors were excluded and 
descriptor values were normalized on a scale from 0 to 1. 
Differences in cytotoxicity across different populations. Analysis of Variance (ANOVA) was 
performed to assess population differences in cytotoxicity between the four screened populations 
for each mixture. See Figure 4.2.  
Genotypes. The primary source of genoytpes was obtained as described in Abdo et al., 2014. 
SNPs with a call rate below 99%, minor allele frequency (MAF)<0.05, or HWE p-value<1X10
-3
 
were excluded. 
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Multivariate Association Analysis (MAGWAS). The MAGWAS multivariate analysis of 
covariance model (Brown et al. 2012) was used for primary association mapping 
(http://www4.stat.ncsu.edu/~motsinger/Lab_Website/Software.html). The approach allows for 
use of the full concentration-response profile, as opposed to a univariate summary (such as 
EC10) as a single response, with the advantage of robustness and power under a wide variety of 
association patterns (Pillai, 1955). The model used for association for the jth individual and 
genotype i for the chemical/SNP was 
 
                 
          , 
 
where     is the vector of responses (across the eight concentrations) for the j
th
 individual having 
genotype i,     is the design matrix of covariates, including sex, indicator variables for 
laboratory batch, and the first ten genotype principal components, and    is the eight-vector of 
parameters modeling the effects of genotype i on the response.  The model assumes that the error 
terms are multivariate normally distributed, with mean vector 0 and variance-covariance matrix 
Σ, allowing for dependencies in the observations. P-values were obtained using Pillai’s trace 
(Pillai 1955). Because this method makes use of asymptotic theory, markers with fewer than 20 
individuals representing any genotype were removed, leaving 692,013 SNPs for analysis.   
 
In vitro to in vivo extrapolation. In vitro Pharmacokinetic Assays were applied to chemicals as 
described previously (Wetmore et al. 2012). Plasma protein binding was determined for each 
chemical using the rapid equilibrium dialysis (RED) method (Wetmore et al. 2012). The rate of 
hepatic metabolism of the parent compound was determined using the substrate depletion 
 161 
 
approach as previously (Wetmore et al. 2012; Rotroff et al. 2010).  
Estimation of Css using In Vitro-to-In Vivo Extrapolation (IVIVE) and Monte Carlo Simulation. 
The chemical steady-state blood concentrations (Css) were estimated as previously described 
(Wetmore et al. 2012) Wetmore et al in preparation) with modification. The base equation used 
to calculate static Css is based on constant uptake of a daily oral dose and factors in hepatic 
clearance and non-metabolic renal clearance:  
 
     
  
(
               
               
)           
 
 
where ko = chemical exposure rate set to 0.042 g/kg/hr (i.e., 1 g/kg/day); QH = hepatic blood 
flow (90 L/hr; Davies and Morris, 1993), Fub = unbound fraction of parent compound in the 
blood; ClintH = hepatic intrinsic metabolic clearance; and GFR = glomerular filtration rate.  The 
Fub was calculated based on the experimentally measured Fu plasma divided by the blood:plasma 
ratio (B:P).  The right side of the denominator considers non-metabolic renal clearance (GFR   
Fub), with GFR (6.7 L/hr) back calculated based on the serum creatinine Cockcroft-Gault 
equation (Cockcroft and Gault 1976). The CLint values were derived using the following 
equation, which scales CLuin vitro (L/min/million cells) experimentally measured in hepatocytes 
to represent whole organ clearance with units of L/hr: 
                                  
 
      
   
     
   
 
Where HPGL = hepatocytes per gram liver 110 million cells per g liver; (Barter et al. 2007) 
(HPGL) and Vl = liver volume (1596 g; (Johnson et al. 2005).  
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A correlated Monte Carlo approach was employed (Jamei et al. 2009) using Simcyp 
(Simcyp V. 13; Certara, Sheffield, UK) to simulate variability across a population of 10,000 
individuals equally comprised of both genders, 20-50 years of age. A coefficient of variation of 
30% was used for intrinsic and renal clearance. The median, upper and lower fifth percentiles for 
the Css were obtained as output.  
Calculation of oral equivalent dose values.  In conventional use, pharmacokinetic models are 
used to relate exposure concentrations to a blood or tissue concentration.  This is typically 
referred to as “forward dosimetry.”  In contrast, the models can also be reversed to relate blood 
or tissue concentrations to an exposure concentration, which is referred to as “reverse dosimetry” 
(Tan et al. 2007).  Based on the principal of reverse dosimetry, the median, upper and lower 5
th
 
percentiles for the Css were used as conversion factors to generate oral equivalent doses 
according to the following formula: 
 
                (
  
  
 
)                                        
 
In the equation above, the oral equivalent dose value is linearly related to the in vitro EC10 and 
inversely related to Css. This equation is valid only for first-order metabolism that is expected at 
ambient exposure levels. An oral equivalent value was generated for each chemical-cell line 
combination and summed to provide a cumulative oral equivalent value for each cell line.  
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Predicted exposure limits. Pesticide specific predicted exposure limits were obtained as 
previously detailed in (Wambaugh et al. 2013). The pesticide specific exposure limit was 
available for 35 out of the 36 pesticides in the current-use pesticide mixture and for 6 out of 10 
pesticides in the chlorinated pesticide mixture. Missing values were replaced by the highest 
exposure within each mixture. Then, a cumulative exposure was computed for each mixture from 
the upper 95
th
 percentile. See flow chart in Figure 4.3.  
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D. RESULTS 
Cytotoxicity of pesticide mixtures in vitro.  
Screening was conducted in a 96-well plate format using a robotic system. The 146 cell 
lines were randomly assigned to two batches with gender and population blocking. Each cell line 
was dispensed by the robot to two separate plates where both pesticide mixtures where dispensed 
at 8 different concentrations ranging from (0.032 to 370.4 µM) for current-use pesticide mixture 
and from (0.022 to 65.7 µM) for chlorinated pesticide mixture. Positive and negative controls 
were aliquoted to the same plate. Normalization to the control for each plate was performed as 
described in the Materials and Methods section for each cell line separately.  EC10s were derived 
on log10 scale as described in materials and methods, batch-corrected and averaged across 
replicated for each cell line.   
The availability of cytotoxicity screening on 146 individuals, with the assay performed 
under controlled conditions, enables sensitive investigation of variation in individual dose-
response profiles (National Research Council 2009). To visualize “individual” vs. “population” 
response to each pesticide mixtures, we fitted our 3-parametric logistic regression, described in 
the materials and methods, to each cell line’s concentration-response illustrated in Figure 4.1a 
and 1b corresponding to chlorinated- and current-used- pesticide mixtures respectively. For each 
concentration-response EC10 was estimated and shown as the inset red histogram to show the 
populations variability in response to each mixture. The mean of these EC10 values offers a 
population-wide summary of the cytotoxicity, of a mixture and is very similar to the EC10 
produced when the data are first pooled for all individuals and then fit using a single 
concentration-response curve (red-dashed curve in Figure 4.1a and 1b). Both mixtures 
demonstrated considerable inter-individual variability in cytotoxicity response (Figure 4.1). 
However, aggregation across the population ignores the variability in toxic susceptibility and the 
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variability across replicates, and the EC10 estimated fifth percentile may be used to illustrate the 
concept of a “vulnerable” subpopulation. 
To increase the robustness of the cytotoxicity measurement, duplicate plates were run. To 
evaluate the reproducibility of our EC10 estimates, pair-wise Pearson and Spearman correlations 
among replicate plate pairs using log10(EC10) values for each mixture were calculated. Highly 
significant correlations were seen in each pesticide mixture (p<0.0001). For current pesticides 
mixtures r[Pearson’s] =0.62 and r[Spearman]=0.55 (See Figure 4.1). For chlorinated pesticides 
mixture, r[Pearson’s] =0.65 and r[Spearman]=0.56 (see Figure 4.1). Overall reproducibility for 
both mixtures was also significant (p<0.0001) with r[Pearson’s] =0.62 and r[Spearman]=0.54. 
Overall, Duplicate measures revealed excellent experimental reproducibility (See Figure 4.1).  
 
Comparative analysis of cytotoxicity of pesticide mixtures using population-based model.  
Both the mean and the median cytotoxicity (EC10) for current use pesticide mixture were 
slightly lower than chlorinated pesticide mixture (see Figure 4.4a and 4.4b and table 4.4 for 
summary statistics) indicating slightly more potency for current-used pesticide mixture. The 
median EC10 for current-use pesticide mixture was almost 12 µM and 13 µM for chlorinated 
pesticide mixture. However, there was no significant difference in their mean cytotoxicity 
between the two mixtures. Interestingly, the current pesticide mixture demonstrated a slightly 
wider distribution across the population than chlorinated pesticide mixture (see Figure 4.4a and 
4.4b). The toxicodynamic uncertainty factor (UFd) for human variability was around 3 fold for 
each mixture (see table 4.4).  
In order to translate our cytotoxicity measures into a meaningful potential health risk 
hazard, we computed oral equivalent doses for both mixtures using reverse toxicokinetics 
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approach (Wetmore et al. 2012; Rotroff et al. 2010). In vitro pharmacokinetic data (see complete 
list at: http://comptox.unc.edu/Toxcast_I_II_RTK_List.pdf) were available for 31 of the 36 
chemicals present in the current use pesticides laboratory mixture, and for 4 of the 10 chemicals 
in the chlorinated pesticide environmental mixture. Review of the Css values predicted for the 31 
current use pesticides revealed a similar distribution as observed across the 180 ToxCast Phase II 
chemicals similarly assessed for in vitro PK: a median Css <1 µM;  95th percentile ≈200 µM. 
Two of the chemicals assessed had very high Css values: ethalfluralin (350 µM) and flumetralin 
(277 µM); the rest were below 8 µM. The distribution of data for 4 chlorinated pesticides was 
different from the laboratory mixture: the max Css value estimated = 58.46 µM. Since there are 
no standard PK approach for dealing with mixtures, we assumed for this analysis that there is not 
interaction or potentiation between chemicals in terms of toxicity and pharmacokinetics (PK) 
modeling. For the purposes of this work, for the PK modeling, we assumed that the PK of each 
chemical will not be significantly impacted by the presence of other chemicals present at these 
low levels anticipated in the environment. Given this, we expect that the in vitro PK that was 
derived using clearance and plasma protein binding data measured for individual chemicals will 
provide an adequate estimate of PK behavior for this assessment. Our data involved only one 
assay measured across 146 individuals, and so a separate oral equivalent was calculated for each 
individual based on the percentage of chemical in the mixture. To be conservative, missing in 
vitro pharmacokinetic data were assigned a value based on the most conservative simulation 
assuming no hepatic clearance, high blood binding and only renal clearance, which we defined as 
the “worst case scenario” (See Figure 4.4C).  
The oral equivalent (OE) dose was computed based on four different scenarios in which 
we substituted the missing Css with either the median Css of known chemicals or worst-case-
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scenario value, where  OE was calculated with and without weighting of the EC10 by the 
percentage of chemical in the mixture (Figure 4.5) for an illustrative flowchart of OE 
calculations). Supplemental Figure 4.6 shows OE doses for each scenario for each pesticide 
mixture across the 146 cell lines.  
The simulations were run using Simcyp  software (Simcyp Ltd, 2001), which 
incorporates Monte Carlo Simulation to capture population variability in PK. The Css values 
were derived using a population of healthy volunteers (Northern European, 20-50 years of age, 
equally mixed gender). The simulation was run using 10 trials, 1000 volunteers per trial. The 
upper 95th percentile values were used to determine the oral equivalents (Figure 4.4C), as this 
approach results in a reasonably conservative value. Across the four different scenarios, these in 
vitro-to-in vivo extrapolation data show that a significantly (p<0.001) lower dose of chlorinated 
pesticide would lead to the internal concentrations that are equal to the EC10 values that elicited 
cytotoxicity (See Figure 4.4C and Figure 4.6). Oral Equivalent doses for both mixtures were not 
substantially altered (<0.5 fold difference) when the median Css value was used instead of the 
worst case scenario. However, oral equivalent dose was remarkably shifted for both mixtures 
(>1.2 fold change) with non-weighted EC10 vs. EC10 weighted by the percentage of chemicals 
used in each mixture (See  Figure 4.6). However, the relation between the two mixtures were 
maintained in all scenarios, in which the chlorinated pesticide mixture was more toxic the current 
use pesticide mixture.  
To better evaluate the human health risk of exposure to such mixtures, we examined the 
relationship of our calculated oral-dose-equivalent with actual real-human-exposures to such 
mixtures. We computed a cumulative exposure value for each mixture based on individual 
exposure estimates for each chemical obtained from ExpoCast (Wambaugh et al. 2013). The 
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ExpoCast framework has created an estimated human exposure potential for 1936 chemicals 
(Wambaugh et al. 2013), which incorporated both biomonitoring data and uncertainty factors in 
their predictions. Predicted estimates were available for 35 of the 36 chemicals present in the 
current use pesticides laboratory mixture, and 6 of the 10 chemicals in the chlorinated pesticide 
environmental mixture. We presumed the highest predicted exposure for chemicals with no 
predicted exposure value and calculated the cumulative exposure for each mixture from the 
upper 95
th
 percentile to be conservative. The actual real human exposure estimates were lower 
than our calculated oral dose equivalent indicating no real human hazard (See Figure 4.4c). Our 
oral equivalent dose was ~1-fold higher for current-use pesticide mixture and ~6 fold higher for 
chlorinated pesticide mixture than their corresponding real human exposure estimate (See Table 
4.6 and Table 4.7).  This indicates a wider margin of safety for the chlorinated pesticide mixture 
than the current-use pesticide mixture.  
 
Similarities between pesticide mixtures.  
We wanted to assess the similarity of cytotoxic response for the pesticide mixtures across 
different cell lines.  A significant correlation (Spearman r=0.25 p<0.01) was observed between 
the two mixtures, illustrating concordance in individual cell line’s responses to both tested 
mixtures (see Figure 4.7a). These findings are interesting, considering that none of the individual 
chemicals appear in both mixtures. Furthermore, the results might suggest potential shared 
mechanisms of susceptibility to toxicity. There were no suggestive patterns of population 
clustering in the correlation between the two mixtures. To make sure that the significant 
correlation was not substantially influenced by outlying points, we removed the three most 
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outlying points and rederived the correlation. The correlation still remained significant (p<0.05, 
spearman r= 0.2). 
 None of the individual chemicals within each mixture overlapped with the other mixture, 
but there was a significant correlation between cytotoxic responses to the mixtures, we 
investigated similarities in their chemical structure. Principal Component Analysis (PCA) 
(Hotelling 1933) showed great similarities between single chemical compounds in both mixtures 
in their chemical descriptor space (see Figure 4.7b). This observation may partially explain the 
significant correlation between the two mixtures and the lack of significant difference in their 
mean cytotoxicity. We explored the potential of chemical descriptors in clustering the chemicals 
within each mixture by their pesticid mode of action (See Table 4.2 and 4.3 for a complete list of 
pesticidMOA (Wood 2014). We did not find any meaningful clusters. Only 4 of 5 chemical that 
acted as nematicides clustered together in the 1
st
 principal component (see Figure 4.7b).  
We were further interested in assessing the strength of the correlation between the two 
mixtures when compared to any other correlation between two random chemicals. Previously, 
we had screened 1086 LCLs with 179 diverse chemicals (Abdo et al, in preparation). The 
Spearman correlation between the two pesticide mixtures (r=0.25) was slightly above the median 
correlation of a randomly picked correlation chosen from 15931 possible correlations in the 
previous cytotoxicity experiment (see Figure 4.7c).  
 
Differences in cytotoxicity across ancestral populations.   
The regulation of pesticided is a high priority in many countries due to their widespread 
use. Therefore,investigating susceptible sub-populations is of great interest. The current use 
pesticide mixture exhibited marginally significant differences among the populations tested (p = 
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0.058), while chlorinated pesticide mixture did not show any significant differences (see Figure 
4.2).   Interestingly, GBR (British from England & Scotland) population was the most sensitive 
population, while YRI (Yoruban in Ibadan, Nigeria) population appeared to be the least sensitive 
in both mixtures. Moreover, within-population variability was larger within the current use 
pesticide mixture compared to the chlorinated pesticide mixture, especially when comparing the 
range of the upper quartile to the lower quartile within each population (see Figure 4.2). 
 
Susceptibility loci, genes, and pathways. 
The availability of densely genotyped data from the 1000 Genomes Project for the LCLs 
used in this study allows for exploration of possible genetic determinants of cytotoxicity. Despite 
being relatively underpowered, with a sample size of 146, in comparison with modern disease 
genome-wide association studies, we attempted to identify possible loci, genes, or pathways 
associated with cytotoxicity. After careful frequency and genetic pruning and quality control 
(SNPs with a call rate below 99%, minor allele frequency (MAF) < 0.05, or HWE p-value < 1 X 
10
-3
 were excluded), 1,015,304 SNPs were included in the analysis. Concentration-responses 
were subjected to quality control as described in (Abdo et al., in preparation), in which outliers 
were removed and subjected to fitted smoothing as described in (Abdo et al., in preparation). 
Sex, experimental batch and date, population, and the first ten genotype principal components 
were included as covariates for running Multivariate ANCOVA Genome-Wide Association 
Software (MAGWAS) on the curated concentration-responses. MAGWAS is a sensitive method 
in identifying any pattern of variation of cytotoxicity measurements due to genotype (Brown et 
al. 2012).  Even though in this study we used a relatively small population of 146 cell lines, we 
were able to observe a finding of genome-wide suggestive significance. The cytotoxicity 
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measurement of current used pesticide was associated (p<6.5e
-08
) with a locus on Chr17 (Figure 
4.8a and 4.8b), which is near the commonly used GWAS threshold of 5X10
-8
 (Dudbrige and 
Gusnanto 2008). Figure 4.8a shows the corresponding MAGWAS Manhattan plot, with a 
regional LocusZoom plot (Figure 4.8b) (Pruim et al. 2010).  The associated SNP (rs1947825), is 
located in an open reading frame C17orf54 (See Figure 4.8b). We examined the cytotoxicity 
patterns for each genotype in Figure 4.5c. Interestingly, while the measured cytotoxicity of the 
heterozygous genotype (AT) consistently was in the middle between the measurements of the 
homozygous genotypes across all concentrations, the homozygous genotypes elicited an 
interesting pattern: AA was higher than TT at lowest concentration, but dropped dramatically 
faster than TT at higher concentrations (See Figure 4.8c).  
“Pathway” association analysis of gene sets/ontologies was performed for EC10 
phenotypes and the 1.0 million SNPs using gene set scan (Schaid et al. 2012), which performs 
resampling to compute significance of SNPs, genes, and ontologies (KEGG and Gene 
Ontologies) in a hierarchical manner.  For each mixture and ontology, we applied family-wise 
error rate (FWER) control using 10,000 resamples, and report in Table 4.7 all of the ontology 
findings with FWER<0.3. Several metabolism pathways were significantly associated with 
current-use pesticide mixture (Table 4.7). The top contributing eight genes within each of those 
pathways were mainly from the uridine diphosphate (UDP) glucuronosyltransferases (UGT) 
family. The UGT genes regulate of the UGT enzymes responsible for glucuronidation which is 
generally accountable for transforming compounds into water-soluble glucuronides for excretion 
in bile and urine (Burchell 2003).  
 
 
 172 
 
E. DISCUSSION 
With the recent shift in the focus of many toxicology studies from in vivo to in vitro 
methods, substantial advancements in high-throughput approaches to characterize in vitro 
biological activity have been implemented (Dix et al. 2007; Bucher et al, 2008). Nonetheless, 
several challenges remain in establishing meaningful human health risk assessments from in 
vitro endpoints. Additionally, a lack in comprehensive understanding of population variability in 
susceptibility to chemicals remains. Regulatory risk assessment incorporates multiple uncertainty 
factors that are based on assumptions. Furthermore, no clear framework has been set to 
determine the toxicity of chemical mixtures.  Regulatory authorities have raised some concern 
about the risks posed by complex chemical mixtures in the environment (Kepner, 2004).  Few 
environmental chemical mixtures have been evaluated, especially at environmentally relevant 
concentrations (Carvalho et al., 2014), with regulatory decisions primarily based on a single 
compound evaluation. However, potentiation and synergistic interactions of chemicals in 
mixtures is of great concern (Cedergreen, 2014). It has been shown that exposure to chemical 
mixtures, including pesticides, often occurs with each chemicals in the mixture present at 
respective safety limit concentrations (Carvalho et al., 2014). Moreover, evaluation of chemical 
mixtures with similar modes of action, without consideration of realistic exposure in the 
environment, might underestimate the toxicological risk associated with their exposure (Hadrup, 
2014).  
In response to these needs, we aimed to provide a quantitative experimental measurement 
for population-based in vitro toxicity that could be applied to regulatory risk assessments of 
environmentally-relevant concentrations of pesticide mixtures. This screening paradigm provides 
quantitative data on population-wide variability in toxicity, which may be used to establish data-
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driven uncertainty estimates when extrapolating in vitro data to potential in vivo toxicity (Judson 
et al. 2011). Our results show that both of the pesticide mixtures we tested exhibited a similar, 
considerable inter-individual variation in the induction of toxicity.  The toxicodynamic 
uncertainty factor (UFd) for population variability was approximately 3-fold from the median to 
largest tail for both mixtures. Interestingly, this finding is consistent with the assumed 
uncertainty factor of 3.2 (100.5) that is used for toxicodynamic studies in risk assessment (WHO 
2005). The calculated UFd can be used to obtain a chemical-specific adjustment factor by adding 
the toxickinetics uncertainty factor (UFk) (WHO 2005). To our knowledge, this is the first study 
to examine inter-individual variability in response to chemical mixtures. Investigation of 
population variability to more than 100 individual chemicals has been previously investigated 
(Abdo et al., in preparation). Interestingly, the toxicodynamic uncertainty factor in our present 
study for pesticide mixtures was similar to the median inter-individual variability for the 179 
individual chemicals previously tested.  
On average, there was no significant difference between the in vitro cytotoxicity of the 
current-used pesticide mixture and the chlorinated pesticide mixture. However, the in vitro-to-in 
vivo extrapolation data showed that a significantly lower dose of chlorinated pesticides would 
lead to the internal concentration equal to the cytotoxicity-eliciting EC10.  This observation 
confirms that relying on the quantitative in vitro potencies alone for ranking chemical mixtures 
might not accurately reflect the potential risk associated with these chemicals, due to differences 
in bioavailability, clearance, and in vivo exposure (Blaauboer, 2010). Incorporation of human 
dosimetry and predicted human exposure will contribute tremendously to the “presumed hazard” 
calculated by in vitro high throughput screening alone, and provides improved estimates for 
informed regulatory decisions (Blaauboer, 2010; Cohen Hubal et al., 2010). 
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It is not surprising that the cumulative human predicted exposure limit is much higher for 
the current-use pesticide mixture compared to the chlorinated pesticide mixture, which mostly 
consisted of banned-used pesticides. The current-use pesticide mixture included 36 currently 
used pesticides and mimicked real exposure levels in Eastern North Carolina, with Atrazine 
(ATZ) pesticides being the most abundant. ATZ is the most highly applied pesticide (64-80 
million pounds annually in the United States), and the second most widely used agricultural 
pesticide in the United States (Donaldson et al. 2002; Kiely et al. 2004; Barr et al., 2007). 
Therefore, the predicted exposure limit for the current-use pesticide mixture was expected to be 
high, and in our case it was very close to our calculated oral equivalent dose.  
With the availability of genetic information for our screened cell lines from the 1000 
Genomes Project (Durbin et al., 2010), we were able to establish genotype-phenotype 
associations. Recognizing the genetic underpinning of cytotoxicity may offer exceptional insight 
as to the underlying casual physiological variation and biologically associated pathways. One of 
the major challenges in the interpretation of GWAS results is posed by SNPs located in non-
coding regions. While hundreds of loci have been identified from many GWAS studies for 
diverse diseases and quantitative phenotypes (Hindorff et al., 2012), more than 90% of them 
were in non-coding regions (Jones et al. 2012; Fraser 2013). However, while some of those 
locations were discovered to have a role in transcriptional regulatory mechanisms, including 
modulation of promoter and enhancer elements (Cookson et al., 2009; Pomerantz et al., 2009; 
Musunuru et al., 2010; Harismendy et al., 2011), and enrichment within expression quantitative 
trait loci (eQTL) (Cookson et al., 2009; Nicole et al., 2010; Denger et al., 2012), the roles of 
others have yet to be determined.  While we see a suggestive association between cytotoxicity 
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and the rs1947825 polymorphisms, we do not yet know how this open reading frame affects the 
cytotoxicity phenotype.  
Through pathway analyses we found that the chlorinated pesticide mixture is 
significantly associated with UGT metabolism enzymes. UGTs can reduce the toxic effects of 
pesticides and other drugs by facilitating their excretion in bile and urine through transforming 
them to less-toxic water-soluble glucuronides (Burchell, 2003; Ahmad & Forgash, 1976; Meech 
et al., 2012). Although glucuronidation typically produces less toxic compounds, it may activate 
xenobiotics to produce reactive acylglucuronides that can cause cytotoxicity (Wieland et al., 
2000; Bailey & Dickinson, 2003; Stingl et al., 2014). This is particularly important because UGT 
enzymes are genetically polymorphic with more than 200 alleles (Stingl et al., 2014). 
Polymorphisms in UGT1 and UGT2 families can alter enzymatic role, cellular processes, or gene 
expression (Stingl et al., 2014), thereby possibly affecting individual’s cytotoxic response.  The 
majority of compounds are metabolized mainly by 1A1, 1A3, 1A4, 1A9 and 2B7 (Stingl et al., 
2014), which were the top ten significant genes associated with the cytotoxicity of the 
chlorinated pesticide mixture (see Table 4.7).  This finding suggests that variation in the genes 
coding for these enzymes may be particularly relevant in metabolizing chlorinated pesticide 
mixtures. 
Like any toxicological model system, in vitro toxicity profiling using LCLs has a number 
of limitations for the extrapolation to intact humans, including a lack of metabolism, as well as 
the inability to establish cell-cell interactions, assess target organ adverse effects, investigate 
potential role of other environmental factors such as lifestyle, diet, or co-exposures, or evaluate 
chronic toxicity. Furthermore, a great deal of debate exists regarding how chemicals may interact 
with one another in mixtures, both in terms of PK and in terms of toxicity. Establishing a safety 
 176 
 
assessment of mixtures may be somewhat constrained by the assumptions we have made. There 
remains a pressing need to screen individual pesticides, in addition to mixtures, in order to test 
these assumptions. In addition, our work highlights the need for a more complete assessment of 
oral equivalent and real human exposures for pesticides and other chemicals. 
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FIGURES 
 
 
Figure 4.1. Inter-individuals and Population Variability and Reproducibility of the 
Mixtures. Left panel, a population concentration response was modeled using in vitro qHTS data 
using chlorinated pesticide mixture (panel a) and current-use pesticide mixture (panel b) data. 
Logistic concentration-response modeling was performed for each individual to the values 
shown in gray, providing individual 10% effect concentration values (EC10). The red dashed line 
represents the logistic concentration-response for the population’s mean (the data are first 
pooled for all individuals and then fit using a single concentration-response curve).  The EC10 
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obtained by performing the modeling on average assay values for each concentration (see 
frequency distribution) are shown in the inset.  
Right panel, experimental reproducibility for cytotoxicity of chlorinated pesticide mixture (panel 
a) and current-use pesticide mixture (panel b). EC10 cytotoxicity values for replicate pairs  were 
plotted and Spearman and Pearson’s correlations are shown.   
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Figure 4.2. Boxplots of Population Differences for Each Mixture. Boxplots* of EC10 values 
by population for chlorinated pesticide mixture (a) and chlorinated pesticide mixture (b), which 
showed marginally significant population differences by ANOVA for current-use pesticide 
mixture (p=0.058).  
*The bottom, band inside the box, and top of the box are the first, second (the median) and third 
quartiles, The whiskers represent 1.5 the lowest and highest datum within 1.5 Inter Quantile 
Range (IQR). Small circles are outliers with >1.5 IQR above minimum or maximum datum. 
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Figure 4.3 Illustrative Flow Chart of Predicted Exposure Limits Calculations. Chemical 
specific predicted exposure was obtained as previously described in Wambaugh et al., 2013. 
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Figure 4.4 Distribution of EC10s and Oral Equivalent Dose Across 146 cell lines for each 
mixture. Panel a, represents a density plot for the distribution and mean of EC10 of each 
pesticide mixture
ϕ
 across 146 cell lines.Panel b, boxplots* of EC10 values for each of pesticide 
mixtures
ϕ
 across 146 cell lines . Panel c, boxplots* of the cumulative oral doses in mg/kg/day for 
each of pesticide mixtures
ϕ
 across the 146 cell lines. The triangles represent the computed 
predicted exposure limit for each pesticide mixture 
ϕ
. 
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*The bottom, band inside the box, and top of the box are the first, second (the median) and third 
quartiles, The whiskers represent 1.5 the lowest and highest datum within 1.5 Inter Quantile 
Range (IQR). Small circles are outliers with >1.5 IQR above minimum or maximum datum. 
ϕ
 blue: Current Pesticide Mixture; red: Chlorinated Pesticide Mixture 
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Figure 4.5.  Illustrative Flow chart of Oral Equivalent Dose Calculations. Chemical specific 
steady-state values were obtained as previously described in Wetmore et al. 2012.  
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Figure 4.6 Oral Equivalent Doses with the Four Different Scenarios. Boxplots* of the 
cumulative oral doses in log10(µg/kg/day) for each of pesticide mixtures (red: chlorinated 
pesticide mixture, and blue: current pesticide mixture) across the 146 cell lines in four different 
scenarios: weighted by chemical percentage in mixture or not, and assuming worst case scenario 
(WCS) vs median  for missing values.  
*The bottom, band inside the box, and top of the box are the first, second (the median) and third 
quartiles, The whiskers represent 1.5 the lowest and highest datum within 1.5 Inter Quantile 
Range (IQR). Small circles are outliers with >1.5 IQR above minimum or maximum datum. 
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Figure 4.7. Inter-individual and Population Variability and Reproducibility of the 
Mixtures. Panel a, a scatter plot comparison of EC10 values for each pesticide mixture. Each 
symbol represents one of the four populations. Pearson and Spearman correlations are shown at 
the top left side.  Panel b, a scatter plot of 1
st
 and 3
rd
 principal components of individual pesticide 
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chemical structures within both mixtures colored blue for current-use pesticide mixture and red 
for chlorinated pesticide mixture.  Five pesticides were Nematicides and were marked by an 
outer black circle. Panel c, represents a frequency histogram of 15931 spearman correlations 
produced pairwise correlations of 179 random chemicals. The green dashed line represents the 
median r value for all correlations, and the red dashed line represents the pairwise correlation of 
pesticide mixtures in comparison to all chemicals. Blue shading represents non-significant 
correlations with FDR correction.  
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Figure 4.8 MAGWAS Results for Current-Use Pesticide Mixture. Upper panel. Manhattan 
plot of MAGWAS -log10(P) vs. genomic position, for association of genotype and cytotoxicity 
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to current-use pesticide mixture.  The line of suggestive association (expected once per genome 
scan) is in dashed blue. Middle panel, a LocusZoom plot of the most significant region, SNP 
rs1947825 was the most significant (P=6.5×10
-8
).  Lower panel, Average concentration-response 
profiles of cytotoxicity of current-use pesticide mixture plotted for each rs1947825 genotype. 
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Table 4.1. The Screened Population’s Distribution 
Population  # of Cell lines 
Screened 
% of 
Total 
N 
males 
N 
females 
CEU: Utah residents with Northern & Western 
European ancestry  
47 32.2% 24 23 
YRI: Yoruban in Ibadan, Nigeria  40 27.4% 19 21 
TSI: Tuscan in Italy  32 21.9% 16 16 
GBR: British from England & Scotland  27 18.5% 14 13 
Total 146 100% 73 73 
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Table 4.2. Individual Pesticides in Chlorinated Pesticide Mixture. 
Organochrlorine pesticides     
PSD extract from 
waste site 
MW CAS # µg in 
1 mL 
µmoles in 
1 mL 
% in 
1mL 
alpha-BHC 290.8 319-84-6 107 0.368 5.60 
beta-BHC  290.8 319-85-7 55 0.189 2.88 
gamma-BHC 
(lindane) 
290.8 58-899/ 
55963-79-6 
151 0.519 7.90 
delta-BHC 290.8 319-86-8 41 0.141 2.15 
cis-chlordane 409.8 5103-71-9 18 0.044 0.67 
trans-chlordane 409.8 5103-74-2 15 0.037 0.56 
4,4'-DDD  320.1 72-54-8 293 0.915 13.94 
4,4'-DDE  318.0 72-55-9 1193 3.75 57.11 
4,4'-DDT  354.5 50-29-3 176 0.496 7.56 
Dieldrin  380.9 60-57-1 41 0.108 1.64 
Cumulative Concentration  2090 6.57 100 
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Table 4.3. Individual Pesticides Current-use Pesticide Mixture. 
Current-Use Pesticide 
Mixture 
MW CAS # µg in 1 
mL 
µmoles 
in 1 mL 
% in 
1mL 
2,6-Diethylaniline 149.2 579-66-8 1259 8.44 19.76 
Aldicarb 190.3 116-06-3 92 0.484 0.74 
Benfluralin 335.3 1861-40-1 76 0.227 1.31 
Butylate 217.4 2008-41-5 193 0.888 1.35 
Carbaryl 201.2 63-25-2 106 0.527 0.39 
Carbofuran 221.3 1563-66-2 85 0.384 0.50 
Desethyl atrazine 187.6 6190-65-4 1352 7.21 0.37 
Atrazine-desisopropyl 173.6 1007-28-9 1271 7.32 1.04 
Ethalfluralin 333.3 55283-68-6 82 0.246 0.63 
Flumetralin 421.7 62924-70-3 81 0.192 0.37 
Metribuzin 214.3 21087-64-9 98 0.457 0.89 
Napropamide 271.4 15299-99-7 37 0.136 0.12 
Pebulate (Tilliam) 203.4 1114-71-2 56 0.275 0.61 
Pendimethalin 281.3 40487-42-1 33 0.117 0.29 
Tebuthiuron 228.3 34014-18-1 65 0.285 14.74 
Trifluralin 335.5 1582-09-8/ 
75635-23-3 
78 0.232 2.40 
Alachlor 269.8 15972-60-8 37 0.137 1.23 
Atrazine 215.7 1912-24-9 1178 5.46 0.35 
Chlorothalonil 265.9 1897-45-6 29 0.109 2.00 
Chlorpyrifos (Dursban) 350.6 2921-88-2 71 0.202 0.48 
Cyanazine 240.7 21725-46-2/ 
11096-88-1 
31 0.129 0.55 
Dacthal 332.0 65862-98-8 
/1861-32-1 
15 0.045 0.37 
Tribufos (DEF 6) 314.5 78-48-8 41 0.130 0.26 
Diazinon 304.4 333-41-5 89 0.292 0.79 
Disulfoton 274.4 298-04-4 26 0.095 0.77 
Fonofos (Dyfonate) 246.3 944-22-9 32 0.130 0.32 
Ethoprop 242.3 13194-48-4 45 0.186 1.09 
Fenamiphos 303.4 22224-92-6 54 0.178 0.27 
Methyl parathion 263.2 298-00-0 36 0.137 0.66 
Metolachlor 283.8 94449-58-8/ 
51218-45-2 
115 0.405 22.77 
Molinate 187.3 2212-67-1 139 0.742 19.45 
Permethrin 391.3 52645-53-1 39 0.100 0.52 
Prometon 225.3 1610-18-0 74 0.328 1.42 
Prometryne 241.4 7287-19-6/ 
83653-07-0 
42 0.174 0.47 
Simazine 201.7 122-34-9 101 0.501 0.35 
Terbufos 288.4 13071-79-9 42 0.146 0.35 
Cumulative Concentration 261.3  7200 37.0 100 
 
 192 
 
 
Table 4.4. Summary Statistics of EC10 for each mixture. 
Pesticide Mixture Mean STD+ Range Median  Q05* Q95ϕ Ufdλ 
Chlorinated Pesticide Mixture 11.6 1.96 (0.180-40.6) 13.1 4.36 21.7 3.00 
Current Pesticide Mixture 11.1 1.85 (0.649-39.9) 11.9 3.89 24.7 3.05 
  
    + The standard deviation of EC10 
* The value corresponding the 5
th
 percentile of EC10 across 146 averaged values for each 
individual  
ϕ The value corresponding the 5
th
 percentile of EC10 across 146 averaged values for each 
individual  
λ The population toxicodynamic uncertainty factor corresponding to each pesticide.  
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Table 4.5. Margin of Exposure for Current-Use Pesticide Mixture. 
Margin of Exposure for Current-Use Pesticide Mixture  
Scenario 
Margin of Exposure* 
Minimum 5th percentile Median 
Weighted by chemical % 
Worst Case Scenario 1.0 1.8 2.3 
Median 1.1 1.8 2.3 
Equally Weighted 
Worst Case Scenario 2.9 3.7 4.2 
Median 3.0 3.7 4.2 
 
*Margin of exposure is measure by obtaining the fold difference for each of the 4 scenarios of oral 
equivalent dose and the predicted exposure limits (minimum, 5
th
 percentile, and median) 
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Table 4.6. Margin of Exposure for Chlorinated Pesticide Mixture. 
Margin of Exposure for Chlorinated Pesticide Mixture  
Scenario 
Margin of Exposure 
Minimum 5th percentile Median 
Weighted by chemical % 
Worst Case Scenario 5.9 7.2 7.7 
Median 6.4 7.8 8.3 
Equally Weighted 
Worst Case Scenario 7.1 8.5 8.9 
Median 7.5 8.9 9.3 
 
*Margin of exposure is measure by obtaining the fold difference for each of the 4 scenarios of oral 
equivalent dose and the predicted exposure limits (minimum, 5
th
 percentile, and median) 
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Table 4.7: Top Results from Pathway Analysis of Pesticide Mixtures  
compound ID Term N 
gene
s 
pval.f
wer 
Top 7 Genes for each pathway 
Chlorinated 
Pesticides 
KE
GG 
Ascorbate and aldarate 
metabolism 
22 0.009 UGT2B11 UGT2B7 UGT1A3 UGT1A7 
UGT1A4 UGT1A5 UGT1A6 
Chlorinated 
Pesticides 
KE
GG 
Starch and sucrose 
metabolism 
48 0.034 UGT2B11 UGT2B7 UGT1A3 UGT1A7  
UGT1A4 UGT1A5 UGT1A6 
Chlorinated 
Pesticides 
KE
GG 
Porphyrin and chlorophyll 
metabolism 
39 0.06 EARS2 UGT2B11 UGT2B7 BLVRA 
UGT1A3  
UGT1A7 UGT1A4 
Chlorinated 
Pesticides 
KE
GG 
Pentose and glucuronate 
interconversions 
28 0.08 UGT2B11 UGT2B7 UGT1A3 UGT1A7 
UGT1A4 UGT1A5 UGT1A6 
Chlorinated 
Pesticides 
KE
GG 
Nitrogen metabolism 23 0.08 CA6 GLUL CA2 CA4 HALCTH 
CA5A 
Chlorinated 
Pesticides 
KE
GG 
p53 signaling pathway 68 0.185 DDB2 CCNE2 CHEK1 TP73 CD82 SFN 
SERPINE1 
Chlorinated 
Pesticides 
KE
GG 
Other types of O-glycan 
biosynthesis 
42 0.201 UGT2B11 UGT2B7CHST10 UGT1A3 
UGT1A7 UGT1A4 UGT1A5 
Chlorinated 
Pesticides 
KE
GG 
Prion diseases 35 0.204 IL1B C8A PRKACA C8B IL1A IL6 C8G 
Chlorinated 
Pesticides 
KE
GG 
Vitamin digestion and 
absorption 
24 0.246 BTD MMACHC SLC19A2 APOA4 PLB1 
SLC19A1 APOA1 
Chlorinated 
Pesticides 
KE
GG 
Drug metabolism - other 
enzymes 
48 0.288 UGT2B11 UGT2B7 IMPDH2 UGT1A3 
UGT1A7 UGT1A4 UGT1A5 
Current-use 
Pesticides 
KE
GG 
Sulfur relay system 10 0.218 MOCS2 TRMU MPST CTU2 CTU1 TST 
MOCS3 
Current-use 
Pesticides 
KE
GG 
Other types of O-glycan 
biosynthesis 
42 0.299 RFNG CHST10 UGT1A10 UGT1A8 
UGT1A7 UGT1A9 UGT1A6 
Chlorinated 
Pesticides 
GO regulation of triglyceride 
biosynthetic process 
5 0.286 NR1H3 NR1H2 FITM2 GPAM ACSL5 
Chlorinated 
Pesticides 
GO regulation of lipoprotein 
lipase activity 
21 0.3 NR1H3 NR1H2 SORT1 APOA4 APOC1 
APOC3 APOH 
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CHAPTER 5: GENERAL DISCUSSION 
A. SUMMARY AND CONCLUSIONS. 
 
 Quantitative assessment of both the hazard and the degree of inter-individual biological 
variability in the human population is critical for proper evaluation of chemicals for potential 
adverse human health outcomes (Zeise et al. 2013). A comprehensive characterization of human 
genome sequence variation is important for understanding observed inherited variation in 
toxicity phenotypes. Genetic polymorphisms can have a profound influence on risk and should 
be considered for human risk assessment (Baynes 2012). However, such characterization and 
assessment is difficult to quantitatively evaluate using current in vivo animal test systems or in 
vitro methods with established cell lines.  
 The availability of genetically-defined, genetically-diverse renewable sources of human cells, 
such as lymphoblasts from the International HapMap and 1000 Genomes projects, enables in 
vitro testing at the population level. As the focus of risk assessment processes shifts toward in 
vitro data, the quantitative assessment of inter-individual variability in response to chemicals, 
and an understanding of the underlying genetic causes are necessary for regulatory decisions to 
be based on scientific data rather than on default assumptions. Our population-based quantitative 
high-throughput model is a valuable tool in evaluating both the hazard and the degree of inter-
individual variability in response to chemicals. 
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1. QUANTITATIVE HIGH-THROUGHOUT SCREENING FOR CHEMICAL TOXICITY IN 
A POPULATION-BASED IN VITRO MODEL 
With the recent shift in toxicity testing from in vivo to in vitro, several quantitative high-
throughput screening (qHTS) approaches for computational toxicology were developed to 
prioritize compounds, reveal new mechanisms, and enable predictive modeling. We strived in 
this study to design predictive in vitro models of chemical-induced toxicity with a focus on inter-
individual genetic variability. We exposed 81 LCLs from 27 Centre d’Etude du Polymorphisme 
Humain (CEPH) trios to 240 chemical substances at 12 concentrations and evaluated for 
cytotoxicity and apoptosis. We demonstrated the feasibility of LCLs in creating an in vitro 
model system to evaluate inter-individual and population-wide variability of chemical-induced 
toxicity phenotypes. Indeed, the in vitro genetics–anchored human model system used in the 
study has not only been fruitful in measuring toxicity in a population-level, but also it carried the 
potential to recognize candidate genetic susceptibility for individual variability. Our in vitro 
population model has proven to produce robust reproducible toxicity values for a wide variety of 
chemicals across the different cell lines.  
 Regardless of toxicity phenotype used (cytotoxicity or apoptosis); variability across 
individual cell lines varied from one chemical to another in magnitude but was consistent for 
each chemical. Through combining our toxicity data with publicly available genetic information 
for LCLs, we were able to generate plausible hypotheses for the associations identified by either 
the genotypes or the RNA-expression levels. We recognize that our sample size combined with 
the likely small genomic effect size will probably hinder our ability for detecting meaningful 
biological associations. However, we consider this study as a successful proof of concept and as 
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a motivation to carry out a larger scale population based screening to better understand human 
and genetic variability.  
 
2. GENETIC MAPPING OF IN VITRO SUSCEPTIBILITY TO CYTOTOXIC 
COMPOUNDS-THE 1000 GENOMES HIGH THROUGHPUT SCREENING STUDY 
 There is a significant lack of understanding of human variation in response to toxic 
environmental chemicals. We strived in this study to address this critical gap in next generation 
risk assessment. We used 1086, representing 9 populations from 5 continents, drawn from the 
1000 Genomes Project to assess variation in cytotoxic response to 179 chemicals. We ranked 
chemicals by average response and assessed population variation and heritability. Genome-wide 
association mapping was also performed, with attention to phenotypic relevance to human 
exposures. This study provides an example of how a large-scale systems biology experiment that 
integrates toxicity phenotyping with genetic mapping can aid in translation to public health 
protection. For example, our data did not only provided quantitative assessments of hazard for 
hundreds of chemicals, but most importantly, the hazard was identified in the most sensitive 
individuals. The next few paragraphs will illustrate some of the conclusions drawn from the 
second aim.  
 
 Some, but not all chemicals elicit inter-individual variation in cytotoxicity responses. The 
degree of inter-individual variability varies from one chemical to another. The degree of inter-
individual variability varies from one chemical to another and was less than 10 fold for about 2/3 
of the compounds. However, some compounds exhibited more than 100-fold range in variability. 
Overall, the median inter-individual variability across all chemicals is similar to the default 
assumption for toxicodynamic study, even in chemical mixtures.  However, assuming a 3-fold 
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uncertainty factor for toxicodynamic assessment might be overestimating or underestimating the 
actual inter-individual variation for some chemicals. The degree of inter-individual variability, in 
addition to the degree of cytotoxicity, may aid in prioritization of utilized compounds for further 
testing using additional in vitro or in vivo approaches. 
 Inter-individual variability in cytotoxicity could be within and/or between the populations 
tested in these experiments. While certain populations were more sensitive than others to certain 
chemicals, the variation tended to be modest. Furthermore, the variation within populations was 
generally greater than across populations. The pattern for variation across population was unique 
for each chemical. Consequently, no population was sensitive to all or most of the chemicals. 
There was some evidence of hierarchical clustering by continental ancestry, indicating that on 
average certain populations might exhibit similar sensitivity to the same chemicals. 
 Combining toxicity data and publicly available genotyping and RNA-Seq information 
enabled the possibility to probe and select candidate susceptibility genes and pathways/networks. 
Genetic mapping suggested important roles for variation in membrane and trans-membrane 
genes with a number of chemicals showing association with rs13120371 in the solute carrier 
SLC7A11, which has been implicated in chemo-resistance. Analysis of public RNA-sequencing 
profiles on the same cell lines provided evidence of association between basal transcription and 
cytotoxic response, with enrichment for genes with membrane localization. 
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3. IN VITRO SCREENING FOR INTER-INDIVIDUAL AND POPULATION VARIABILITY 
IN TOXICITY OF PESTICIDE MIXTURES 
   
 Population-based human in vitro models offer exceptional opportunities for evaluating the 
potential hazard and mode of action of chemicals, as well as variability in response as shown in 
the previous two studies. Potential challenges of screening and assessing the cytotoxicity of 
complex mixtures requires further assessment to increase the utility of the information obtained 
from in vitro models. We strived in this study to explore the potential of a population-based in 
vitro model in evaluating chemical mixtures and the possibility of integrating real human 
exposures in assessing in vitro data. We used 146 lymphoblast cell lines from 4 ancestrally and 
geographically diverse populations that were densely genotyped and with publically available 
basal RNA-seq data.  Cells were exposed to two pesticide mixtures (an organochlorine pesticide 
environmental mixture extracted from a passive surface water sampling device and a mixture of 
36 currently used pesticides) at 8 concentrations and were evaluated for cytotoxicity. 
Cytotoxicity measures for replicates produced robust and reproducible results. On average, the 
two mixtures exhibited a similar range of in vitro cytotoxicity and showed considerable inter-
individual variability across the screened cell lines. However, in vitro-to-in vivo extrapolation 
(IVIVE), which was performed by reverse pharmacokinetics, suggested a significantly lower oral 
equivalent dose for the chlorinated pesticide mixture compared to the current-use pesticide 
mixture. Multivariate genome-wide association mapping revealed an association between the 
current use-pesticide mixture and a polymorphism in rs1947825 in C17orf54. Moreover, genetic 
pathway analysis showed a significant association between metabolism pathways and the 
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cytotoxicity of the chlorinated pesticide mixture. Our model was not only valuable in 
quantitatively estimating hazard and understanding inter-individual variability for individual 
chemicals, but was also amenable to rapidly and efficiently test mixtures of chemicals as well. 
Moreover, through integration of our cytotoxicity data with proper dose estimation through PK 
modeling and real human exposure limits, we were able to advance our assessment of pesticide 
mixtures and understand the actual human health hazard associated with them. 
 
Overall Conclusions 
 Our population-based toxicity screening that is based on genetically-defined and genetically 
diverse human in vitro model system is a more powerful approach than traditional in vitro 
approaches. First, it allowed for efficient quantitative assessment of both hazard and inter-
individual variability in toxicodynamics for individual chemical and chemical-mixtures. From 
the concentration-response in vitro, we have been able to establish a quantitative toxicity 
phenotype (EC10) that is similar to the Lowest Observed Adverse Effect Level (LOAEL). This 
toxicity phenotype can serve as an in vitro point of departure where chemical exposures could be 
identified without major biological perturbations, which in our case is a meaningful depletion in 
ATP or cell death. Because testing was conducted from many cell lines from many human 
donors from representative populations, we were able to gauge population and inter-individual 
variability associated with the hazard for each chemical. Identifying both the hazard and inter-
individual variability was useful in establishing meaningful prioritization of chemicals and 
exploring potential differences/similarities in modes of action between chemical substances.  
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 Second, the availability of cell lines from many human donors representing several ancestral 
populations afforded identification of susceptible sub-populations. Third, combining toxicity 
data and publicly available genetic information for LCLs from 1000 Genomes and HapMap 
Projects offered the possibility to probe and select candidate susceptibility genes and 
pathways/networks. Consequently, we were able to understand of the genetic determinants of the 
inter-individual variability, the contribution of genetics to adverse toxicity phenotype, and 
generate testable hypotheses about toxicity pathways by leveraging genetic and genomic data. 
Furthermore, while most of the variability between different cell lines that is can be attributed to 
genetics is modest and similar to complex chronic diseases, the genetic variation identified may 
have a profound effect on differences between individual cell lines. Consequently, such 
variability can be quantified and used to generate testable hypotheses about the mechanisms of 
toxicity. 
 Finally, incorporation of reverse dosimetry and exposure estimates when exploring 
concentration-response relationships for individual chemicals aided tremendously in assessing 
human hazard. Because the in vitro assay endpoint does not incorporate metabolic clearance and 
plasma protein binding, ranking the chemical mixtures by nominal assay concentrations might 
result in over- or under- estimation of the steady-state of a chemical mixture. 
 In conclusion, our population-based high throughput model enabled us to capture a 
population-wide measure of uncertainty, where we are able to quantitatively estimate chemical-
specific or mixture-specific range in individual variability and to understand contributing genetic 
variation associated with it.   
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B. SIGNIFICANCE, INNOVATION, AND IMPACT OF THIS STUDY 
 
 We have utilized a human lymphoblast cells representing diverse populations to understand 
the hazard and magnitude of inter-individual variability to different environmental chemicals 
and/or chemical mixtures. There are several advantages to make use of LCLs for toxicity 
screening, as opposed to other current in vitro approaches, that make our study innovative. First, 
LCLs are derived from healthy adult individuals as opposed to tumor driven cell lines that are 
being utilized by Tox21 and other current human in vitro screening paradigms. Consequently, 
LCLs provide a better understanding of toxicological effects and improved translation to a real 
human population when compared to cancer cell lines. Second, LCLs represent geographically 
diverse populations from different continents and ancestral backgrounds which facilitate the 
assessment of variability within and between populations. Third, the public availability of the 
genome-wide genotype and gene-expression data allows for investigating the molecular-genetic 
mechanistic underpinnings of chemical toxicity for no additional cost. This availability of data 
also presents the opportunity for Genome Wide Association Studies (GWAS) and identification 
of SNPs, genes, and/or pathways that are primarily associated with toxicity of chemicals. Such 
findings permit the generation of novel hypotheses of how chemicals cause toxicity, and/or 
validate our understanding of what is known about the mechanism of chemical toxicity. Fourth, 
the immortalization of LCLs grants a renewable source for repeated experiments with easy 
manipulation at no additional cost.  In conclusion, all those qualities of LCLs provide the 
possibility for effective and innovative in vitro population-based screening of chemicals without 
in vivo confounders and surpasses other in vitro testing paradigms.   
 With the first aim, we were able to test hundreds of chemicals with LCLs at different 
concentrations, allowing for the identification of a concentration-specific toxicity in addition to 
 209 
 
recognizing population variability. The study was first of its kind and proved the remarkable 
value of our model in achieving several gains. It served as a proof of principle that population in 
vitro screening with LCLs and careful experimental design can be used to assess both hazard and 
population variability, cluster chemicals for further prioritization, and help uncover potential 
genetic underpinnings.   
 With the second aim, we were able to conduct the largest scale study, in terms of number of 
cell lines and chemicals used, to address major gaps in current risk assessment. This study was 
innovative in its hypotheses, the approach and model system to be utilized, the combination of 
methodologies and analyses to be performed, the organizational structure, and the outstanding 
translational potential to human populations. We were able to quantitatively assess and address 
population based toxicological effects or hazard of environmental contaminants, determine the 
extent of human inter-individual variability in chemical toxicity, identify susceptible sub-
populations or races, understand the genetic determinants of the inter-individual variability, 
generate testable hypotheses about toxicity pathways by leveraging genetic and genomic data 
from 1000 Genomes and HapMap Projects,  use the data obtained from this research to build 
predictive in silico models, capture a population-wide measure of uncertainty in dose-response, 
and explore potential differences/similarities in modes of action between chemicals. 
Furthermore, the second aim provided data for improved prioritization and clustering of 
chemicals according to a number of differing criteria. Clustering of chemicals can be done 
according to toxicity, variability between individuals, genetic mode of action, and similarity in 
toxicological pattern.   
 Finally, the high-throughput information derived from our 1000 Genomes Toxicity Screening 
Project was utilized to build models that can predict cytotoxicity based on either chemicals 
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structure or genomic profiles without the need of additional experiments. With the collaboration 
between Sage Bionetworks and DREAM, University of North Carolina (UNC), the National 
Institutes of Environmental Health Sciences (NIEHS), and the National Center for Advancing 
Translational Sciences (NCATS), the NIEHS-NCATS-UNC DREAM Toxicogenetics Challenge 
was launched in 2013. This challenge represents an innovative new track for toxicity testing and 
is intended to help comprehend how genetic variation affects individual response to exposure to 
environmental chemicals. The Toxicogenetics Challenge approached researchers to utilize the 
data obtained from the 1000 Genomes Toxicity Project in order to elucidate the extent to which 
adverse effects (e.g. cytotoxicity) of compounds can be inferred from genomic and/or chemical 
structure data. Participants are tasked with solving two related sub-challenges: (1) develop 
predictive models of cytotoxicity using genetic and genomic data to predict individual responses 
to compound exposure and (2) use chemical attributes to predict population-based cytotoxicity 
characteristics (median, variance) for a set of compounds. The challenge engaged 232 registered 
participants with 99 submissions from 34 teams for first sub-challenge and 91 submissions from 
24 teams for the second sub-challenge. Successful models/participants were selected for each 
sub-challenge. The computational models built for each sub-challenge could be considered in 
certain decision-making contexts to inform government agencies as to which environmental 
chemicals and drugs are of the greatest potential concern to human health. Moreover, Nature 
Biotechnology will consider an overview paper describing the results and insights of successful 
models. 
 In the third aim, we wanted to expand our model to address remaining challenges in risk 
assessment of chemical mixtures. While high-throughput in vitro toxicity screening provides an 
efficient way to identify hazard for environmental and industrial chemicals while conserving 
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limited testing resources. It is hard to  interpret cytotoxicity values without proper understanding 
of in vivo dose. Differences in clearance, protein binding, and other pharmacokinetic factors have 
tremendous consequence on the bioactivity of a chemical. With this particular study, we were 
able to quantify hazard and population variability in with respect to two pesticides mixtures in 
vitro, extrapolate the in vitro concentration to an in vivo associated dose, and compare its 
relevance to real human exposure amounts for a full assessment of the pesticide mixtures.  
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C. LIMITATIONS OF THIS STUDY  
 
  There are several disadvantages associated with utilizing LCLs for in vitro population-
based screening that are related to all three studies/aims. While high-throughput in vitro testing 
offers many potential benefits, there are potential challenges in extrapolating a particular 
perturbing concentration in one cell type to a dose of a chemical that results in an observable 
change in the health or normal functioning of the whole human. First, in vitro testing does not 
necessarily cover the full biological pathway or all critical changes that be consequent to 
exposure to a chemical. Despite our ability to identify potential genetic pathways associated with 
exposure to a specific chemical, other factors such as epigenetics and cell-cell interactions might 
mitigate or enhance the observed a toxic response in LCLs, leading to underestimation or 
overestimation of the actual risk from chemical exposure. Second, while we are trying to account 
for human population diversity in response to chemicals by using LCLs that represent different 
populations, we still cannot account for other sources of population variability such as 
epigenomics, age, pre-existing health conditions, life style, and co-exposures. Third, while 
frequency, duration, and route of exposure to a chemical are key elements that need to be 
considered in toxicity assessment, those factors cannot be accounted in in vitro screening. 
Consequently, caution and thoughtful deliberation is required in translating of in vitro data to an 
intact organism to avoid over-interpretation or erroneous conclusions (Rothman, 2002).  
  The biggest shortcoming of in vitro toxicity testing is the lack of metabolism.  When it 
comes to binning compounds to dichotomized categories (toxic vs non-toxic), false-positives or 
false-negatives might arise as consequence of absence of metabolism.  LCLs are derived from B-
lymphocytes whose main function is humoral adaptive immunity. Unlike hepatocytes, human 
lymphoblasts do not function to metabolize chemicals and therefore do not have the metabolic 
 213 
 
capacity of the liver, or even that of freshly isolated hepatocytes. However, there is evidence that 
LCLs express a number of nuclear receptors, as well as most genes of the phase I and II 
metabolism, and transporters (Siest et al. 2008). Nevertheless, the expression of metabolism 
genes and nuclear receptor in lymphoblasts (Stranger et al. 2007) is about 10 to 100 times lower 
when compared to hepatocytes (Schadt et al. 2008a). While using high concentrations in 
experimental design could potentially overcome the low metabolism in LCLs, we still lack a 
clear understanding of metabolism in LCLs. Nonetheless, screening parent compounds with their 
major metabolites may offer an improved measure of true toxicity.  
   While LCLs have been a promising model for pharmacogenomic discoveries, their 
utility has been questioned because of concern with changes in cell biochemistry stemming from 
the immortalization process. Potential confounders that affect the utility of LCLs include 
baseline growth rates, EBV copy numbers and ATP levels (Choy et al. 2008). While growth rate 
of LCLs was associated with chemotherapeutic-induced cytotoxicity in one study (Stark et al. 
2010), it was not associated with cytotoxicity of 100+ chemicals (Lock et al. 2012). Altered 
apoptosis responses have been observed as a result of EBV transformation in LCLs with cancer 
drugs (Liu et al. 2004).  
  The immortalization process or EBV transformation has been observed to affect gene-
expression and promoter-methylation profiles of majority of genes compared to primary B cells 
(Caliskan et al. 2011). However, the difference in expression levels between the primary and 
immortalized cells was small in magnitude (<1.5 fold). Moreover, the inter-individual variability 
in gene expression was the same between primary B cells and LCLs (Caliskan et al. 2011). 
Furthermore, many expression quantitative trait loci eQTLs observed in LCLs were observed in 
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primary tissues like the liver, lung, and skin (Bullaughey et al. 2009; Ding et al. 2010; Schadt et 
al. 2008b). 
 In the first specific aim, we acknowledge that our sample size combined with the likely small 
genomic effect size will probably hinder our ability to detect meaningful associations. Moreover, 
in both first and second aims, further evaluation is needed to better understand the in vitro 
cytotoxicity values obtained from our model. In vitro-to-in vivo extrapolation might 
tremendously help get better comprehension of hazards associated with screened chemicals. 
However, such analysis is depended on availability of PK specific values for screened chemicals.  
Other limitations inherent to the third aim are the strong assumptions we made in 
evaluating toxicity of mixtures. With mixtures, there is a great deal of debate in the toxicology 
community about how chemicals may interact with one another, both in terms of PK modeling 
and in terms of toxicity. While we assumed that the chemicals do not potentiate or inhibit the 
cytotoxicity of each other, we have no way of knowing if that assumption was entirely true. 
Furthermore, we assumed that the chemicals in each mixture are equipotent. However, we tried 
to extract cytotoxicity data for the chemicals component for each mixture from the ToxCast data.  
Furthermore, we had missing data in both human exposure estimates and PK modeling data for 
some the chemicals within each mixtures. While we tried to be conservative by considering 
different scenarios for substituted missing values and picking the worst case ones, we do not 
know if we are overestimating the actual exposure or oral equivalent dose. This is especially 
true, since some of the chemicals were contributing more heavily than others to oral equivalent 
dose and we do not know how the missing chemicals might be influencing our estimates. We 
need better estimates for oral equivalent dose and real human exposures for some of our 
pesticides that have missing data for an improved risk assessment.  
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D. FUTURE DIRECTIONS 
 
 There are several directions in which this research could proceed. First, we can functionally 
validate the discoveries made with GWAS and other analyses like RNA-Seq and pathway 
analyses. The confirmation of the potential association between a certain SNP or gene and the 
cytotoxicity in LCLs could be performed in several ways. One way is to knock down the gene of 
interest by SiRNA in LCLs and compare cytotoxicity across broad range of concentrations in 
“wild type” LCLs vs knocked down LCLs. Another potential way is to pick cell lines 
representing each genotype of the associated SNP and test them across a broad range of 
concentrations. Then statistically test the difference in cytotoxicity (either EC10 or whole 
concentration response) between the three different genotypes.  
 Second, we could elucidate modes and mechanisms of toxicities of our cell lines by 
quantitatively assessing gene expression variation for chemicals across different concentrations. 
The evolving of the new technology that can quantify mRNA responses in thousands of genes, 
called RASL-Seq, has been rapidly growing to accommodate the high-throughput screening of 
many compounds screened in many cell lines across multiple concentrations at different 
endpoints. The gene expression in RASL-Seq technology is characterized by excellent 
reproducibility, high accuracy, excellent gene specificity, amenability for high-throughput 
multiplex economical approach (Fu et al., 2012). This technology can enable us assess 
quantitatively mRNA expression for our screened pesticide mixtures, drug-metabolites, and 
cadmium chloride at different concentrations. The gene expression profiles can illuminate our 
understanding of the mechanism of cytotoxicity.  
 Third, we can explore the potential differences/and similarities in modes of action between 
chemicals either on a population-wide compared to individual effects. Through our screenings, 
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we were able to cluster chemicals by their similarities in toxic response across different cell 
lines. We concluded that those similarities exist due to shared mechanism of action (MOA). 
Thousands of chemicals have been screened in Tox21 and ToxCast through multiple assays 
indifferent cell lines. We can leverage the data produced by ToxCast and Tox21 and try to see if 
shared MOA for certain chemicals across different assays was a factor in chemical’s profiles 
across cell lines.  
 Finally, we can further understand cytotoxicity of mixtures by screening both the individual 
components and the mixtures. This approach will help us test and validate some of the 
assumptions we made with the mixtures study. By comparing the cytotoxicity of each chemical 
and comparing it to the cumulative cytotoxicity of the whole mixture, we can assess whether 
chemicals potentiate or inhibit the activity of other chemicals within a mixture, and we can 
evaluate the assumption of equal potency for chemical within each mixture. 
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